<SEC-DOCUMENT>0001193125-23-185962.txt : 20230712
<SEC-HEADER>0001193125-23-185962.hdr.sgml : 20230712
<ACCEPTANCE-DATETIME>20230712163111
ACCESSION NUMBER:		0001193125-23-185962
CONFORMED SUBMISSION TYPE:	DEF 14A
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20230822
FILED AS OF DATE:		20230712
DATE AS OF CHANGE:		20230712

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CATALYST PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001369568
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		DEF 14A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33057
		FILM NUMBER:		231085006

	BUSINESS ADDRESS:	
		STREET 1:		355 ALHAMBRA CIRCLE
		STREET 2:		SUITE 801
		CITY:			CORAL GABLES
		STATE:			FL
		ZIP:			33134
		BUSINESS PHONE:		(305) 529-2522

	MAIL ADDRESS:	
		STREET 1:		355 ALHAMBRA CIRCLE
		STREET 2:		SUITE 801
		CITY:			CORAL GABLES
		STATE:			FL
		ZIP:			33134

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CATALYST PHARMACEUTICAL PARTNERS, INC.
		DATE OF NAME CHANGE:	20110215

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Catalyst Pharmaceutical Partners, Inc.
		DATE OF NAME CHANGE:	20060719
</SEC-HEADER>
<DOCUMENT>
<TYPE>DEF 14A
<SEQUENCE>1
<FILENAME>d500830ddef14a.htm
<DESCRIPTION>DEF 14A
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:cprx="http://www.catalystpharma.com/20221231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022q4" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:ecd="http://xbrl.sec.gov/ecd/2022q4" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>DEF 14A</title>
<meta content="text/html; charset=UTF-8" http-equiv="Content-Type"/>
</head>
<body style=""><div style='display: none'><ix:header><ix:hidden><ix:nonNumeric name="dei:DocumentType" id="hidden83060743" contextRef="P01_01_2022To12_31_2022">DEF 14A</ix:nonNumeric><ix:nonNumeric name="dei:AmendmentFlag" contextRef="P01_01_2022To12_31_2022">false</ix:nonNumeric><ix:nonNumeric name="dei:EntityCentralIndexKey" contextRef="P01_01_2022To12_31_2022">0001369568</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="cprx-20221231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="cprx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="cprx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="cprx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references><ix:resources><xbrli:context id="P01_01_2022To12_31_2022" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:NonPeoNeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:ChangeInValueOfPriorYearAwardsThatVestDuringYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:NonPeoNeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NonPeoNeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:NonPeoNeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:ValueOfNewUnvestedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_NonPeoNeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:NonPeoNeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:SCTEquityAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:PeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:ChangeInValueOfPriorYearAwardsThatVestDuringYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:PeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:PeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:ValueOfNewUnvestedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2020To12_31_2020_PeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:PeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:SCTEquityAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2020-01-01</xbrli:startDate> <xbrli:endDate>2020-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:NonPeoNeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:ChangeInValueOfPriorYearAwardsThatVestDuringYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:NonPeoNeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NonPeoNeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:NonPeoNeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:ValueOfNewUnvestedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_NonPeoNeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:NonPeoNeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:SCTEquityAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:PeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:ChangeInValueOfPriorYearAwardsThatVestDuringYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:PeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:PeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:ValueOfNewUnvestedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2021To12_31_2021_PeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:PeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:SCTEquityAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2021-01-01</xbrli:startDate> <xbrli:endDate>2021-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:NonPeoNeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:ChangeInValueOfPriorYearAwardsThatVestDuringYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:NonPeoNeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NonPeoNeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:NonPeoNeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:ValueOfNewUnvestedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_NonPeoNeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:NonPeoNeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:SCTEquityAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:PeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:ChangeInValueOfPriorYearAwardsThatVestDuringYearMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:PeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:PeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:ValueOfNewUnvestedAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_PeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis" >ecd:PeoMember</xbrldi:explicitMember> <xbrldi:explicitMember dimension="ecd:AdjToCompAxis" >cprx:SCTEquityAwardsMember</xbrldi:explicitMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_4TypedMemberecdMeasureAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ecd:MeasureAxis" > <ecd:MeasureAxis.domain >4</ecd:MeasureAxis.domain> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_3TypedMemberecdMeasureAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ecd:MeasureAxis" > <ecd:MeasureAxis.domain >3</ecd:MeasureAxis.domain> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_2TypedMemberecdMeasureAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ecd:MeasureAxis" > <ecd:MeasureAxis.domain >2</ecd:MeasureAxis.domain> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:context id="P01_01_2022To12_31_2022_1TypedMemberecdMeasureAxis" > <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001369568</xbrli:identifier> <xbrli:segment> <xbrldi:typedMember dimension="ecd:MeasureAxis" > <ecd:MeasureAxis.domain >1</ecd:MeasureAxis.domain> </xbrldi:typedMember> </xbrli:segment> </xbrli:entity> <xbrli:period> <xbrli:startDate>2022-01-01</xbrli:startDate> <xbrli:endDate>2022-12-31</xbrli:endDate> </xbrli:period> </xbrli:context><xbrli:unit id="Unit_USD" > <xbrli:measure>iso4217:USD</xbrli:measure> </xbrli:unit></ix:resources></ix:header></div><div><div><div style="background-color:white;display: inline;"><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div><div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">UNITED STATES </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">SECURITIES AND EXCHANGE COMMISSION </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Washington, D.C. 20549 </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><span style="-sec-ix-hidden:hidden83060743">SCHEDULE 14A</span> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Proxy Statement Pursuant to Section&#160;14(a) of the </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 12pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">Securities Exchange Act of 1934 </div></div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="text-align:center"><div style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by the Registrant&#160;&#160;&#9746; </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Filed by a Party other than the <div style="display:inline;">Registrant&#160;&#160;</div>&#9744; </div><div style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">&#9744;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Preliminary Proxy Statement </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div>&#9744;<div style="letter-spacing: 0px; top: 0px;;display:inline;"></div><div style="letter-spacing: 0px; top: 0px;;display:inline;"></div></td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><div style="font-weight:bold;display:inline;">Confidential, for Use of the Commission Only (as permitted by Rule <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14a-6(e)(2))</div> </div></div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">&#9746;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Definitive Proxy Statement </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">&#9744;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Definitive Additional Materials </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">&#9744;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Soliciting Material Pursuant to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">&#167;240.14a-12</div> </div></td></tr></table><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 18pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;"><ix:nonNumeric name="dei:EntityRegistrantName" contextRef="P01_01_2022To12_31_2022">Catalyst Pharmaceuticals, Inc.</ix:nonNumeric> </div></div><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Name of Registrant as Specified In Its Charter) </div></div><div style="margin-top: 12pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">(Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) </div></div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Payment of Filing Fee (Check the appropriate box): </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">&#9746;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">No fee required. </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">&#9744;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Fee paid previously with preliminary materials </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">&#9744;</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">14a-6(i)(1)</div> and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0-11.</div> </div></td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</div><div style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g500830g0707050509901.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">NOTICE OF ANNUAL MEETING OF STOCKHOLDERS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">TO BE HELD ON AUGUST&#160;22, 2023 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CATALYST PHARMACEUTICALS, INC. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">355 ALHAMBRA CIRCLE, SUITE 801, CORAL GABLES, FLORIDA 33134 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dear Stockholder: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You are cordially invited to our Annual Meeting of Stockholders. The meeting will be a virtual meeting held via the internet on Tuesday, August&#160;22, 2023, beginning at 9:00 a.m. Eastern Time. The meeting will be held for the following purposes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To elect seven directors to serve a term of one year or until their successors are duly elected and qualified, or until their earlier death, resignation, or removal; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve an amendment to our 2018 Stock Incentive Plan to increase the shares available for issuance by three million shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve, on an advisory basis, the 2022 compensation of our named executive officers as set forth herein; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To ratify Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2023; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To transact such other business as may properly come before the meeting. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Annual Meeting will be a virtual meeting of stockholders, which will be conducted exclusively via the internet at a virtual web conference. There will not be a physical meeting location, and stockholders will not be able to attend the Annual Meeting in person. This means that you can attend the Annual Meeting online, vote your shares during the online meeting and submit questions for consideration at the online meeting. Stockholders of record as of the close of business on July&#160;5, 2023 are entitled to notice of and to vote at the Annual Meeting. In order to attend the meeting online, vote your shares electronically during the meeting and submit questions, you must register in advance. Upon completing your registration, you will receive further instructions via email, including your unique links that will allow you access to the meeting and will also permit you to submit questions. Please be sure to follow instructions found on your Notice, proxy card and/or voting instruction form, and subsequent instructions that will be delivered to you via email. We believe that hosting a &#8220;virtual meeting&#8221; will enable greater stockholder attendance and participation from any location around the world. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We encourage all stockholders to attend the Annual Meeting online. Whether or not you plan to attend the Annual Meeting online, we encourage you to read this Proxy Statement and submit your proxy or voting instructions as soon as possible by using the internet as described in the instructions included on your Notice, by calling the toll-free telephone number included in the Proxy Statement, or, if you received a paper copy of the proxy materials, by completing, signing, dating and returning your proxy card. Further </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
information about how to register for the Annual Meeting, attend the Annual Meeting online, vote your shares and submit questions for consideration at the meeting is included in the accompanying Proxy Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thank you for your ongoing support of and your continued interest in Catalyst Pharmaceuticals, Inc. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:100%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">BY ORDER OF THE BOARD OF DIRECTORS</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">


<img src="g500830g0707050510098.jpg" alt="LOGO" />
</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Patrick J. McEnany</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><span style="font-weight:bold">Chairman of the Board</span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Coral Gables, Florida</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">July&#160;12, 2023</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc">TABLE OF CONTENTS </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:96%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>
<td></td>
<td></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_1">General Information About the Annual Meeting and Voting</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_2">Proposal One &#8211; Election of Directors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_3">Information Regarding Directors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">9</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_4">Member of the Board of Directors Not Standing for Re-election</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_5">Corporate Governance</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_6">Compensation of Directors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_7">Proposal Two &#8211; Amending Our 2018 Stock Incentive Plan</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">17</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_8">2018 Stock Incentive Plan</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_9">2014 Stock Incentive Plan</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_10">Proposal 3 &#8211; Advisory Approval of the Compensation of Named Executive Officers</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">25</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_11">Compensation Discussion and Analysis</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">28</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_12">Compensation Committee Report</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">36</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_13">Pay Versus Performance</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">37</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_14">CEO Pay Ratio</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_15">Proposal Four &#8211; Ratification of Appointment of Independent Public Accounting Firm</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_16">Audit Committee Report</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">43</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_17">Security Ownership of Certain Beneficial Owners and Management</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_18">Certain Relationships and Related Party Transactions</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_19">Other Matters</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_20">Contacting the Board of Directors</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_21">Stockholder Proposals</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">47</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_22">Additional Information</a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">48</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><a href="#toc500830_23">Annex A &#8211; Amendment to 2018 Stock Incentive Plan </a></p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">A-1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt;margin-bottom:0pt;text-align:center">


<img src="g500830g0707050509901.jpg" alt="LOGO" />
 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">PROXY STATEMENT FOR THE 2023 ANNUAL MEETING OF STOCKHOLDERS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">TO BE HELD ON TUESDAY, AUGUST&#160;22, 2023 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">INFORMATION REGARDING SOLICITATION AND VOTING </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Proxy Statement contains information about our 2023 Annual Meeting of Stockholders (the &#8220;<span style="font-weight:bold">Annual Meeting</span>&#8221;). The Annual Meeting will be held on Tuesday, August&#160;22, 2023, beginning at 9:00 a.m. Eastern Time. Holders of record of shares of our common stock, par value $0.001 per share (the &#8220;<span style="font-weight:bold">Common Stock</span>&#8221;), as of the close of business on July&#160;5, 2023 (the &#8220;<span style="font-weight:bold">Record Date</span>&#8221;), will be entitled to notice of and to vote at the Annual Meeting and any continuation, postponement or adjournment thereof. As of the Record Date, there were 106,507,108 shares of our Common Stock outstanding and entitled to vote at the Annual Meeting. Each share of Common Stock is entitled to one vote on any matter presented to stockholders at the Annual Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Annual Meeting will be a virtual meeting held via the internet. In order to attend the Annual Meeting online, you must register in the manner set forth below under &#8220;How can I virtually attend the Annual Meeting of Stockholders?&#8221;. Upon completing your registration, you will receive further instructions via <span style="white-space:nowrap">e-mail,</span> including your unique links that will allow you access to the meeting. Please be sure to follow instructions found on your proxy card and subsequent instructions that will be delivered to you via <span style="white-space:nowrap">e-mail.</span> There will not be a physical meeting location, and stockholders will not be able to attend the annual meeting of stockholders in person. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except where the context otherwise requires, references to &#8220;Catalyst Pharmaceuticals&#8221;, &#8220;Catalyst&#8221;, &#8220;the Company&#8221;, &#8220;we&#8221;, &#8216;us&#8221;, &#8220;our&#8221;, and similar terms refer to Catalyst Pharmaceuticals, Inc. and its consolidated subsidiary. References to our website are inactive textual references only and the contents of our website are not incorporated by reference to this Proxy Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Proxy Statement and the enclosed proxy card are being furnished in connection with the solicitation of proxies by our board of directors for use at the Annual Meeting and any adjournment thereof. All proxies will be voted in accordance with the instructions they contain. If you do not specify your voting instructions on the proxy, your shares will be voted in accordance with the recommendations of our board of directors. This Proxy Statement, the related proxy card and our annual report to stockholders are being mailed to stockholders on or about July&#160;12, 2023. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">FOR THE ANNUAL MEETING OF STOCKHOLDERS: </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">This Proxy Statement and our 2022 Annual Report to Stockholders are available at: </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">http://ir.catalystpharma.com/annual-proxy.cfm</span>. </p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_1">G<small>ENERAL</small> I<small>NFORMATION</small> A<small>BOUT</small> <small>THE</small> A<small>NNUAL</small> M<small>EETING</small> <small>AND</small> V<small>OTING</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Why did I receive this proxy statement? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You have received these proxy materials because the board of directors is soliciting your proxy to vote at the Annual Meeting. This proxy statement contains information that we are required to provide you under the rules of the Securities and Exchange Commission (&#8220;<span style="font-weight:bold">SEC</span>&#8221;). This information is designed to assist you in voting your shares. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What is the purpose of the Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At the Annual Meeting, stockholders will consider and vote on the following matters: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To elect seven directors to serve a term of one year or until their successors are duly elected and qualified, or until their earlier death, resignation, or removal; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve an amendment to our 2018 Stock Incentive Plan to increase the shares available for issuance by three million shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To approve, on an advisory basis, the 2022 compensation of our named executive officers as set forth herein; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To ratify Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2023; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">To transact such other business as may properly come before the meeting. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently know of no other business that will be presented at the Annual Meeting. If any other matter properly comes before the stockholders for a vote at the Annual Meeting, however, the proxy holders named on the Company&#8217;s proxy card will vote your shares in accordance with their best judgement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What are the recommendations of the Board of Directors? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board recommends that you vote your shares as indicated below. If you return a properly completed proxy card, or vote your shares by telephone or internet, your shares of Common Stock will be voted on your behalf as you direct. If not otherwise specified, the shares of common stock represented by the proxies will be voted, and the Board recommends that you vote, as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold">FOR</span> the election of seven directors to serve a term of one year or until their successors are duly elected and qualified, or until their earlier death, resignation, or removal; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold">FOR</span> the approval of an amendment to our 2018 Stock Incentive Plan to increase the shares available for issuance by three million shares; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold">FOR</span> the approval, on an advisory basis, the 2022 compensation of our named executive officers as set forth herein; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="font-weight:bold">FOR</span> the ratification of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2023. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">2 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If any other matter properly comes before the stockholders for a vote at the Annual Meeting, the proxy holders named on our proxy card will vote your shares in accordance with their best judgement. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Who is entitled to vote on matters presented at the Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Record Date for the Annual Meeting is July&#160;5, 2023. You are entitled to vote on the matters presented at the Annual Meeting if you owned shares of our common stock as the close of business on the Record Date. Each outstanding share of Common Stock is entitled to one vote for all matters before the Annual Meeting. At the close of business on the Record Date, there were 106,507,108 shares of Common Stock outstanding and entitled to vote at the Annual Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What is the difference between being a &#8220;Record Holder&#8221; and holding shares in &#8220;Street Name&#8221;? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, on the Record Date, your shares were registered directly in your name with our transfer agent, you are a stockholder of record. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If, on the Record Date, your shares were held in an account at a brokerage firm, bank, dealer or other similar organization, then you are the beneficial owner of shares held in &#8220;street name&#8221; and these proxy materials are being forwarded to you by that organization. The organization holding your account is considered the stockholder of record for purposes of voting at the Annual Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Am I entitled to vote if my shares are held in &#8220;Street Name&#8221;? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. If your shares are held in street name, these proxy materials, along with instructions on how to vote your shares, are being provided to you by your brokerage firm, bank, dealer or other similar organization. As the beneficial owner, you have the right to direct your brokerage firm, bank, dealer or other similar organization how to vote your shares, and the brokerage firm, bank, dealer or other similar organization is required to vote your shares in accordance with your instructions. If your shares are held in street name, you may not vote your shares at the Annual Meeting unless you obtain, and present at the Annual Meeting, a legal proxy from your brokerage firm, bank, dealer or other organization. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">How many shares must be present to hold the Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A quorum must be present at the Annual Meeting for any business to be conducted. Under Delaware law and our Bylaws, the presence at the Annual Meeting online, or by proxy, of the holders of a majority in voting power of the Common Stock issued and outstanding entitled to vote, on the Record Date, will constitute a quorum for the transaction of business at the Annual Meeting. The inspector of elections will determine whether a quorum is present and will tabulate the votes cast at the Annual Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">How can I virtually attend the Annual Meeting of Stockholders? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As noted above, we have decided to hold the Annual Meeting entirely online. You may virtually attend the Annual Meeting only if you are a record holder or beneficial owner of our Common Stock as of the Record Date. The process for attending the Annual Meeting and casting your vote at the Annual Meeting depends on the manner in which you hold your shares: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Registered Stockholders</span></span><span style="font-weight:bold">. </span>If your shares are registered in your name with our transfer agent, Continental Stock Transfer and Trust Company (&#8220;<span style="font-weight:bold">Continental</span>&#8221;) and you wish to attend the online-only virtual Annual Meeting, go to <span style="font-weight:bold"><span style="text-decoration:underline">www.cstproxy.com/catalystpharma/2023</span></span>, enter the control number you received on your proxy card (printed in the box and marked with an arrow) and click on the &#8220;<span style="font-style:italic">Click Here to Preregister for the Online Meeting</span>&#8221; link at the top of the page. Just prior to the start of the meeting you will need to log back into the meeting site using your control number. <span style="white-space:nowrap">Pre-registration</span> is recommended but is not required to attend. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">3 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="font-weight:bold"><span style="font-style:italic">Street Name Stockholders</span></span><span style="font-weight:bold">. </span>Street name stockholders who wish to attend the online-only virtual Annual Meeting must obtain a legal proxy by contacting their account representative at the bank, broker, or other nominee that holds their shares and email a copy (a legible photograph is sufficient) of their legal proxy to <span style="font-weight:bold"><span style="text-decoration:underline">proxy@continentalstock.com</span></span>. Street name stockholders who email a valid legal proxy will be issued a meeting control number that will allow them to register to attend and participate in the online-only Annual Meeting. After contacting Continental, a street name stockholder will receive an <span style="white-space:nowrap">e-mail</span> prior to the meeting with a link and instructions for entering the virtual Annual Meeting. Street name stockholders should contact Continental at least five (5)&#160;business days prior to the Annual Meeting date. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Will there be a question and answer session during the annual meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders participating in the virtual Annual Meeting will be in a listen-only mode and will not be able to speak during the webcast. However, in&#160;order to maintain the interactive nature of the virtual meeting, virtual attendees are able to: (i)&#160;vote using the online meeting website, and (ii)&#160;submit&#160;questions or comments to our officers during the meeting via <span style="white-space:nowrap">e-mail</span> or the virtual meeting webcast. Starting Tuesday, August&#160;15, 2023 at 9:00&#160;a.m. Eastern Time, stockholders may submit questions or comments before or during the meeting through the virtual meeting portal by typing in the &#8220;<span style="font-style:italic">Submit a Question</span>&#8221; box. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Can I listen to the Annual Meeting without attending? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders will have the option to call in to the virtual Annual Meeting by telephone and listen (in listen-only mode) by calling: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:44%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:12%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:42%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Within the U.S. and Canada (toll free):</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center"><span style="white-space:nowrap">(800)&#160;450-7155</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Outside the U.S. and Canada (standard rates apply):</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">(857) <span style="white-space:nowrap">999-9155</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Passcode for telephone access:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top" align="center">7086542#</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What if a quorum is not present at the Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If a quorum is not present at the scheduled time of the Annual Meeting, the Chairperson of the Annual Meeting is authorized by our Bylaws to adjourn the Annual Meeting until a quorum is present or represented. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What does it mean if I receive more than one set of proxy materials? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you receive more than one set of proxy materials, your shares are held in more than one account at the transfer agent and/or with banks or brokers. Please vote all of your shares. To ensure that your shares are voted, for each set of proxy materials, please submit your proxy via phone, via the internet or by signing, dating and returning the enclosed proxy card in the enclosed <span style="white-space:nowrap">pre-paid</span> envelope. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">How do I vote? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">You may vote over the internet, the phone, via mail, or at the Annual Meeting. Your proxy will have specific information on the manner in which you can vote your shares. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">4 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Can I change my vote after I submit my proxy? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Yes. If you are a record holder, you may revoke your proxy and change your vote at any time before the proxy is voted at the Annual Meeting: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by submitting a duly executed proxy bearing a later date than your prior proxy; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by granting a subsequent proxy through the internet or via telephone; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by giving written notice of revocation to our corporate secretary at or prior to the Annual Meeting; or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">by voting online at the Annual Meeting. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Your most recent proxy is the one that is counted. Your attendance virtually at the Annual Meeting will not by itself revoke your proxy. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If your shares are held in street name, you may change or revoke your voting instructions by following the specific directions provided to you by your bank or broker, or you may vote virtually at the Annual Meeting by obtaining a legal proxy from your bank or broker and submitting the legal proxy along with your ballot at the Annual Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Who will count the votes? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A representative from Continental will tabulate and certify the votes, and a representative from the Company will act as inspector of elections. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What if I do not specify how my shares are to be voted? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a record holder and you indicate when voting on the Internet or by telephone that you wish to vote as recommended by the Board, then your shares will be voted at the Annual Meeting in accordance with the Board&#8217;s recommendation on all matters presented for a vote at the Annual Meeting. Similarly, if you are a record holder and submit a proxy but do not indicate any voting instructions, the persons named as proxies will vote in accordance with the recommendations of the Board. The Board&#8217;s recommendations are indicated on page 2 of this proxy statement, along with the description of each proposal in this proxy statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If you are a beneficial owner of shares held in street name and do not provide the organization that holds your shares with specific voting instructions, then, the organization that holds your shares may generally vote your shares in their discretion on &#8220;routine&#8221; matters but cannot vote on <span style="white-space:nowrap">&#8220;non-routine&#8221;</span> matters. If the organization that holds your shares does not receive instructions from you on how to vote your shares on a <span style="white-space:nowrap">non-routine</span> matter, that organization will inform the inspector of election that it does not have the authority to vote on that matter with respect to your shares. This is generally referred to as a &#8220;broker <span style="white-space:nowrap">non-vote.&#8221;</span> </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What are broker <span style="white-space:nowrap">non-votes</span> and do they count for determining the quorum? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares represented by proxies that reflect a broker <span style="white-space:nowrap">non-vote</span> will be counted as present for purposes of determining the presence of a quorum. As discussed above, broker <span style="white-space:nowrap">non-votes</span> occur when shares held by a broker in &#8220;street name&#8221; for a beneficial owner are not voted with respect to a particular proposal because (i)&#160;the broker has not received voting instructions from the beneficial owner and (ii)&#160;the broker lacks discretionary voting power to vote those shares on a particular matter. A broker has discretionary power to vote shares without instruction from the beneficial owner on routine matters, such as the ratification of the appointment of Grant Thornton LLP as our independent registered public accounting firm. Thus, broker </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">5 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<span style="white-space:nowrap">non-votes</span> are not expected on that proposal. On the other hand, absent instructions from the beneficial owner of such shares, a broker is not entitled to vote shares held for a beneficial owner on <span style="white-space:nowrap">non-routine</span> matters. Broker <span style="white-space:nowrap">non-votes</span> on the election of directors, which is considered a <span style="white-space:nowrap">non-routine</span> matter, will have no effect because they are not considered votes cast. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">What is an abstention and how will votes withheld and abstentions be treated? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of common stock held by persons attending the Annual Meeting but not voting, and shares represented by proxies that reflect withheld votes or abstentions as to a particular proposal, will be counted as present for purposes of determining the presence of a quorum. A &#8220;vote withheld,&#8221; in the case of the proposal regarding the election of directors, or an &#8220;abstention,&#8221; in the case of the ratification of the appointment of Grant Thornton LLP, represents a stockholder&#8217;s affirmative choice to decline to vote on a proposal. Votes withheld have no effect on the election of directors, as the seven directors that receive the highest number of votes will be elected, and abstentions are not considered to be a vote cast and will have no effect on the ratification of the appointment of Grant Thornton LLP. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">How many votes are required for the approval of the proposals to be voted on and how will abstentions and broker <span style="white-space:nowrap">non-votes</span> be treated? </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center">Proposal</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center">Votes Required</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:center">Effect of Votes</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;text-align:center">Withheld/Abstentions and</p> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center">Broker <span style="white-space:nowrap">Non-Votes</span></p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal 1: Election of Directors</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The affirmative vote of a plurality of the votes cast by the holders of our common stock for each director nominee.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Votes withheld and broker <span style="white-space:nowrap">non-votes</span> will have no effect.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal 2: Amendment to our 2018 Stock Incentive Plan</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The affirmative vote of a majority of the votes cast for or against the matter.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Votes withheld and broker <span style="white-space:nowrap">non-votes</span> will have no effect.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal 3: Advisory Approval of the Compensation of Named Executive Officers</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The affirmative vote of a majority of the votes cast for or against the matter.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Votes withheld and broker <span style="white-space:nowrap">non-votes</span> will have no effect.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Proposal 4: Ratification of Appointment of our Independent Registered Public Accounting Firm</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">The affirmative vote of a majority of the votes cast for or against the matter.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Abstentions will have no effect. We do not expect any broker <span style="white-space:nowrap">non-votes</span> on this proposal.</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Will any other business be conducted at the Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We currently know of no other business that will be properly presented at the Annual Meeting. If any such business does properly come before the meeting, however, your shares will be voted in accordance with the best judgement of the proxy holders named on your proxy card. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">6 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Where can I find the voting results of the Annual Meeting? </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We plan to announce the preliminary voting results at the Annual Meeting and will report the final results in a Current Report on Form <span style="white-space:nowrap">8-K,</span> which we intend to file with the SEC within four business days after the Annual Meeting. If final voting results are not available to us in time to file a Form <span style="white-space:nowrap">8-K</span> within four business days after the Annual Meeting, we intend to file a Form <span style="white-space:nowrap">8-K</span> to publish preliminary results and, within four business days after the final results are known to us, file an additional Form <span style="white-space:nowrap">8-K</span> to publish the final results. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="text-decoration:underline">P<small>ROPOSALS</small> <small>TO</small> <small>BE</small> V<small>OTED</small> O<small>N</small></span><small></small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_2">P<small>ROPOSAL</small> O<small>NE</small> &#8211; E<small>LECTION</small> <small>OF</small> D<small>IRECTORS</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following paragraphs provide information as of the date of this Proxy Statement about each director and nominee for director, as furnished to us by the directors and nominees for director. The information presented includes information each such individual has given us about his or her age, all positions he or she holds, his or her principal occupation and business experience for the past five years, and the names of other publicly held companies of which he or she currently serves as a director or has served as a director during the past five years. In addition to the information presented below regarding each such individual&#8217;s specific experience, qualifications, attributes and skills that led our board of directors to the conclusion that he or she should serve as a director, we also believe that each of our directors and director nominees has a reputation for integrity, honesty and adherence to high ethical standards. Each has demonstrated business acumen and an ability to exercise sound judgment, as well as a commitment of service to our company and our board of directors. Finally, we value their significant experience on other public company boards of directors and board committees. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about the number of shares of common stock beneficially owned by each of our directors and nominees for director appears below under the heading &#8220;Security Ownership of Certain Beneficial Owners and Management.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships between or among any of our executive officers, directors or nominees for director. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">7 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">N<small>OMINEES</small> <small>FOR</small> E<small>LECTION</small> <small>TO</small> <small>THE</small> B<small>OARD</small> <small>OF</small> D<small>IRECTORS</small> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:19%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:15%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:53%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Age</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center">Independent</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Committee Membership</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. McEnany</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">76</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Chairman,&#160;President and CEO</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard J. Daly</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">62</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">X</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Compensation; Nominating and Corporate Governance</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Donald A. Denkhaus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">77</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">X</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Audit (Chair); Nominating and Corporate Governance</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Molly Harper</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">47</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">X</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Compensation; Nominating and Corporate Governance</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles B. O&#8217;Keeffe</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">83</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Lead Independent Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">X</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Audit; Compensation; Nominating and Corporate Governance</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tamar Thompson</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">49</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">X</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David S. Tierney, MD</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">60</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">X</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Compensation (Chair), Nominating and Corporate Governance</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event any of the nominees should become unable to serve, or for good cause will not serve, as a director, it is intended that votes will be cast for a substitute nominee designated by the Board or the Board may elect to reduce its size. The Board has no reason to believe that the nominees named below will be unable to serve if elected. Each of the nominees has consented to being named in this proxy statement and to serve if elected. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All of the persons whose names and biographies appear below are currently serving as our directors. Each of our directors brings to the Board significant leadership experience derived from their professional experience and service as executives or board members of other corporations and/or private equity and venture capital firms. The process undertaken by the Nominating and Corporate Governance Committee in recommending qualified director candidates is described below under &#8220;Board Diversity&#8221; and &#8220;Director Qualifications and Attributes.&#8221; Certain individual qualifications and skills of our directors that contribute to the Board&#8217;s effectiveness as a whole are described in the following paragraphs. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The election of directors requires a plurality of the votes cast by the holders of our common stock. A &#8220;plurality&#8221; means that each director must receive a greater number of votes cast for their retention on the board of directors than those cast against. Consequently, any shares not voted (whether by abstention, broker <span style="white-space:nowrap">non-vote</span> or otherwise) have no impact on the election of directors. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Board of Directors recommends a vote in favor of the seven persons listed above who have been nominated for election to the Board of Directors. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">8 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Consideration of Future Nominees </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating&#160;&amp; Corporate Governance Committee will consider director candidates recommended by our stockholders. Any stockholder wishing to submit a recommendation with respect to the 2024 Annual Meeting of Stockholders should send a signed letter of recommendation to us at 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134, Attention: Corporate Secretary. To be considered, recommendation letters must be received between February&#160;6, 2024 and March&#160;7, 2024, and must include: (i)&#160;all information about the nominee required to be disclosed in solicitations of proxies in an election contest; (ii)&#160;the written consent of the nominee to the nomination and such nominee&#8217;s willingness to serve if elected; and (iii)&#160;the name and address of the stockholder making such recommendation, the class and number of shares of capital stock the stockholder owns, and a representation by the stockholder that such stockholder is a holder of record of stock of the corporation entitled to vote at such meeting and intends to appear, in person or by proxy, to propose such nomination. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_3">I<small>NFORMATION</small> R<small>EGARDING</small> D<small>IRECTORS</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The information set forth below as to the directors and nominees for director has been furnished to us by the directors and nominees for director. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Nominees for Election to the Board: </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Patrick J. McEnany</span> is a <span style="white-space:nowrap">co-founder</span> of our company and currently serves as our Chairman, President and Chief Executive Officer (&#8220;CEO&#8221;). Mr.&#160;McEnany has been our CEO and a director since our formation in January 2002. He became Chairman and President in March 2006. From 1999 to 2002, Mr.&#160;McEnany was a consultant to the pharmaceutical industry. From 1991 to 1997, Mr.&#160;McEnany was Chairman and CEO of Royce Laboratories, Inc., a generic pharmaceutical manufacturer. From 1997 to 1998, after the merger of Royce into Watson Pharmaceuticals, Inc., Mr.&#160;McEnany served as president of the wholly-owned Royce Laboratories subsidiary and vice president of corporate development for Watson Pharmaceuticals, Inc. From 1993 to 1997, he also served as vice chairman and a director of the National Association of Pharmaceutical Manufacturers. He currently serves on an emeritus board of directors of the Jackson Health Foundation and on the board of directors of the Humane Society of Greater Miami, and over the last 30 years has served as a director for numerous public companies. The Board believes the characteristics that qualify Mr.&#160;McEnany as a director to serve on our Board include his long-term experience in the pharmaceutical industry and his extensive business leadership experience. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Richard J. Daly</span>&#160;joined our Board in February 2015. Mr.&#160;Daly currently serves as President of CARsgen Therapeutics Corporation, an emerging oncology company focused on developing <span style="white-space:nowrap">CAR-T</span> therapies for both liquid and solid tumors. From July 2018 through January 2022, Mr.&#160;Daly served as Chief Operating Officer of BeyondSpring Pharmaceuticals, <span style="white-space:nowrap">a&#160;pre-commercial&#160;biotech</span> company focused on oncology with assets in late Phase 3 clinical trials. Before joining BeyondSpring in August 2018, (i) from February 2016 to July 2018 Mr.&#160;Daly served as Chairman and CEO of Neuralstem, Inc., a biopharmaceutical company focused on the development of central nervous system therapies based on its neuronal stem cell technology, (ii)&#160;from October 2014 to September 2016, Mr.&#160;Daly served as a partner of RavineRock Partners, a commercial consulting practice focused on biotech and pharmaceuticals, and (iii)&#160;from February 2013 to September 2014, Mr.&#160;Daly served as President of AstraZeneca US Diabetes. Mr.&#160;Daly served on the board of directors of Opiant Pharmaceuticals, and as a member of that board&#8217;s Compensation and Audit Committees, from 2018 until the sale of that company in 2023. From June 2015 to June 2018 Mr.&#160;Daly also served on the Board of Directors of Synergy Pharmaceuticals, where he chaired the Nominations/Corporate Governance Committee and was a member of the Compensation Committee. Mr.&#160;Daly received his Bachelor of Science in Microbiology from the University of Notre Dame in 1983 and his MBA from the Kellogg School of Management, Northwestern University in 1998. The Board believes that the </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">9 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
characteristics that qualify Mr.&#160;Daly to be a director of our company include his significant pharmaceutical industry experience and his experience in launching and managing sales of numerous pharmaceutical products, including several products that are used to treat orphan/rare diseases. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Donald A. Denkhaus </span>joined our Board in February 2015 and currently chairs the Audit Committee of our Board. Since 2005, Mr.&#160;Denkhaus has been Chairman and Chief Financial Officer of The Kitchen, LLC, a company providing language dubbing and subtitling services to the media and entertainment industry. From 1970 through 2002, Mr.&#160;Denkhaus, who is a retired certified public accountant, worked for Arthur Andersen LLP, a global professional services organization, where he was an audit partner for <span style="white-space:nowrap">twenty-two</span> years and held numerous leadership positions, including as head of Andersen&#8217;s South Florida audit practice and, from 1998 through 2002, as Audit Practice Partner responsible for Andersen&#8217;s offices in Florida and Puerto Rico. From 2010 to 2013, Mr.&#160;Denkhaus was Chair of Nuovo Biologics, a privately held biotech company that was developing an antiviral drug for animal use, and, from 2004 until its sale in 2009, Mr.&#160;Denkhaus served on the board of directors and as chair of the audit committee of Noven Pharmaceuticals, a publicly-traded specialty pharmaceutical company focused on women&#8217;s health and psychiatry. Mr.&#160;Denkhaus received a Master&#8217;s in Business Administration degree with a major in finance from the University of Maryland and a Bachelor of Business Administration with a major in accounting from Kent State University. The Board believes that the characteristics that qualify Mr.&#160;Denkhaus to be a member of our Board include his extensive financial experience and his prior experience serving as a director of two pharmaceutical companies, one of which was publicly-traded. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Molly Harper </span>joined our Board in June 2021. Ms.&#160;Harper has over 20 years of experience focusing on strategic planning and cross-functional leadership at life sciences companies of all sizes. Since September 2021, Ms.&#160;Harper has been the Chief Business Officer of Synlogic, Inc., a clinical-stage biopharmaceutical company focused on the discovery and development of Synthetic Biotics using Synlogic&#8217;s proprietary drug discovery and development platform. Prior thereto, from May 2020 until September 2021, Ms.&#160;Harper served as Executive Vice President of Operations for Relmada Therapeutics, Inc., a late-stage biotechnology company addressing diseases of the central nervous system. Prior to joining Relmada, Ms.&#160;Harper served in positions of increasing responsibility with Akcea Therapeutics, a development and commercialization company focused on rare diseases, where she was most recently Senior Vice President and Global Franchise General Manager with cross-functional responsibility for a six drug portfolio including two approved rare disease drugs. She was one of the first employees at Akcea, which she joined as VP of Commercial Development. Prior to joining Akcea, Ms.&#160;Harper was Head of US Endocrinology in the Rare Disease division of Sanofi Genzyme. Ms.&#160;Harper&#8217;s experience at Genzyme included global and U.S. marketing leadership positions, and she previously held positions across sales and marketing in both primary care and hospital businesses at Merck&#160;&amp; Co. Prior to joining Merck, Ms.&#160;Harper worked in life sciences equity research at UBS Warburg, and as a strategy consultant with The Wilkerson Group/IBM. Ms.&#160;Harper received her Bachelor of Arts from Cornell University and her Master of Business Administration from the Wharton School of the University of Pennsylvania. Ms.&#160;Harper also serves on the Board of Directors of PreciseDx, a privately held oncology AI pathology company. The Board believes that the characteristics that qualify Ms.&#160;Harper to be a director of our company include her significant pharmaceutical industry experience and her experience in pharmaceutical company operations overseeing the development, launch and commercialization of several pharmaceutical products, including several products that are used to treat orphan/rare diseases. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Charles B. O&#8217;Keeffe </span>has served as a member of our Board since December 2004 and became our lead independent director in July 2011. Mr.&#160;O&#8217;Keeffe also served as a consultant to us from December 2004 until June 2011. Mr.&#160;O&#8217;Keeffe is a Professor in the Departments of Pharmacology, Epidemiology and Community Health at Virginia Commonwealth University (&#8220;VCU&#8221;) and has served in such capacity since January&#160;1, 2004. Mr.&#160;O&#8217;Keeffe joined VCU after retiring as President and Chief Executive Officer of Reckitt Benckiser Pharmaceuticals, Inc., a position Mr.&#160;O&#8217;Keeffe held from 1991 until 2003. As President </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">10 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
of Drug Abuse Rehabilitation Services (from 1970 until 1971), he developed the first child-resistant, abuse-resistant vehicle for dispensing methadone. He served as president of Washington Reference Laboratories from 1972 until 1975, which provided toxicology services to the Department of Defense during the Vietnam War. He has served in the White House (from 1970 until 1973 and from 1976 until 1980) for three presidents&#8212;as advisor, special assistant for international health and deputy director for international affairs in the Office of Drug Abuse Policy&#8212;and has served on U.S. delegations to the World Health Assembly and the U.N. Commission on Narcotic Drugs. The Board believes the characteristics that qualify Mr.&#160;O&#8217;Keeffe to serve as a member of our Board include his extensive history of leadership roles in the pharmaceutical industry and his extensive knowledge of all parts of the pharmaceutical industry. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Tamar Thompson</span> joined our Board on May&#160;25, 2023. Ms.&#160;Thompson has served as Vice President/Head of Global Corporate Affairs for Alexion Pharmaceuticals/AstraZeneca Rare Disease since 2021, when Alexion was acquired by AstraZeneca. Prior thereto, from 2019 to 2021, Ms.&#160;Thompson was Vice President, Global Corporate Affairs for Alexion Pharmaceuticals. Further, prior to joining Alexion, from February 2015 to November 2019, when she joined Alexion, Ms.&#160;Thompson served in several capacities for Bristol-Myers Squibb Company, most recently as executive director of State Government Affairs and Federal Policy. Prior to joining Bristol-Myers Squibb, Ms.&#160;Thompson was a strategic policy advisor and consultant for premiere Washington, DC based governmental affairs firms, including ADVI, Kimbell and Associates and Avalere Health. Finally, since 2020, Ms.&#160;Thompson has served as an independent director of Avidity Biosciences, Inc., where she serves on the Nominating and Governance Committee and on the Compensation Committee of that board. She also serves as Vice Chair of the board of directors of MassBio, a premier state level trade association representing the biotech sector in Massachusetts. Ms.&#160;Thompson holds an M.S. in Health Sciences with a concentration in Public Health from Trident University in Cypress, California. The Board believes that Ms.&#160;Thompson&#8217;s extensive health policy and government affairs experience, as well as her focus on rare diseases in her current position, have contributed to our Board of Directors&#8217; conclusion that she should serve as a Director of our company. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">David S. Tierney, M.D.</span> has served as a member of our Board since October 2002 and currently chairs the Compensation Committee of our Board. Dr.&#160;Tierney currently serves as Chief Executive Officer and Director of Aramis Biosciences, a privately held clinical stage ophthalmology pharmaceutical company. From February 2020 until December 2020, Dr.&#160;Tierney served as CEO of Pharma Two B, a CNS specialty pharmaceutical company. From September 2018 until January 2020, Dr.&#160;Tierney served as President&#160;&amp; CEO of BioPharmX Corporation, a dermatology specialty pharmaceutical company. He also served on the Board of Directors of BioPharmX from September 2018 until May 2020. From January 2014 until March 2018, he served as President&#160;&amp; CEO of Icon Bioscience, Inc., a privately held ophthalmic drug delivery company. Dr.&#160;Tierney served as President and Chief Operating Officer (and a member of the board of directors) of Oceana Therapeutics, Inc., a private specialty pharmaceutical company between the organization of that company in 2008 and the sale of that company to Salix Pharmaceuticals, Ltd. in December 2011. Dr.&#160;Tierney also served as the President and CEO (and as a member of the board of directors) of Valera Pharmaceuticals, Inc. a specialty pharmaceutical company, between August 2000 and April 2007, when Valera completed a merger with Indevus Pharmaceuticals, Inc. Further, from January 2000 to August 2000, Dr.&#160;Tierney served as President of Biovail Technologies, a division of Biovail Corporation, a Canadian drug delivery company, where he was responsible for all of Biovail&#8217;s research and development, regulatory and clinical activities. Finally, from March 1997 to January 2000, Dr.&#160;Tierney was Senior Vice President of Drug Development at Roberts Pharmaceutical Corporation, where he was responsible for all research and development activities, and for drug development, medical affairs, worldwide regulatory affairs and chemical process development, as well as being part of the executive management team, and from December 1989 to March 1997, Dr.&#160;Tierney was employed by &#201;lan Corporation, a pharmaceutical company, in a variety of management positions. Dr.&#160;Tierney was until recently a director of Kempharm, Inc. (n/k/a Zevra Therapeutics) and is currently a director of Bimeda, Inc. Dr.&#160;Tierney received his medical degree from the Royal College of Surgeons in Dublin, Ireland and was </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">11 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
subsequently trained in internal medicine. The Board believes the characteristics that qualify Dr.&#160;Tierney to serve on our Board include his business leadership experience and his pharmaceutical industry experience. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_4">M<small>EMBER</small> <small>OF</small> <small>THE</small> B<small>OARD</small> <small>OF</small> D<small>IRECTORS</small> N<small>OT</small> S<small>TANDING</small> <small>FOR</small> R<small>E</small><span style="white-space:nowrap">-</span><small>ELECTION</small> </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:19%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:6%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:7%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:62%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Age</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman">Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;text-align:center">Independent</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Committee Membership</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philip H. Coelho</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">79</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Director</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top" align="center">X</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Audit; Nominating and Corporate Governance (Chair)</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Philip H. Coelho</span><span style="font-weight:bold"></span>&#160;has served as a member of our board of directors since October 2002. On March&#160;29, 2023, Mr.&#160;Coelho informed the board of directors of his decision not to stand for <span style="white-space:nowrap">re-election</span> at the Annual Meeting when his current term expires. Upon the expiration of his term as a director, Mr.&#160;Coelho will also cease serving as the chair of our Nominating and Corporate Governance Committee and as a member of our Audit Committee. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_5">C<small>ORPORATE</small> G<small>OVERNANCE</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Section&#160;16(a) Beneficial Ownership Reporting Compliance </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&#160;16(a) of the Securities Exchange Act of 1934 (the &#8220;<span style="font-weight:bold">Exchange Act</span>&#8221;) requires our officers and directors and persons who own more than 10% of our outstanding common stock to file with the Securities and Exchange Commission reports of changes in their ownership of common stock. Officers, directors, and greater than 10% stockholders are also required to furnish us with copies of all forms they file under this regulation. To our knowledge, based solely on a review of the copies of such reports furnished to us and representations made to us that no other reports were required, during the year ended December&#160;31, 2022 all Section&#160;16(a) filings required to be filed by our officers, directors, and greater than 10% stockholders were timely filed. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Independent Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As required under applicable NASDAQ listing standards, a majority of the members of a listed company&#8217;s board of directors must qualify as &#8220;independent,&#8221; as affirmatively determined by the listed company&#8217;s board of directors. The Board consults with our counsel to ensure that its determinations are consistent with all relevant securities and other laws and regulations regarding the definition of &#8220;independent,&#8221; including those set forth in pertinent NASDAQ listing standards, as in effect from time to time. Consistent with these considerations, the Board has affirmatively determined that all of our directors (other than Mr.&#160;McEnany, who serves as our CEO) are &#8220;independent directors&#8221; within the meaning of the applicable NASDAQ listing standards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Corporate Governance </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board and management are committed to utilizing good corporate governance practices to ensure we are managed for the long-term benefit of our stockholders. We have in place a variety of policies and practices to promote good corporate governance. A majority of our Board is independent, in accordance with applicable NASDAQ listing standards, and all members of the Audit Committee, Compensation Committee, and Nominating&#160;&amp; Corporate Governance Committee of our Board also meet applicable NASDAQ listing standards for independence. We have also established: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">written charters for the Audit, Compensation, and Nominating&#160;&amp; Corporate Governance Committees that address corporate governance practices in accordance with the Sarbanes-Oxley Act, current NASDAQ corporate governance guidelines, and other applicable rules and regulations; </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">12 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a Code of Business Conduct and Ethics applicable to our officers, directors, and employees; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">a procedure for receipt and treatment of anonymous and confidential complaints or concerns on any matter, including audit or accounting matters; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">disclosure control policies and procedures. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Nominating&#160;&amp; Corporate Governance Committee is responsible for establishing and reviewing our corporate governance guidelines from time to time and reporting and making recommendations to the Board concerning corporate governance matters. Among the matters addressed by our corporate governance guidelines are: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Director Independence</span> &#8211; Independent directors shall constitute at least a majority of our Board and of our Board committees in accordance with the independence standards set forth in the applicable NASDAQ listing standards. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left"><span style="text-decoration:underline">Executive Sessions of Independent Directors</span> &#8211; Our independent directors regularly meet in executive session without management present. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Copies of our Code of Business Conduct and Ethics can be found on the corporate governance page of the Investor Relations section of our website, which is located at <span style="text-decoration:underline">http://ir.catalystpharma.com/governance.cfm</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Diversity </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Nominating&#160;&amp; Corporate Governance Committee considers diversity as one of several factors relating to overall composition when recommending nominations to our Board. Although we do not have a formal policy governing how diversity is considered, the Nominating&#160;&amp; Corporate Governance Committee believes that diversity is an aspect that should be considered with respect to director nominations. The Nominating&#160;&amp; Corporate Governance Committee considers diversity by examining the entire Board membership and construes&#160;board&#160;diversity&#160;broadly to include many factors, including, but not limited to, gender, age, race and ethnicity. As a result, the Nominating&#160;&amp; Corporate Governance Committee strives to ensure when recommending nominations to our Board that our Board is represented by individuals with a variety of different opinions, perspectives, personal, professional, and industry experience and backgrounds, skills, and expertise. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Information about the diversity of our Board of Directors and our Board Diversity Matrix is as follows. Information is as of the conclusion of the Annual Meeting and assumes that all directors standing for <span style="white-space:nowrap">re-election</span> have indeed been <span style="white-space:nowrap">re-elected</span> to the Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><span style="font-style:italic">[chart on next page] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">13 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:76%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Female</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Male</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="white-space:nowrap">Non-</span><br />Binary</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Did Not<br />Disclose<br />Gender</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Part I: Gender Identity</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td>
<td style="height:6pt" colspan="4"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman;font-weight:bold">Part II: Demographic Background</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">African-American or Black</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alaskan Native or Native American</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hispanic or Latinx</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Native Hawaiian or Pacific Islander</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">White</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Two or More Races or Ethnicities</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">LGBTQ+</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The table above provides certain information regarding the composition of our Board. Each of the categories listed in the above table has the meaning as it is used in Nasdaq Rule 5605(f) and related instructions. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Director Qualifications and Attributes </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have concluded that all of our directors have the skills, experience, knowledge, and personal attributes that are necessary to effectively serve on our Board and to contribute to the overall success of the Company. We believe that the diverse professional background of each of our directors ensures that we have a Board that has a broad range of industry-related knowledge, experience, and business acumen. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Leadership Structure </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Patrick J. McEnany serves as both our Chairman of the Board and CEO. The Board and its independent members believe that the most effective board leadership structure at the present time is for the CEO to serve as both Chairman of the Board and CEO, a structure that has served us well in the past. The independent members of the Board believe that because the CEO is ultimately responsible for our <span style="white-space:nowrap"><span style="white-space:nowrap">day-to-day</span></span> operations and for executing our strategy, and because our performance is an integral part of the deliberations undertaken by the Board, the CEO is the director best qualified to act as the Chairman of the Board. The Board reserves the authority to modify this structure to best address and advance the interests of all stockholders, as and when appropriate. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board believes that independent oversight of management is also an important component of an effective board of directors. The Board believes that, for the reasons set forth below, our existing corporate governance practices achieve independent oversight and management accountability. Our governance practices provide for strong independent leadership, independent discussion among directors and for independent evaluation of, and communication with, our officers. These governance practices are reflected in our various committee charters, which are available on our website at <span style="text-decoration:underline">www.catalystpharma.com</span>. Some of the relevant processes and other corporate governance practices include: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">At each regularly scheduled Board meeting, all of our independent directors meet in an executive session without Mr.&#160;McEnany. In these executive sessions, the independent directors deliberate on matters such as those involving the performance of our officers. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">14 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">Each of our directors is elected annually by our stockholders. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">All of our directors, except for Mr.&#160;McEnany, are independent directors. Each director is an equal participant in decisions made by the full Board. All of the committees of the Board are comprised of only independent directors. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Lead Independent Director </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has appointed a <span style="white-space:nowrap">non-management</span> director to serve in a lead capacity (the &#8220;<span style="font-weight:bold">Lead Independent Director</span>&#8221;) to perform such duties and responsibilities as the Board may determine. Charles B. O&#8217;Keeffe serves as the Lead Independent Director. The role of the Lead Independent Director includes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">in consultation with the Chairman, determining the length and timing of Board meetings, including regular and special meetings; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">determining the agenda and materials to be provided to directors in advance of each meeting of the Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">serving as chair of executive sessions of the Board and other meetings of the Board in the absence of the Chairman of the Board; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">serving as liaison between the Chairman of the Board and the other independent directors; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">overseeing the Board&#8217;s stockholder communication policies and procedures; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">calling meetings of independent directors. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Board Meetings and Attendance at Board and Board Committee Meetings </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2022, our Board held ten meetings and took actions by unanimous written consent on three occasions. For 2022, all of our directors attended at least 75% or more of the aggregate number of meetings held by our Board and the Board committees on which they served. Four of our seven directors attended the 2022 Annual Meeting of Stockholders which was held on September&#160;19, 2022. Directors are encouraged, but not required, to attend the Annual Meeting. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Audit Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee assists the Board in fulfilling its responsibility for oversight of the quality and integrity of the accounting, auditing, and reporting practices of our company, and such other duties as directed by the Board. The committee&#8217;s purpose is to oversee our accounting and financial reporting processes, the audits of our financial statements, the qualifications of the independent registered public accounting firm engaged as our independent auditor to prepare or issue an audit report on our financial statements, and the performance of our internal and independent auditors. The committee&#8217;s role includes a particular focus on the qualitative aspects of financial reporting to stockholders, our processes to manage business and financial risk, and compliance with applicable legal, ethical, and regulatory requirements. The Audit Committee is directly responsible for the appointment, compensation, retention and oversight of our independent auditor. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board has determined that Donald A. Denkhaus, the current chair of the Audit Committee, is an &#8220;audit committee financial expert&#8221; as defined in Regulation <span style="white-space:nowrap">S-K</span> under the Exchange Act. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">15 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee held four meetings in 2022 and took two actions by unanimous written consent. The Audit Committee operates under a written charter which describes the role, responsibilities, and functioning of the Audit Committee. The Audit Committee&#8217;s charter can be found at <span style="text-decoration:underline">http://ir.catalystpharma.com/governance.cfm</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Compensation Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The role of the Compensation Committee is to discharge the Board&#8217;s responsibilities related to compensation of our executive officers, to produce an annual report on executive compensation for inclusion in our Form <span style="white-space:nowrap">10-K</span> or proxy statement, and to oversee and advise the Board on the adoption of policies that govern our compensation programs, including our stock incentive plans and our benefit plans. The Compensation Committee held five meetings in 2022 and took three actions by unanimous written consent. The Compensation Committee operates under a written charter which describes the role, responsibilities, and functioning of the Compensation Committee. A copy of this charter can be found on our website at <span style="text-decoration:underline">http://ir.catalystpharma.com/governance.cfm</span>. Pursuant to its charter, the Compensation Committee has authority to retain compensation consultants to assist in its evaluation of executive and director compensation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Nominating&#160;&amp; Corporate Governance Committee </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The role of the Nominating&#160;&amp; Corporate Governance Committee (&#8220;<span style="font-weight:bold">N&amp;CG Committee</span>&#8221;) is to appoint nominees for election to our Board, to identify and recommend candidates to fill vacancies between annual stockholder meetings, to review, evaluate and recommend changes to our corporate governance policies, and to review our policies and programs that relate to matters of corporate responsibility, including public issues of significance to our company and our stockholders. The N&amp;CG Committee held two meetings in 2022. The N&amp;CG Committee operates under a written charter which describes the role, responsibilities, and functioning of the N&amp;CG Committee. A copy of the N&amp;CG Committee&#8217;s charter can be found on our website at <span style="text-decoration:underline">http://ir.catalystpharma.com/governance.cfm</span>. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Risk Oversight </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Risk oversight is administered through the Board as a whole. The Board does not believe that risk management issues have an effect on our leadership structure. The Board provides feedback to management at regularly held Board meetings. The independent directors meet in executive session at each regular meeting of the Board and provide insight to our management on a variety of topics, including risk oversight. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_6">C<small>OMPENSATION</small> <small>OF</small> D<small>IRECTORS</small> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information regarding compensation earned by our <span style="white-space:nowrap">non-employee</span> directors for the year ended December&#160;31, 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:56%"></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Fees&#160;Earned&#160;or&#160;Paid<br />in Cash ($)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Stock&#160;Based&#160;Awards&#160;(1)<br />(2) ($)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Total ($)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philip H. Coelho</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">71,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">327,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">398,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles B. O&#8217;Keeffe</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">98,625</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">327,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">425,677</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David S. Tierney</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">71,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">327,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">398,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Donald A. Denkhaus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">76,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">327,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">403,302</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Daly</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63,125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">327,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">390,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Molly Harper</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">63,125</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">327,052</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">390,177</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Footnotes on next page </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">16 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts reported in this column represent the grant date fair value of stock option awards granted in accordance with FASB ASC Topic 718 for 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The aggregate number of stock options held by each <span style="white-space:nowrap">non-employee</span> director as of December&#160;31, 2022 is indicated in the table below: </p></td></tr></table> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:65%"></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:10%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Number&#160;of&#160;Options</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Number&#160;of&#160;Unvested<br />RSUs</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philip H. Coelho</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">298,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles B. O&#8217;Keeffe</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">298,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David S. Tierney</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">298,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Donald A. Denkhaus</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">298,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Daly</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">298,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Molly Harper</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">95,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">16,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">2022 Compensation of Directors </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For 2022, <span style="white-space:nowrap">non-employee</span> directors received an annual retainer of $50,000, the chairs of the Audit, Compensation and N&amp;CG Committees received an additional retainer of $21,000, $15,750 and $10,500, respectively, and members of the Audit, Compensation and N&amp;CG Committees received an additional retainer of $10,500, $7,875 and $5,250, respectively. Additionally, the Lead Director received an additional fee of $25,000 for his services as lead director. No meeting fees were paid. Further, directors received a grant of stock options and RSUs for 2022 services. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_7">P<small>ROPOSAL</small> T<small>WO</small> &#8211; A<small>MENDING</small> O<small>UR</small> 2018 S<small>TOCK</small> I<small>NCENTIVE</small> P<small>LAN</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock-based compensation is a fundamental component of our compensation program. Our equity compensation program is designed to attract and retain key employees, directors and consultants, many of whom view equity incentives as a key component of their compensation. Stock-based compensation encourages and rewards employee performance and helps align employee interests with those of our stockholders. We currently award stock options on an annual basis to our employees and to members of our Board of Directors as part of our overall compensation package for each year. The amendment will add additional shares into our 2018 Stock Incentive Plan (the &#8220;<span style="font-weight:bold">2018 Plan</span>&#8221;) so that we are able to continue to grant stock-based awards in order to continue to motivate existing key employees, consultants and members of our Board of Directors and align their financial interests with those of our stockholders. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon recommendation from the Compensation Committee, the Board of Directors approved an amendment to our 2018 Stock Incentive Plan (the &#8220;<span style="font-weight:bold">Amendment</span>&#8221;) on May&#160;25, 2023. The Board of Directors believes that the Amendment serves a critical role in attracting and retaining the high-caliber employees, consultants and directors that are essential to our success and in motivating these individuals to strive to reach our goals. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">By approving the Amendment, stockholders will be approving the addition of three million shares to the 2018 Plan, representing approximately 2.8% of our outstanding common stock as of the Record Date on a fully diluted basis. The 2018 Plan, as amended previously, has reserved 15&#160;million shares of common stock for issuance, 1,675,960 of which remain available for future issuance. This Amendment will increase the number of shares available for issuance to 18&#160;million shares, 4,675,960 of which will remain available for future issuance. Such terms are described in &#8220;2018 Stock Incentive Plan&#8221; below. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">17 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively. Abstentions and broker <span style="white-space:nowrap">non-votes</span> are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Board unanimously recommends a vote FOR the proposal to amend our 2018 Stock Incentive Plan to add an additional three million shares to the Plan. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_8">2018 S<small>TOCK</small> I<small>NCENTIVE</small> P<small>LAN</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2018, our Board adopted the 2018 Plan, which became effective in May 2018 when the 2018 Plan was approved by our stockholders at the 2018 annual meeting of stockholders. Amendments adding additional shares to the 2018 Plan were approved by our stockholders at the 2020 annual meeting of stockholders and at the 2021 annual meeting of stockholders. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Administration </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee of the Board administers the 2018 Plan and determines which persons will receive grants of awards and the type of award to be granted to such persons. The Compensation Committee will also interpret the provisions of the 2018 Plan and make all other determinations that it deems necessary or advisable for the administration of the 2018 Plan. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Eligibility to Participate in the 2018 Plan </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">All eligible individuals are able to participate in the 2018 Plan. Eligible individuals include our directors, officers, employees, independent contractors and consultants, as well as individuals who have accepted an offer of employment from us. As of the date of this proxy statement, six <span style="white-space:nowrap">non-employee</span> directors, seven executive officers, approximately 128 other employees, and approximately seven consultants are eligible to receive grants under the 2018 Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because benefits under the 2018 Plan will require future actions by the Compensation Committee and the fair market value of our common stock at various dates, it is not possible to determine the benefits that will be received by eligible individuals under the 2018 Plan, if any. The securities that are underlying grants of awards under the 2018 Plan is our common stock. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Form of Awards </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Awards under the 2018 Plan may be granted in any one or all of the following forms: (i)&#160;Incentive Stock Options within the meaning of Section&#160;422 of the Internal Revenue Code of 1986, as amended (the &#8220;<span style="font-weight:bold">Code</span>&#8221;), (ii)&#160;stock options that are not Incentive Stock Options (&#8220;<span style="font-weight:bold"><span style="white-space:nowrap">Non-Qualified</span> Stock Options</span>&#8221;, unless otherwise noted herein, &#8220;<span style="font-weight:bold">Options</span>&#8221; refers to both Incentive Stock Options and <span style="white-space:nowrap">Non-Qualified</span> Stock Options), (iii)&#160;the right to receive all or some portion of the increase in value of a fixed number of shares of the Company&#8217;s common stock (&#8220;<span style="font-weight:bold">Stock Appreciation Rights</span>&#8221; or &#8220;<span style="font-weight:bold">SAR</span>s&#8221;), which may be awarded either in tandem with Options or on a stand-alone basis, (iv)&#160;shares of Common Stock that are restricted (&#8220;<span style="font-weight:bold">Restricted Shares</span>&#8221;), (v)&#160;the right to receive shares of the Company&#8217;s common stock at the end of a specified period (&#8220;<span style="font-weight:bold">RSU</span>s&#8221;), (vi)&#160;the right to receive a fixed number of shares of the Company&#8217;s common stock, or the cash equivalent, which is contingent on the achievement of certain performance goals (&#8220;<span style="font-weight:bold">Performance Shares</span>&#8221;), and (vii)&#160;the right to receive a designated dollar value, or shares of the Company&#8217;s common stock of the equivalent value, which is contingent on the achievement of certain performance goals (&#8220;<span style="font-weight:bold">Performance Units</span>&#8221;). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">18 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Stock Options </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Options may be granted under the 2018 Plan for the purchase of shares of our common stock. The Compensation Committee may designate Options as either Incentive Stock Options or <span style="white-space:nowrap">Non-Qualified</span> Stock Options. The term of each Option granted will be determined by the Compensation Committee. However, no Incentive Stock Option will be exercisable more than ten years after the date it is granted, or in the case of an Incentive Stock Option granted to an employee owning more than 10% of the total combined voting power of all classes of stock of the Company (a &#8220;<span style="font-weight:bold">10% Stockholder</span>&#8221;), more than five years after the date it is granted. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The purchase price per share under each Incentive Stock Option will be specified by the Compensation Committee, but in no event may it be less than 100% of the market price per share of our common stock on the date the Incentive Stock Option is granted. In the case of an Incentive Stock Option granted to a 10% Stockholder, the purchase price per share must not be less than 110% of the market price of our common stock on the date of grant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Options may be exercised in whole or in part. Payment for such exercise must be made in cash or through the delivery to the Company of shares of common stock previously owned by the Option holder. The Compensation Committee, in its sole and absolute discretion, may allow other forms of payment. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Stock Appreciation Rights </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stock Appreciation Rights may be awarded by the Compensation Committee in such amounts and on such terms and conditions as the Compensation Committee shall determine, in its sole and absolute discretion. The terms and conditions of any Stock Appreciation Right shall be substantially identical to the terms and conditions that would apply if the grant of such Stock Appreciation Right had been the grant of an Option. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Upon exercise of a Stock Appreciation Right, the owner of such Stock Appreciation Right shall be entitled to receive payment in cash, in shares of common stock, or a combination thereof, as determined by the Compensation Committee in its sole and absolute discretion. The amount of such payment shall be determined by multiplying the excess, if any, of the fair market value of a share of common stock on the date of exercise over the fair market value of the common stock on the grant date, by the number of shares of common stock with respect to which the Stock Appreciation Rights are being exercised. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Restricted Stock </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Shares of Restricted Stock may be granted, in such amounts and on such terms and conditions as the Compensation Committee may determine, in its sole and absolute discretion. The Compensation Committee shall impose such restrictions on any Restricted Stock granted under the 2018 Plan as it may deem advisable. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Except as provided by the Compensation Committee in its sole and absolute discretion, Restricted Stock granted under the 2018 Plan will vest over a four year period after the grant date in equal annual increments of 25%. Shares of Restricted Stock may also be granted subject to performance goals, and such shares will be released from restrictions only after the attainment of such performance goals has been certified by the Compensation Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless otherwise provided by the Compensation Committee, until the expiration of all applicable restrictions, and subject to the terms of the Plan, (i)&#160;the Restricted Stock is treated as outstanding common stock in the Company, (ii)&#160;the participant holding shares of Restricted Stock may exercise full voting rights with respect to such shares, and (iii)&#160;the participant holding shares of Restricted Stock is entitled to all dividends and other distributions paid with respect to such shares while they are so held. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">19 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">RSUs </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">RSUs may be granted, in such amounts and on such terms and conditions as the Compensation Committee may determine, in its sole and absolute discretion. The Compensation Committee shall impose such restrictions on any RSUs granted under the 2018 Plan as it may deem advisable. Unless otherwise provided by the Compensation Committee in an award agreement, upon the expiration of all applicable restrictions, shares of the Company&#8217;s common stock will be paid within 60 days following the date the restrictions lapse. Participant&#8217;s holding RSUs will not have any rights of a stockholder until the underlying shares of the Company&#8217;s common stock are delivered. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Performance Shares and Performance Units </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Performance Shares and Performance Units may be granted, in such amounts and on such terms and conditions as the Compensation Committee may determine, in its sole and absolute discretion. Performance Shares and Performance Units will be subject to the attainment of one or more <span style="white-space:nowrap">pre-established</span> performance goals. Such performance goals shall be established by the Committee in writing (other than options and SARs) and shall be based on one or more of the following business criteria: (i)&#160;the attainment of certain target levels of, or a specified increase in, the Company&#8217;s enterprise value or value creation targets; (ii)&#160;the attainment of certain target levels of, or a percentage increase in, the Company&#8217;s <span style="white-space:nowrap">after-tax</span> or <span style="white-space:nowrap">pre-tax</span> profits including, without limitation, that attributable to the Company&#8217;s continuing and/or other operations; (iii)&#160;the attainment of certain target levels of, or a specified increase relating to, the Company&#8217;s operational cash flow or working capital, or a component thereof; (iv)&#160;the attainment of certain target levels of, or a specified decrease relating to, the Company&#8217;s operational costs, or a component thereof; (v)&#160;the attainment of a certain level of reduction of, or other specified objectives with regard to limiting the level of increase in all or a portion of bank debt or other of the Company&#8217;s long-term or short-term public or private debt or other similar financial obligations of the Company, which may be calculated net of cash balances and/or other offsets and adjustments as may be established by the Committee; (vi)&#160;the attainment of a specified percentage increase in earnings per share or earnings per share from the Company&#8217;s continuing operations; (vii)&#160;the attainment of certain target levels of, or a specified percentage increase in, the Company&#8217;s net sales, revenues, net income or earnings before income tax or other exclusions; (viii)&#160;the attainment of certain target levels of, or a specified increase in, the Company&#8217;s return on capital employed or return on invested capital; (ix)&#160;the attainment of certain target levels of, or a percentage increase in, the Company&#8217;s <span style="white-space:nowrap">after-tax</span> or <span style="white-space:nowrap">pre-tax</span> return on stockholder equity; (x)&#160;the attainment of certain target levels in the fair market value of the Company&#8217;s common stock; (xi)&#160;the growth in the value of an investment in the common stock assuming the reinvestment of dividends; (xii)&#160;the attainment of certain target levels of, or a specified increase in, EBITDA (earnings before income tax, depreciation and amortization); and/or attainment of synergies and cost reductions in connection with mergers, acquisitions and similar corporate transactions involving the Company. As soon as practicable after the end of a performance period (as set forth by the Compensation Committee), the Compensation Committee shall determine to what extent the Performance Shares or Performance Units have been earned on the basis of the Company&#8217;s performance. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Transferability of Awards </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Awards are <span style="white-space:nowrap">non-transferable</span> other than by will or by the laws of descent and distribution or as otherwise expressly allowed by the Compensation Committee pursuant to a gift to members of an eligible person&#8217;s immediate family. The gift may be directly or indirectly transferred, by means of a trust, partnership, or otherwise. Stock options and SARs may be exercised only by the optionee, any such permitted transferee or a guardian, legal representative or beneficiary. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">20 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Treatment of Awards upon a Change in Control </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If there is a change in control of Catalyst Pharmaceuticals, Inc., any award that is not exercisable and vested may immediately become exercisable and vested in the sole and absolute discretion of the Compensation Committee. Vested awards will be deemed earned and payable in full. The Compensation Committee may also terminate the awards, entitling participants to a cash payment. If we are liquidated or dissolved, awards may also be converted into the right to receive liquidation proceeds. In the event that the Compensation Committee does not terminate or convert an award upon a change of control, then the award will be assumed, or substantially equivalent awards will be substituted, by the acquiring or succeeding corporation. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Amendments, Modifications and Termination </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Board may, at any time, amend, suspend or terminate the 2018 Plan, but the Board may not impair the rights of holders of outstanding awards without the holder&#8217;s consent. No amendment to the 2018 Plan may be made without consent of our stockholders. In the event that an award is granted to a person residing outside of the United States, the Board may, at its discretion, modify the terms of the agreement to comply with the laws of the country of which the eligible individual is a resident. The 2018 Plan will terminate 10&#160;years after its effective date. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Material Federal Income Tax Consequences </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following is a brief description of the principal federal income tax consequences, as of the date of this proxy statement, associated with the grant of awards under the 2018 Plan. This summary is based on our understanding of present United States federal income tax law and regulations. The summary does not purport to be complete or applicable to every specific situation. Furthermore, the following discussion does not address foreign, state or local tax consequences. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Stock Options </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Grant</span>. There is generally no United States federal income tax consequence to the participant solely by reason of the grant of incentive stock options or nonqualified stock options under the 2018 Plan, assuming the exercise price of the option is not less than the fair market value of the shares on the date of grant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Exercise</span>. The exercise of an incentive stock option is not a taxable event for regular federal income tax purposes if certain requirements are satisfied, including the requirement that the participant generally must exercise the incentive stock option no later than three months following the termination of the participant&#8217;s employment with us. However, such exercise may give rise to alternative minimum tax liability (see &#8220;Alternative Minimum Tax&#8221; below). Upon the exercise of a nonqualified stock option, the participant will generally recognize ordinary income in an amount equal to the excess of the fair market value of the shares at the time of exercise over the amount paid by the participant as the exercise price. The ordinary income recognized in connection with the exercise by a participant of a nonqualified stock option will be subject to both wage and employment tax withholding, and we generally will be entitled to a corresponding deduction. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The participant&#8217;s tax basis in the shares acquired pursuant to the exercise of an option will be the amount paid upon exercise plus, in the case of a nonqualified stock option, the amount of ordinary income, if any, recognized by the participant upon exercise thereof. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">21 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Disqualifying Disposition</span>. If the participant disposes of shares of our common stock acquired upon the exercise of an incentive stock option (other than in certain tax free transactions) within two years from the date on which the incentive stock option was granted or within one year after the transfer of shares to the participant pursuant to the exercise of the incentive stock option, at the time of disposition the participant will generally recognize ordinary income equal to the lesser of: (i)&#160;the excess of each such share&#8217;s fair market value on the date of exercise over the exercise price paid by the participant, or (ii)&#160;the participant&#8217;s actual gain. If the total amount realized on a taxable disposition (including return on capital and capital gain) exceeds the fair market value on the date of exercise of the shares of our common stock purchased by the participant under the option, the participant will recognize a capital gain in the amount of the excess. If the participant incurs a loss on the disposition (the total amount realized is less than the exercise price paid by the participant), the loss will be a capital loss. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Other Disposition</span>. If a participant disposes of shares of our common stock acquired upon exercise of a nonqualified stock option in a taxable transaction, the participant will recognize capital gain or loss in an amount equal to the difference between the participant&#8217;s basis (as discussed above) in the shares sold and the total amount realized upon disposition. Any such capital gain or loss (and any capital gain or loss recognized on a disqualifying disposition of shares of our common stock acquired upon exercise of incentive stock options as discussed above) will be short-term or long-term depending on whether the shares of our common stock were held for more than one year from the date such shares were transferred to the participant. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Alternative Minimum Tax</span>. Alternative minimum tax is payable if and to the extent the amount thereof exceeds the amount of the taxpayer&#8217;s regular tax liability, and any alternative minimum tax paid generally may be credited against future regular tax liability (but not future alternative minimum tax liability). Alternative minimum tax applies to alternative minimum taxable income. Generally, regular taxable income as adjusted for tax preferences and other items is treated differently under the alternative minimum tax. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For alternative minimum tax purposes, the spread upon exercise of an incentive stock option (but not a nonqualified stock option) will be included in alternative minimum taxable income, and the taxpayer will receive a tax basis equal to the fair market value of the shares of our common stock at such time for subsequent alternative minimum tax purposes. However, if the participant disposes of the incentive stock option shares in the year of exercise, the alternative minimum tax income cannot exceed the gain recognized for regular tax purposes, provided that the disposition meets certain third party requirements for limiting the gain on a disqualifying disposition. If there is a disqualifying disposition in a year other than the year of exercise, the income on the disqualifying disposition is not considered alternative minimum taxable income. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no federal income tax consequences to us by reason of the grant of incentive stock options or nonqualified stock options or the exercise of an incentive stock option (other than disqualifying dispositions). At the time the participant recognizes ordinary income from the exercise of a nonqualified stock option, we will be entitled to a federal income tax deduction in the amount of the ordinary income so recognized (as described above), provided that we satisfy our reporting obligations described below. To the extent the participant recognizes ordinary income by reason of a disqualifying disposition of the stock acquired upon exercise of an incentive stock option, and subject to the requirement of reasonableness, the provisions of Section&#160;162(m) of the Code and the satisfaction of a tax reporting obligation, we generally will be entitled to a corresponding deduction in the year in which the disposition occurs. We are required to report to the Internal Revenue Service any ordinary income recognized by any participant by reason of the exercise of a nonqualified stock option. We are required to withhold income and employment taxes (and pay the employer&#8217;s share of the employment taxes) with respect to ordinary income recognized by the participant upon exercise of nonqualified stock options. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">22 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Stock Appreciation Rights </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are generally no tax consequences to the participant or us by reason of the grant of stock appreciation rights. In general, upon exercise of a stock appreciation rights award, the participant will recognize taxable ordinary income equal to the excess of the stock&#8217;s fair market value on the date of exercise over the stock appreciation rights&#8217; base price, or the amount payable. Generally, with respect to employees, we are required to withhold from regular wages or supplemental wage payments an amount based on the ordinary income recognized. Subject to the requirement of reasonableness, the provisions of Section&#160;162(m) of the Code and the satisfaction of a tax reporting obligation, we generally will be entitled to a business expense deduction equal to the taxable ordinary income realized by the participant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Restricted Stock </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Unless a participant makes a Section&#160;83(b) election, as described below, with respect to restricted stock granted under the 2018 Plan, a participant receiving such an award will not recognize U.S. taxable ordinary income and we will not be allowed a deduction at the time such award is granted. While an award remains unvested or otherwise subject to a substantial risk of forfeiture, a participant will recognize compensation income equal to the amount of any dividends received and we will be allowed a deduction in a like amount. When an award vests or otherwise ceases to be subject to a substantial risk of forfeiture, the excess of the fair market value of the award on the date of vesting or the cessation of the substantial risk of forfeiture over the amount paid, if any, by the participant for the award will be ordinary income to the participant and will be claimed as a deduction for federal income tax purposes by us. Upon disposition of the shares received, the gain or loss recognized by the participant will be treated as capital gain or loss, and the capital gain or loss will be short-term or long-term depending upon whether the participant held the shares for more than one year following the vesting or cessation of the substantial risk of forfeiture. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">However, by filing a Section&#160;83(b) election with the Internal Revenue Service within 30 days after the date of grant, a participant&#8217;s ordinary income and commencement of holding period and the deduction will be determined as of the date of grant. In such a case, the amount of ordinary income recognized by such a participant and deductible by us will be equal to the excess of the fair market value of the award as of the date of grant over the amount paid, if any, by the participant for the award. If such election is made and a participant thereafter forfeits his or her award, no refund or deduction will be allowed for the amount previously included in such participant&#8217;s income. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, with respect to employees, we are required to withhold from regular wages or supplemental wage payments an amount based on the ordinary income recognized. Subject to the requirement of reasonableness, the provisions of Section&#160;162(m) of the Code the satisfaction of a tax reporting obligation and any tax withholding condition, we generally will be entitled to a business expense deduction equal to the taxable ordinary income realized by the recipient. Upon disposition of stock, the recipient will recognize a capital gain or loss equal to the difference between the selling price and the sum of the amount paid for such stock, if any, plus any amount recognized as ordinary income upon acquisition (or vesting) of the stock. Such gain or loss will be long- or short-term depending on whether the stock was held for more than one year from the date ordinary income is measured. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Restricted Stock Units (RSUs) </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Generally, the recipient of a restricted stock unit award structured to conform to the requirements of Section&#160;409A of the Code or an exception to Section&#160;409A of the Code will recognize ordinary income at the time the shares are delivered to the participant in an amount equal to the excess, if any, of the fair market value of the shares received over any amount paid by the recipient in exchange for the shares. If a restricted stock unit award is subject to Section&#160;409A of the Code, the shares subject to a restricted stock unit award may </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">23 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
generally only be delivered upon one of the following events: a fixed calendar date (or dates), separation from service, death, disability, or a change in control. If delivery occurs on another date, unless the restricted stock unit awards otherwise comply with or qualify for an exception to the requirements of Section&#160;409A of the Code, in addition to the tax treatment described above, the recipient will owe an additional 20% federal tax and interest on any taxes owed. The recipient&#8217;s basis for the determination of gain or loss upon the subsequent disposition of shares acquired from a restricted stock unit award will be the amount paid, if any, for shares plus any ordinary income recognized when the stock is delivered. Subject to the requirement of reasonableness, the provisions and limitations of Section&#160;162(m) of the Code and the satisfaction of a tax reporting obligation, we will generally be entitled to an income tax deduction equal to the amount of ordinary income realized by the participant. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Section&#160;409A </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an award under the 2018 Plan is subject to Section&#160;409A of the Code, but does not comply with the requirements of Section&#160;409A of the Code, the taxable events as described above could apply earlier than described, and could result in the imposition of additional taxes and penalties. Participants are urged to consult with their tax advisors regarding the applicability of Section&#160;409A of the Code to their awards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="text-decoration:underline">Potential Limitation on Company Deductions </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Section&#160;162(m) of the Code generally disallows a tax deduction for compensation in excess of $1&#160;million paid in a taxable year by a publicly held corporation to its chief executive officer and certain other &#8220;covered employees&#8221;. Our board of directors and Compensation Committee intend to consider the potential impact of Section&#160;162(m) on grants made under the 2018 Plan, but reserve the right to approve grants of options and other awards for an executive officer that exceeds the deduction limit of Section&#160;162(m). </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_9">2014 S<small>TOCK</small> I<small>NCENTIVE</small> P<small>LAN</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In February 2014, our Board adopted the 2014 Stock Incentive Plan (the &#8220;<span style="font-weight:bold">2014 Plan</span>,&#8221; and together with the 2018 Plan, the &#8220;<span style="font-weight:bold">Plans</span>&#8221;), which became effective in May 2014 when the 2014 Plan was approved by our stockholders at the 2014 annual meeting of stockholders. Amendments adding additional shares to the 2014 Plan were approved by our stockholders at the 2016 annual meeting of stockholders and the 2017 annual meeting of stockholders. Following adoption of the 2018 Plan, no additional shares have been issued under the 2014 Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Administration. </span>The Compensation Committee administers the 2014 Plan and makes all determinations that it deems necessary or advisable for the administration of the 2014 Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Transferability of Awards</span>. Awards are <span style="white-space:nowrap">non-transferable</span> other than by will or by the laws of descent and distribution or as otherwise expressly allowed by the Compensation Committee pursuant to a gift to members of an eligible person&#8217;s immediate family. The gift may be directly or indirectly transferred, by means of a trust, partnership, or otherwise. Stock options and SARs may be exercised only by the optionee, any such permitted transferee or a guardian, legal representative or beneficiary. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Change of control. </span>If there is a change in control of our company, any award that is not exercisable and vested may immediately become exercisable and vested in the sole and absolute discretion of the Compensation Committee. Vested awards will be deemed earned and payable in full. The Compensation Committee may also terminate the awards, entitling participants to a cash payment. If our company is liquidated or dissolved, awards may also be converted into the right to receive liquidation proceeds. In the event that the Compensation Committee does not terminate or convert an award upon a change of control, then the award will be assumed, or substantially equivalent awards will be substituted, by the acquiring or succeeding corporation. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">24 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Amendments, Modifications and Termination. </span>Our Board may, at any time, amend, suspend or terminate the 2014 Plan, but the Board may not impair the rights of holders of outstanding awards without the holder&#8217;s consent. No amendment to the 2014 Plan may be made without consent of our stockholders. The 2014 Plan will terminate 10&#160;years after its effective date. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Hedging and Pledging Policies </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Insider Trading Policy prohibits our executive officers, other <span style="white-space:nowrap">employees,&#160;non-employee&#160;directors</span> and consultants from engaging in short sales, transactions in put or call options, hedging transactions or other inherently speculative transactions with respect to our ordinary shares at any time. In addition, no officer, director, other employee or consultant of Catalyst may margin or pledge, or make any offer to margin or pledge, any of our ordinary shares, including without limitation, borrowing against the value of such ordinary shares, at any time. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_10">P<small>ROPOSAL</small> 3 &#8211; A<small>DVISORY</small> A<small>PPROVAL</small> <small>OF</small> <small>THE</small> C<small>OMPENSATION</small> <small>OF</small> N<small>AMED</small> E<small>XECUTIVE</small> O<small>FFICERS</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 (the &#8220;<span style="font-weight:bold">Dodd-Frank Act</span>&#8221;), our stockholders are entitled to vote at the annual meeting to provide advisory approval of the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the SEC. Pursuant to the Dodd-Frank Act, the stockholder vote on executive compensation is an advisory vote only, and it is not binding on us or our Board. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Although the result of the vote is <span style="white-space:nowrap">non-binding,</span> our Compensation Committee and Board value the opinions of the stockholders and will consider the outcome of the vote when making future compensation decisions. As described more fully in the &#8220;Compensation Discussion and Analysis&#8221; section of this proxy statement, our executive compensation program is designed to attract, retain and motivate individuals with superior ability, experience and leadership capability to deliver on our annual and long-term business objectives necessary to create stockholder value. We urge stockholders to read the &#8220;Compensation Discussion and Analysis&#8221; section of this proxy statement, which describes in detail how our executive compensation policies and procedures operate and are intended to operate in the future. The Compensation Committee and the Board believe that our executive compensation program fulfills these goals and is reasonable, competitive and aligned with our performance and the performance of our executives. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are asking our stockholders to indicate their support for our named executive officer compensation as described in this proxy statement. This proposal, commonly known as a <span style="white-space:nowrap"><span style="white-space:nowrap">&#8220;say-on-pay&#8221;</span></span> proposal, gives our stockholders the opportunity to express their views on our named executive officers&#8217; compensation. This vote is not intended to address any specific item of compensation, but rather the overall compensation of our named executive officers and the philosophy, policies and practices described in this proxy statement. Accordingly, we ask that our stockholders vote &#8220;<span style="font-weight:bold">FOR</span>&#8221; the following resolution: </p> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">RESOLVED</span>, that Catalyst Pharmaceuticals, Inc.&#8217;s stockholders approve, on an advisory basis, the compensation of the named executive officers, as disclosed in Catalyst Pharmaceuticals, Inc.&#8217;s Proxy Statement for the 2023 Annual Meeting. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">25 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The affirmative vote of a majority of the voting power of the votes cast affirmatively or negatively on the proposal will be required to approve the advisory vote regarding the compensation of the named executive officers. Abstentions will not be counted toward the tabulation of votes cast on this proposal and will have no effect on the proposal. Broker <span style="white-space:nowrap">non-votes</span> will have no effect on this proposal as brokers or other nominees are not entitled to vote on such proposal in the absence of voting instructions from the beneficial owner. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Board unanimously recommends a vote FOR the approval of the compensation of our named executive officers as disclosed in this proxy statement pursuant to the compensation disclosure rules of the SEC. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">E<small>XECUTIVE</small> O<small>FFICERS</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following list reflects our executive officers as of the date of this Proxy Statement, the capacity in which they serve us, and when they assumed office: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">


<tr>

<td style="width:22%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td style="width:57%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Position(s)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Age</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">Executive</span><br /><span style="font-weight:bold">Officer&#160;Since</span></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Patrick J. McEnany</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Chairman, President and Chief Executive Officer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">76</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">January&#160;2002</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Steven R. Miller, Ph.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Chief Operating Officer and Chief Scientific Officer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">62</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">April 2007</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Alicia Grande, CPA, CMA</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Vice President, Treasurer and Chief Financial Officer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">53</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">January 2007</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Gary Ingenito, M.D., Ph.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Chief Medical and Regulatory Officer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">68</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">June 2015</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Brian Elsbernd, J.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Chief Compliance Officer and Chief Legal Officer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">59</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">February&#160;2016</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Jeffrey Del Carmen</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Chief Commercial Officer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">53</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">June 2020</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Preethi Sundaram, Ph.D.</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap">Chief Strategy Officer</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">47</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top;white-space:nowrap" align="center">July 2021</td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Executive Officers&#8217; Business Experience </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Patrick J. McEnany.</span> The business experience of Patrick J. McEnany is included above in &#8220;Board of Directors.&#8221; </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Steven R. Miller, Ph.D.</span>, has served as Chief Operating Officer since January 2011 and as our Chief Scientific Officer since October 2009. Previously, commencing in April 2007, Dr. Miller was our Vice President of Pharmaceutical Development and Project Management. Dr. Miller has worked in the healthcare industry for over 30 years. Prior to joining us, Dr. Miller spent 15 years with various divisions of Watson Laboratories, a subsidiary of Watson Pharmaceuticals, Inc., most recently as Executive Director of R&amp;D Operations. In this capacity, Dr. Miller managed a team of 75 in the testing of all R&amp;D products for clinical trials, including method valuation, stability testing, operation of the R&amp;D pilot plant, and assembly of the CMC section of drug applications, in addition to other responsibilities. Prior to holding this position, </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">26 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Dr. Miller was Director of Technology Transfer for Watson Laboratories, and Vice President of Research and Product Development for Royce Laboratories, which was subsequently acquired by Watson Laboratories. Prior to joining Royce Laboratories, Dr.&#160;Miller was Group Leader and Senior Scientist at Dade Behring. Prior to that, he served as an Analytical Chemist at the U.S. Food&#160;&amp; Drug Administration. Dr.&#160;Miller received his Bachelor of Science Degree in Chemistry from the University of Maryland and his Ph.D. from the University of Miami. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Alicia Grande, CPA, CMA</span>, has served as our Vice President, Treasurer and Chief Financial Officer since December 2011 and as our Chief Accounting Officer since January 2007. Prior to joining Catalyst, since 2003 Ms.&#160;Grande was employed by The Hackett Group, Inc., a publicly traded strategic consultancy, enterprise benchmarking and best practices transformation company. Ms.&#160;Grande served in various capacities with The Hackett Group, most recently as Senior Director of Finance, and was responsible for all external and SEC financial reporting. Ms.&#160;Grande also served as head of The Hackett Group&#8217;s Sarbanes-Oxley Act compliance team. Prior to joining The Hackett Group, Ms.&#160;Grande was employed in public accounting, and she began her career with Arthur Andersen LLP. Ms.&#160;Grande earned a Bachelor of Science degree in business administration, with majors in accounting and finance, from Syracuse University and a Master of Accounting degree from Florida International University. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Gary Ingenito, M.D., Ph.D., </span>is our Chief Medical and Regulatory Officer. He joined us as our Chief Medical Officer in June 2015 and took over our regulatory operations in February 2016. Prior to joining Catalyst, Dr.&#160;Ingenito spent more than 25 years in the field of pharmaceutical development; including drugs, biologics, and combination products. During this time, Dr.&#160;Ingenito has held executive responsibilities for clinical research, regulatory, drug safety, and medical affairs at pharmaceutical companies and contract research organizations. Dr.&#160;Ingenito initially joined Sandoz Pharmaceuticals in the neuroendocrine group and progressed to become head of medical affairs. He spent 8 years at Otsuka Pharmaceuticals, overseeing the approval of anti-infective, cardiovascular, and central nervous system products. Dr.&#160;Ingenito has also held positions at Corning-Besselaar, SFBC International, Angiotech Pharmaceuticals, Biotest Pharmaceuticals, and, most recently at Boehringer-Ingelheim Pharmaceuticals, where he served as head of regulatory affairs North America for biosimilars. After obtaining his Bachelor of Arts degree from The Johns Hopkins University, Dr.&#160;Ingenito earned his medical degree at Jefferson Medical College, and a Ph.D. in&#160;philosophy from Thomas Jefferson University. He completed a post-graduate residency in neurology at the University of Miami, Jackson Memorial Hospital. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Brian Elsbernd, J.D.</span>&#160;joined us in February 2016 as our Sr. Vice President of Legal and Compliance and became our Chief Compliance Officer and Chief Legal Officer on January&#160;1, 2019. Prior to joining Catalyst, Mr.&#160;Elsbernd was, from 2004 until February 2016, employed in various capacities with Mallinckrodt Pharmaceuticals and its predecessors, including as Senior Director of U.S. Healthcare Compliance. At Mallinckrodt, he was involved in the building of their formal compliance program including providing leadership and vision on ethics and business conduct while also managing multiple other legal and business functions. Before joining Mallinckrodt, Mr.&#160;Elsbernd was an associate at Proskauer Rose LLP, within its Health Care practice group, representing health care providers nationwide in matters pertaining to regulatory and administrative law, transactional matters, litigation, and reimbursement issues. Mr.&#160;Elsbernd holds a Bachelor of Arts degree in history from the University of Illinois-Urbana and a law degree from the Saint Louis University School of Law. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Jeffrey Del Carmen</span>&#160;has been our Chief Commercial Officer since June&#160;23, 2020. Previously, since July 2018, Mr.&#160;Del Carmen served as our Senior Vice President of Sales and Marketing. Mr.&#160;Del Carmen has over 25 years of experience in pharmaceutical sales and project management. Prior to joining Catalyst, from January 2018 until July 2018, Mr.&#160;Del Carmen served as Vice President of Business Development of Paragon Biosciences evaluating commercial assets to expand Paragon&#8217;s portfolio. From September 2016 until June 2017 (when it was acquired by PTC Therapeutics), Mr.&#160;Del Carmen was Senior Director, Rare </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">27 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Disease Marketing for Marathon Pharmaceuticals, leading Marathon&#8217;s marketing efforts for the commercialization of Emflaza. From January 2016 to August 2016, Mr.&#160;Del Carmen served as Vice President of Sales at Insys Therapeutics. From August 2011 until January 2016, Mr.&#160;Del Carmen was employed by Lundbeck Inc., where for the last two years of his tenure at Lundbeck he was the Movement Disorder National Sales Director. Prior to joining Lundbeck, Mr.&#160;Del Carmen spent 16 years at Abbott Laboratories in various sales and marketing leadership roles, with increasing responsibility. Mr.&#160;Del Carmen holds a Bachelor of Arts degree in Economics from the University of Dayton and an Executive MBA Degree from the University of Wisconsin. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">Preethi Sundaram, Ph.D., </span>has been our Chief Strategy Officer since January&#160;1, 2022. Previously, since July 2021, Dr.&#160;Sundaram served as our Chief Product Development Officer. Dr.&#160;Sundaram has more than 20 years&#8217; experience managing and mentoring teams delivering lifesaving medicines to patients. Prior to her employment with Catalyst, since 2005, Dr.&#160;Sundaram was employed in various positions with Sanofi, including as Global Clinical Research Director, International Development from 2005-2010, Global Project Head, Multiple Therapeutic Area Programs from 2010 to 2017, Global Head and VP, Medical Operations, Primary Care Business Unit from 2017 to 2020, and since October 2020, as Sanofi&#8217;s Global Head and VP, Medical Operations, General Medicines Business Unit. In that last position, Dr.&#160;Sundaram was accountable for leadership of critical global medical operational functions, including the oversight of portfolio financials and delivery of strategic milestones, as well as being responsible for the leadership of multiple portfolio management functions across all therapeutic areas in Sanofi&#8217;s Medicines Business Unit. Prior to joining Sanofi, in 2005 Dr.&#160;Sundaram served as a Project Lead, Immunoscience Development Center for Abbott Laboratories; between 2003 to 2005, Dr.&#160;Sundaram served as a medical writer and project lead at Covance; between 2001 to 2003, Dr.&#160;Sundaram served as a Clinical Director with Neurovision&#160;&amp; Medical Services; between 1997 to 2001, Dr.&#160;Sundaram was a Graduate Teaching Assistant and Clinical Supervisor at West Norwich Hospital in Cambridge, UK; and between 1995 to 1997, Dr.&#160;Sundaram was on the clinical faculty at the Sankara Nethralaya Eye Hospital in Chennai, India. Dr.&#160;Sundaram holds a Bachelor of Arts in Psychology from the University of Madras (India), a Bachelor of Science in Optometry from the Elite School of Optometry&#160;&amp; Bits (India), a Doctor of Philosophy in Optometry from Anglia Ruskin University (United Kingdom), and an Executive Business Masters from the London Business School. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Family Relationships </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There are no family relationships between or among any of our directors and/or executive officers. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_11">C<small>OMPENSATION</small> D<small>ISCUSSION</small> <small>AND</small> A<small>NALYSIS</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The role of the compensation committee in setting executive officer compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee establishes and regularly reviews our compensation philosophy and programs, exercises authority with respect to the determination and payment of base and incentive compensation to our executive officers and administers our 2014 Plan and our 2018 Plan. Our Compensation Committee consists of four members of our Board, each of whom is independent as that term is defined in the Sarbanes-Oxley Act of 2002 and the rules and regulations that have been promulgated thereunder and under the Exchange Act, and in the applicable NASDAQ listing standards. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Executive officers </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During 2022, our Board designated that our &#8220;executive officers&#8221; (as that term is defined in the rules and regulations under the Exchange Act) are our Chief Executive Officer (Patrick J. McEnany), our Chief Operating and Chief Scientific Officer (Dr.&#160;Steven Miller), our Chief Financial Officer (Alicia Grande), our Chief Medical and Regulatory Officer (Dr.&#160;Gary Ingenito), our Chief Commercial Officer (Jeffrey Del Carmen), our Chief Compliance Officer and Chief Legal Officer (Brian Elsbernd), and our Chief Strategy Officer (Preethi Sundaram). Each of our executive officers were employed by us for all of fiscal 2022. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">28 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Overview of executive officer compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In evaluating executive compensation, our Compensation Committee receives third-party data and analysis on market trends and competitive practices from its independent compensation consultant. The Compensation Committee also receives and considers the recommendations of our Chief Executive Officer with respect to goals and compensation of executive officers. Our Compensation Committee assesses the information it receives in accordance with its business judgment. Our Chief Executive Officer is not present when his compensation is discussed by the Compensation Committee. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Compensation Committee believes that our executive officers are instrumental to our success. To that end, our compensation program is designed around the following: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:28%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:16%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:54%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Pay Element</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Form</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Purpose</p></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Base Salary</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cash (Fixed)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Provides a competitive level of compensation that reflects position responsibilities, strategic importance of the position and individual experience.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Short-Term Incentive (Annual Bonus)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cash (Fixed)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Provides a cash-based award that recognizes the achievement of corporate goals in support of an annual business plan.</td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Long-Term Incentive</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Equity (Variable)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Provides incentives for management to execute financial and strategic growth goals that support long-term stockholder value creation and our ability to recruit, retain and motivate key executives.</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also offer health and other insurance benefits to each of our employees, including our executive officers, and the benefits available to our executive officers are equal to the benefits available to all employees. No other perquisite benefits are available to our executive officers. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Process of setting 2022 executive officer compensation </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the fall of 2021, our Compensation Committee engaged Mercer LLC (a business of Marsh McLennan), an independent compensation consultant, to provide advice and recommendations relating to our executive officer and director compensation arrangements for the 2022 fiscal year. Initially, Mercer assisted the Compensation Committee in determining an appropriate peer group to evaluate the Company&#8217;s executive officer and director compensation for alignment with governance and market best practices, and to provide recommendations as to an appropriate compensation philosophy to guide the Compensation Committee in determining executive officer base, bonus and equity compensation for 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">An updated peer group was selected by the Compensation Committee with the advice of Mercer. The criteria used in determining the peer group were U.S. publicly traded biopharmaceutical companies (i)&#160;with a market cap of between $250&#160;million and $2.0&#160;billion; (ii)&#160;with net revenues of between $75&#160;million and $300&#160;million; and (iii)&#160;with a focus on the therapeutics segment of the biopharmaceutical vertical. The peer group selected was as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:24%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:27%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:24%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:22%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Aerie Pharmaceuticals</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Akebia Therapeutics</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Agios Pharmaceuticals</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Anika Therapeutics</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Antares Pharma</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cara Therapeutics</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Eagle Pharmaceuticals</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Harmony Biosciences Holdings</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Heron Therapeutics</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Insmed</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Iteos Therapeutics</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Radius Health</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Rigel Pharmaceuticals</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Seres Therapeutics</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">Travere Therapeutics (Retrophin)</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Vanda Pharmaceuticals</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"></td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">29 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In early 2022, Mercer presented their report to the Compensation Committee of the compensation payable to the executive officers in Company&#8217;s peer group. Based on that information, in February 2022, the Compensation Committee set base compensation and a bonus target for each executive officer for 2022. At the same time, the Compensation Committee, in light of the information presented by Mercer, determined to grant additional RSUs to each executive officer to raise their stock-based compensation for their 2021 performance. </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Further, in February 2022, the Compensation Committee established the corporate goals and objectives for the payment of 2022 cash bonuses to executive officers, as follows: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:68%;border:0;margin:0 auto">


<tr>

<td style="width:91%"></td>

<td style="vertical-align:bottom;width:6%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Objective</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Weight</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Achieving a minimum of $195&#160;million in net revenues</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Transformational acquisition of a company or marketed products, consistent with the strategic plan previously approved by the Board of Directors</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">35</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating to the 2022 budget</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Quality and compliance high grades</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Developing an ESG report</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100</td>
<td style="white-space:nowrap;vertical-align:bottom">%&#160;</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Thereafter, in December 2022, the Compensation Committee considered cash bonus compensation for the Company&#8217;s executive officers for 2022 services based on the previously established corporate goals and objectives. In reaching a determination as to the cash bonuses to grant for 2022 performance, the Compensation Committee considered the following factors: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company exceeded the total revenue target contained in the 2022 goals and objectives as adopted; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In July 2022, the Company acquired RUZURGI<sup style="font-size:75%; vertical-align:top">&#174;</sup> from Jacobus Pharmaceutical Company, Inc., which, while not adding a new product to the Company&#8217;s product line, was transformational to the Company&#8217;s business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">In December 2022, the Company entered into a definitive agreement to acquire a marketed product, FYCOMPA<sup style="font-size:75%; vertical-align:top">&#174;</sup>, from Eisai Co., Ltd. and, further, during 2022, the Company actively considered several significant potential acquisitions that did not occur; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company operated in line with the 2022 budget, and management continued to exert financial discipline over the business; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company has received high quality and compliance grades; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:5%">&#160;</td>
<td style="width:3%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">The Company was actively working on its first ESG report which was expected to be published in the second quarter of 2023 (and was actually published at the end of April 2023). </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">30 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">After considering these factors, none of which was, in and of itself dispositive, but all of which were considered, the Compensation Committee determined that cash bonuses would be paid to executive officers at 120% of the previously established bonus targets. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Finally, in late December 2022, the Compensation Committee granted stock options and RSUs to each of the Company&#8217;s executive officers for their 2022 performance. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The base and bonus compensation for our Principal Executive Officer, Principal Financial Officer and our three most highly compensated officers for services during the fiscal years ended December&#160;31, 2022, 2021 and 2020, as well as the value of the option and RSU grants made to each such executive officer for 2022, 2021 and 2020 services are described in the following summary compensation table: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:39%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom" colspan="30" align="center">Awards ($)</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Name and Principal Position</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Year</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Salary<br />($)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Cash<br />Bonus<br />($)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">RSU<br />Stock<br />Grants (1)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Stock<br />Options<br />(2)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="white-space:nowrap">Non-Equity</span><br />Incentive<br />Compensation</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">All Other<br />Compensation<br />($) (3)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Totals ($)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. McEnany</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chairman, President and CEO</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /><br /></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022<br />2021<br />2020</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br />&#160;<br />&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /><br /></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">691,923<br />632,308<br />604,179</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br />&#160;<br />&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /><br /></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">504,000<br />415,800<br />324,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br />&#160;<br />&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,795,110<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /><br /></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,932,749<br />1,041,324<br />834,093</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br />&#160;<br />&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /><br /></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;<br />&#8212;&#160;&#160;<br />&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br />&#160;<br />&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /><br /></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,923,782<br />2,089,432<br />1,762,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br />&#160;<br />&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alicia Grande,</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CFO</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">2021</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">2020</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">442,115<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">421,539</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">402,875</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">213,600<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">184,800</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">144,000</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">737,270<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">948,830<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">646,006</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">521,308</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,200<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">11,600</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">11,400</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,354,015<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">1,263,945</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">1,079,583</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven R. Miller,</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COO and CSO</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">2021</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">2020</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">496,827<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">474,231</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">453,271</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">300,000<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">259,875</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">202,500</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,091,560<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,574,196<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">713,500</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">573,439</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12,200<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">11,600</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">11,400</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3,474,783<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">1,459,206</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">1,240,610</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Ingenito,</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Chief Medical and Regulatory Officer</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">2021</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">2020</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">484,437<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">469,803</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">448,689</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">232,800<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">205,590</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">160,200</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">729,330<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,002,741<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">520,662</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">417,047</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">34,615<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">31,470</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">30,397</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,483,923<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">1,227,525</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">1,056,333</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Del Carmen,</p> <p style="margin-top:0pt; margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">CCO</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2022<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">2021</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">2020</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">449,000<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">400,749</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">339,207</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">211,200<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">176,000</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">119,531</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">725,900<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">141,000</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">948,830<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">520,662</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">957,032</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">&#8212;&#160;&#160;</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">51,502<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">48,314</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">49,219</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman"></p></td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,386,432<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">1,145,725</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman;text-align:right">1,605,989</p></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;<br /> <p style="margin-bottom:0pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p> <p style="margin-bottom:1pt; margin-top:0pt; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts reported are based on the aggregate grant date fair value computed in accordance with FASB ASC Topic 718 for restricted stock unit grants to the executive officers in the listed fiscal year. In the case of 2022 stock compensation, the value of the RSUs awarded in both February 2022 and December 2022 are included in this chart because they were granted in 2022. However, the February 2022 RSU grants related to increased compensation determined by the Compensation Committee to be payable to executive officers for their 2021 performance based on the compensation analysis prepared by Mercer and presented to the Compensation Committee in early 2022. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The amounts reported represent the grant date fair value of stock option awards granted in accordance with FASB ASC Topic 718 for the listed year. For additional information on the valuation assumptions used in the calculation of these amounts, see Note 16 to &#8220;Notes to Consolidated Financial Statements&#8221; contained in our 2022 Original Form <span style="white-space:nowrap">10-K.</span> </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes, for Dr.&#160;Ingenito and Mr.&#160;Del Carmen, a housing allowance. All other compensation consists of 401(k) employer match. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">31 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Employment Agreements and Potential Payments upon Termination or Change in Control </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have an employment agreement with Patrick J. McEnany, our Chairman, President and Chief Executive Officer, which provides for the payment of a base salary plus bonus compensation based on performance. Mr.&#160;McEnany&#8217;s employment agreement also contains a &#8220;change of control&#8221; severance arrangement if the employee is not retained in our employment after a change of control. The employment agreement for Mr.&#160;McEnany expires on November&#160;8, 2024. After the expiration of his employment agreement, Mr.&#160;McEnany becomes an <span style="white-space:nowrap"><span style="white-space:nowrap">employee-at-will,</span></span> and he will still be entitled to payments for termination without cause or in the event of a change in control, as set forth below. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the employment agreement that we have with Mr.&#160;McEnany, we may terminate his employment at any time for &#8220;cause&#8221;, in which he would have no right to receive compensation or other benefits for any period after termination. Termination for &#8220;cause&#8221; occurs when the executive performs dishonest acts intended to benefit the executive personally, the executive willfully neglects his duties, or the executive fails to perform his duties because of gross negligence on the part of the executive, violation of any obligation under the executive&#8217;s employment agreement not remedied by the executive after ten (10)&#160;days&#8217; notice of such violation, or the executive&#8217;s arrest for, conviction of or plea of nolo contendre to a crime constituting a felony. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In certain circumstances, Mr.&#160;McEnany is entitled to severance pay. These circumstances include (i)&#160;his voluntary resignation after a change in control or a demotion, or our failure to perform our material obligations under his employment agreement and our failure to remedy such violation within ten (10)&#160;days&#8217; notice of such violation, (ii)&#160;his termination without cause, (iii)&#160;his total and permanent disability, or (iv)&#160;his death. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">A change in control under our employment agreement with Mr.&#160;McEnany includes: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the sale, transfer, assignment or other disposition (including by merger or consolidation, but excluding any sales by stockholders made as part of an underwritten public offering of the common stock of the company), in one transaction or a series of related transactions, of more than fifty percent (50%) of the voting power represented by the then-outstanding capital stock of the company to one or more persons (other than to the executive officer or a &#8220;group&#8221; (as defined under the Securities Exchange Act of 1934) in which the executive officer is a member); </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the sale of substantially all of the assets of the company (other than a transfer of financial assets made in the ordinary course of business for the purpose of securitization); or </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">the liquidation or dissolution of the company. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under any of those circumstances, the executive&#8217;s severance package includes: (i)&#160;the payment of any accrued but unpaid annual bonus at the time of termination; (ii)&#160;the payment of the executive&#8217;s base salary for a period of 24 months; (iii)&#160;the vesting of all outstanding stock options and other equity awards held by the executive that have not yet vested; and (iv)&#160;continuation of the executive&#8217;s medical benefits (in case of disability), including to his family (in case of death or disability). </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We also have a severance and change in control plan in place that provides for severance if those of our executive officers designated to participate in the benefits under the plan are terminated for other than &#8220;cause&#8221; or if they terminate their employment with us for &#8220;good reason&#8221;, and for severance compensation in the event of a &#8220;change in control&#8221; (as all of those terms are defined in the plan). </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">32 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Under our severance and change in control plan, </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">on a termination without &#8220;cause&#8221; or a termination for &#8220;good reason&#8221; of a designated executive, the executive will receive one year&#8217;s base salary, any accrued bonus prior to termination, 12 month accelerated vesting of stock options, and benefits continuation for one year; provided that the terminated executive agrees to not compete with the company during the period in which severance is paid; </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon a &#8220;change in control,&#8221; all outstanding stock options and other equity awards held by each designated executive that have not yet vested shall automatically vest; and </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:1%">&#160;</td>
<td style="width:2%;vertical-align:top" align="left">&#8226;</td>
<td style="width:1%;vertical-align:top">&#160;</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt;text-align:left">upon termination of a designated executive within one year of a &#8220;change in control,&#8221; the terminated executive will receive one year&#8217;s base salary, payment in full of any target bonus previously granted for the severance period, and benefits continuation for the severance period, again subject to the terminated executive agreeing not to compete with the company during the period in which severance is paid. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">To date, the Compensation Committee has designated that Ms.&#160;Grande, Mr.&#160;Del Carmen, Mr.&#160;Elsbernd, Dr.&#160;Ingenito, Dr.&#160;Miller, and Dr.&#160;Sundaram will receive benefits under the severance and change in control plan. Pursuant to the terms of the plan, once an executive has been designated to participate in the severance benefits afforded by the plan, the Compensation Committee cannot modify the plan as to that designated executive to eliminate any benefits or to modify the definitions used in the policy to the detriment of the designated executive, unless otherwise agreed to by the designated executive. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following chart sets forth the amounts payable to our CEO, CFO and our three most highly compensated employees assuming the enumerated events had occurred on December&#160;31, 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:48%"></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:7%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:8%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap">Name</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Payment&#160;Due&#160;Upon<br />Termination either<br />by&#160;company&#160;without<br />Cause or Officer for<br />Good Reason (1)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Payment&#160;Due<br />Upon Death<br />or Permanent<br />Disability</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Payment&#160;Due&#160;Upon&#160;a<br />Termination by<br />company&#160;with&#160;Cause&#160;or<br />Resignation or<br />Retirement</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Payment Due<br />upon&#160;a&#160;Change<br />in Control (1)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. McEnany</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">700,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">700,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,400,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alicia Grande</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">445,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 445,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven R. Miller</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Ingenito</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">485,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">485,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;&#160;(2)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 485,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Del Carmen</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">440,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 440,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Excludes the value of any bonus due for services prior to termination, the value of health benefits for the term of the severance and the value of any accelerated vesting of stock options and other equity awards. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Payable under a letter agreement between us and Dr.&#160;Ingenito. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">33 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Grants of Plan-Based Awards for 2022 </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information relating to stock options granted to our CEO, CFO and our three most highly compensated employees during the fiscal year ended December&#160;31, 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:53%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Grant Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Number of<br />Securities<br />Underlying<br />Options&#160;(#)&#160;(1)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Exercise&#160;Price&#160;of<br />Option Awards<br />($/share)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Grant Date Fair<br />Value&#160;of&#160;Option<br />Awards</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. McEnany</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">12/27/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">272,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,932,749</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alicia Grande</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">12/27/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 948,830</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven R. Miller</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">12/27/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">146,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,574,196</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Ingenito</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">12/27/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">93,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,002,741</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Del Carmen</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">12/27/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 948,830</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">All options vest <span style="white-space:nowrap">one-third</span> on the first anniversary of the grant date, <span style="white-space:nowrap">one-third</span> on the second anniversary of the grant date, and <span style="white-space:nowrap">one-third</span> on the third anniversary of the grant date and expire on the seventh anniversary of the grant date. </p></td></tr></table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Additionally, the following table provides information relating to restricted stock units granted to our CEO, CFO and our three most highly compensated employees during 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:54%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Grant Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Number of<br />RSUs<br />Granted(1)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Grant Date</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Number of<br />RSUs<br />Granted(1)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Grant Date<br />Fair Value of<br />Option<br />Awards</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. McEnany</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2/14/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">175,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/27/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2,795,110</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alicia Grande</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2/14/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/27/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 737,270</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven R. Miller</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2/14/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/27/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,091,560</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Ingenito</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2/14/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/27/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 729,330</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Del Carmen</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">2/14/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/27/2022</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right"> 725,900</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">RSUs vest <span style="white-space:nowrap">one-third</span> on the first anniversary of the grant date, <span style="white-space:nowrap">one-third</span> on the second anniversary of the grant date, and <span style="white-space:nowrap">one-third</span> on the third anniversary of the grant date. </p></td></tr></table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Outstanding Stock Options and Restricted Stock Units </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have two stock incentive plans: our 2018 Plan and our 2014 Plan. As of the Record Date, the following derivative securities were outstanding (collectively) under our stock incentive plans: (i)&#160;stock options to purchase an aggregate of 12,214,224 shares of our common stock, at exercise prices ranging from $1.13 to $19.02 per share (7,961,197 of which are currently exercisable); and (ii)&#160;restricted stock units for 584,337 shares of common stock (none of which are currently vested). On the same date, 1,675,960 shares of common stock remained eligible for grant under the 2018 Plan. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On the Record Date, the market price of our common stock on the NASDAQ Capital Market was $12.66 per share. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Outstanding Equity Awards at Fiscal Year End </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth certain information regarding equity-based awards held by our CEO, CFO and our three other most highly compensated employees as of December&#160;31, 2022: </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><span style="font-style:italic">[Table on Following Page] </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">34 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">OUTSTANDING EQUITY AWARDS AT DECEMBER&#160;31, 2022 </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:31%"></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="18" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Option Awards</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="14" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Stock Awards</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Number of<br />Securities<br />Underlying<br />Unexercised<br />Options (#)<br />Exercisable</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Number of<br />Securities<br />Underlying<br />Unexercised<br />Options (#)<br />Unexercisable</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Equity<br />Incentive<br />Plan<br />Awards:<br />Number of<br />Securities<br />Underlying<br />Unexercised<br />Unearned<br />Options (#)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Option<br />Exercise<br />Price<br />($)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Option&#160;Expiration<br />Date</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Number<br />of&#160;Shares<br />or Units<br />of Stock<br />that&#160;Have<br />Not<br />Vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Market<br />Value<br />of<br />Shares<br />or<br />Units<br />of<br />Stock<br />that<br />Have<br />Not<br />Vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Equity<br />Incentive<br />Plan<br />Awards:<br />Number&#160;of<br />Unearned<br />Shares,<br />Units, or<br />Other<br />Rights<br />That Have<br />Not&#160;Vested</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Equity<br />Incentive<br />Plan<br />Awards:<br />Market&#160;or<br />Payout<br />Value of<br />Unearned<br />Shares,<br />Units, or<br />Other<br />Rights<br />That<br />Have Not<br />Vested</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. McEnany</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">200,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">06/15/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">250,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/03/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">300,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/02/2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.54</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">05/29/2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">740,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/02/2026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">266,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133,334</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/30/2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">90,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">180,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.07</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/28/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">272,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/27/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">175,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">79,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alicia Grande</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">06/15/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/03/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">285,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/02/2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">225,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/19/2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">132,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/02/2026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">166,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">83,334</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/30/2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55,833</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">111,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.07</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/28/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/27/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">33,500</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Miller</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">100,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0.79</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">06/15/2023</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/03/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">285,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/02/2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">225,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/19/2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">180,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/02/2026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">183,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">91,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/30/2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">61,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">123,334</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.07</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/28/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">146,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/27/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">41,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">42,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Ingenito</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/03/2024</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">230,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/02/2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">225,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/19/2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">44,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/02/2026</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/30/2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">90,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.07</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/28/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">93,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/27/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">27,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Del Carmen</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">30,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">08/06/2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,983</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/19/2025</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">20,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.21</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">01/06/2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">60,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">90,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.70</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">06/23/2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">133,333</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">66,667</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">3.42</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/30/2027</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">45,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">90,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.07</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/28/2028</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">18.59</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12/27/2029</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">10,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">32,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">26,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">35 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">Option Exercises </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table provides information regarding the exercise of stock options by our executive officers during the year ended December&#160;31, 2022: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:92%;border:0;margin:0 auto">


<tr>

<td style="width:58%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Grant Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Exercise Date</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Number of<br />Securities<br />Underlying<br />Options<br />(#)</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Exercise<br />Price of<br />Option<br />Awards<br />($/<br />share)</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. McEnany</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">12/30/2015</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="white-space:nowrap">08/18-19/2022</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">300,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. McEnany</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">12/19/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="white-space:nowrap">11/18-21/2022</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">500,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alicia Grande</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">12/30/2015</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="white-space:nowrap">08/17-18/2022</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven Miller</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">12/30/2015</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">08/18/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.53</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Ingenito</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">06/30/2015</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center"><span style="white-space:nowrap">06/21-22/2022</span></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">150,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.13</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Ingenito</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">01/02/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">09/14/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">55,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.01</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Ingenito</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">12/02/2019</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">09/14/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">88,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">4.64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Del Carmen</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">12/19/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">11/11/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">19,017</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.24</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Del Carmen</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">08/06/2018</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap" align="center">11/11/2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">120,000</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">2.86</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_12">C<small>OMPENSATION</small> C<small>OMMITTEE</small> R<small>EPORT</small> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Compensation Committee has reviewed the Compensation &#8211; Discussion and Analysis required by Item 402(b) of Regulation <span style="white-space:nowrap">S-K</span> of the SEC&#8217;s rules and regulations with management and based on such review and discussions the Compensation Committee recommended to the Board of Directors that the Compensation &#8211; Discussion and Analysis be included in this Proxy Statement. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Compensation Committee </span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">David S. Tierney, Chair </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Richard J. Daly </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles B. O&#8217;Keeffe </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Molly Harper </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Notwithstanding anything to the contrary set forth in any of our previous filings under the Securities Act of 1933, or the Securities Exchange Act of 1934 that might incorporate future filings, including this Proxy Statement, in whole or in part, the Compensation Committee Report above shall not be incorporated by reference into any such filings. </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">36 </p>

</div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" /><div style='display: none'><ix:header><ix:references><link:schemaRef xlink:type="simple" xlink:href="cprx-20221231.xsd" /><link:linkbaseRef xlink:type="simple" xlink:href="cprx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="cprx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /><link:linkbaseRef xlink:type="simple" xlink:href="cprx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" /></ix:references></ix:header></div><div><div><div style="background-color:white;display: inline;"><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div id="toc500830_13" style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: center;"><div style="font-weight:bold;display:inline;">P<div style="display:inline;;font-size:11.07px">AY</div> V<div style="display:inline;;font-size:11.07px">ERSUS</div> P<div style="display:inline;;font-size:11.07px">ERFORMANCE</div> </div></div><ix:nonNumeric name="ecd:NamedExecutiveOfficersFnTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s principal executive officer (&#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PEO</div></div>&#8221;) and our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO</div> named executive officers (&#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NEO</div></div>s&#8221;) were as follows for the fiscal years ended December&#160;31, 2022, 2021 and 2020: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:15%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:79%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PEO</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-PEO</div> NEOs</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><ix:nonNumeric name="ecd:PeoName" contextRef="P01_01_2022To12_31_2022">Patrick J. McEnany</ix:nonNumeric></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Alicia Grande, Steven Miller, Gary Ingenito, Jeffrey Del Carmen</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Patrick J. McEnany</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Alicia Grande, Steven Miller, Gary Ingenito, Preethi Sundaram</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">2020</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Patrick J. McEnany</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Alicia Grande, Steven Miller, Gary Ingenito, Jeffrey Del Carmen</div></td></tr></table></ix:nonNumeric><ix:nonNumeric name="ecd:PvpTableTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_83060738"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning the compensation of our PEO and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO</div> NEOs for the fiscal years ended December&#160;31, 2022, 2021 and 2020, and our financial performance for each such fiscal year: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value of Initial $100 Fixed<br/>Investment Based on (3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Summary<br/>Compensation<br/>Table Total<br/>for PEO ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compensation<br/>Actually Paid<br/>to PEO ($)<br/>(1)(2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/>Summary<br/>Compensation<br/>Table&#160;Total&#160;for<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO&#160;NEOs</div><br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/>Compensation<br/>Actually Paid<br/>to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO</div><br/>NEOs ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Shareholder<br/>Return ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Peer Group<br/>Total<br/>Shareholder<br/>Return ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/>Income (in<br/>thousands)<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;Product<br/>Revenue (in<br/>thousands)<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,923,782</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">17,549,684</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,674,788</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,393,846</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">496</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:PeerGroupTotalShareholderRtnAmt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">69</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">83,079</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:CoSelectedMeasureAmt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">213,938</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,089,432</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,369,277</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,361,793</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,328,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">181</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:PeerGroupTotalShareholderRtnAmt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">94</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">39,482</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:CoSelectedMeasureAmt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">137,997</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,762,272</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,544,344</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,245,629</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,099,682</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:TotalShareholderRtnAmt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">89</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:PeerGroupTotalShareholderRtnAmt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">113</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="us-gaap:NetIncomeLoss" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">74,983</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:CoSelectedMeasureAmt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="-3" scale="3" format="ixt:num-dot-decimal">118,790</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Amounts represent &#8220;compensation actually paid&#8221; (&#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CAP</div></div>&#8221;) to our PEO and the average compensation actually paid to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO</div> NEOs for the relevant fiscal year, as determined under SEC rules (and described below). </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Fair value or change in fair value, as applicable, of stock options in the &#8220;Compensation <div style="display:inline;">Actually </div>Paid&#8221; columns was estimated using a Black-Scholes option pricing model for the purposes of this disclosure in accordance with SEC rules and do not reflect compensation actually earned, realized or received during each applicable year. The calculation of CAP for purposes of this table includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-in-time</div></div> fair values of equity awards and those values will fluctuate based on our stock price and various accounting valuation assumptions. See the Summary Compensation Table for certain other compensation of our PEO and our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO</div> NEOs for each applicable fiscal year. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;"><ix:nonNumeric name="ecd:PeerGroupIssuersFnTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">For the relevant fiscal year, represents our cumulative &#8220;total shareholder return&#8221; (&#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">TSR</div></div>&#8221;) or the cumulative TSR of the Nasdaq Biotechnology Index, in each case assuming an initial investment of $100 as described under the Narrative Disclosure to Pay Versus Performance heading below. We have never declared or paid a dividend on our common stock and do not anticipate doing so in the foreseeable future.</ix:nonNumeric> </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:exclude>37</ix:exclude> </div></ix:nonNumeric></div></div><ix:continuation id="TextSelection_83060738" continuedAt="TextSelectionAppend_83060738_1"><ix:exclude><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_83060738_1" continuedAt="TextSelectionAppend_83060738_2"><ix:exclude><hr style="color:#999999;height:3px;width:100%"/></ix:exclude></ix:continuation><ix:continuation id="TextSelectionAppend_83060738_2" continuedAt="TextSelectionAppend_83060738_3"><ix:exclude><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div></ix:exclude></ix:continuation><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><ix:continuation id="TextSelectionAppend_83060738_3"><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the table immediately above, the columns &#8220;Compensation Actually Paid to PEO&#8221; and &#8220;Average Compensation Actually Paid to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO</div> NEOs&#8221; reflect the Total Compensation reported in the 2022 Summary Compensation Table (&#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SCT</div></div>&#8221;), as adjusted based on the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SCT&#160;Total&#160;($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Minus SCT<br/>Equity<br/>Awards ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Plus&#160;Value&#160;of<br/>New&#160;Unvested<br/>Awards as of<br/>12/31 ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Plus&#160;Annual<br/>Change in<br/>Value&#160;of&#160;Prior<br/>Year Awards<br/>that Remain<br/>Unvested ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Plus&#160;Value&#160;of<br/>Awards<br/>Vested and<br/>Granted<br/>During Year<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Plus&#160;Change<br/>in Value of<br/>Prior Year<br/>Awards that<br/>Vest During<br/>Year ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;CAP&#160;($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">PEO</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">6,923,782</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2022To12_31_2022_PeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">5,727,859</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2022To12_31_2022_PeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,659,348</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2022To12_31_2022_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,460,212</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2022To12_31_2022_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,234,201</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">17,549,684</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,089,432</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2021To12_31_2021_PeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,041,324</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2021To12_31_2021_PeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">978,593</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2021To12_31_2021_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,424,326</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2021To12_31_2021_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,918,250</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">5,369,277</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:PeoTotalCompAmt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,762,272</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2020To12_31_2020_PeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">834,093</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2020To12_31_2020_PeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">808,368</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2020To12_31_2020_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">264,158</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2020To12_31_2020_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">71,955</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:PeoActuallyPaidCompAmt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,544,344</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="9" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td colspan="8" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-PEO</div> NEOs</div></div></td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,674,788</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2022To12_31_2022_NonPeoNeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">1,939,664</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2022To12_31_2022_NonPeoNeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,316,864</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2022To12_31_2022_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,394,265</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2022To12_31_2022_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,947,593</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="P01_01_2022To12_31_2022" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">7,393,846</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,361,793</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2021To12_31_2021_NonPeoNeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">767,761</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2021To12_31_2021_NonPeoNeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">804,173</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2021To12_31_2021_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">456,388</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2021To12_31_2021_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">473,572</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="P01_01_2021To12_31_2021" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">2,328,165</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:NonPeoNeoAvgTotalCompAmt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,245,629</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2020To12_31_2020_NonPeoNeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">652,457</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2020To12_31_2020_NonPeoNeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">574,265</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(<ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2020To12_31_2020_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis" unitRef="Unit_USD" decimals="0" scale="0" sign="-" format="ixt:num-dot-decimal">70,986</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:AdjToCompAmt" contextRef="P01_01_2020To12_31_2020_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">3,231</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;"><ix:nonFraction name="ecd:NonPeoNeoAvgCompActuallyPaidAmt" contextRef="P01_01_2020To12_31_2020" unitRef="Unit_USD" decimals="0" scale="0" format="ixt:num-dot-decimal">1,099,682</ix:nonFraction></td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables illustrate the valuation assumptions as of the vesting date for awards that vested in each of 2022, 2021 and 2020. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="5" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For Stock Options Vesting in</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.30%&#160;-&#160;4.00%</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.35%&#160;-&#160;1.17%</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.24%&#160;-&#160;1.53%</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">4.5 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">4.5 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">4.5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">68.4% - 69.5%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">68.6% - 72.8%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">80.5% - 83.7%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">&#8212;&#160;&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected forfeiture rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">&#8212;&#160;&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average&#160;Fair&#160;Value&#160;of&#160;Full&#160;Value<br/>Awards&#160;Vesting in</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">For Restricted Stock Units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table></ix:continuation><div style="margin-top: 18pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">2022 Performance Measures </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following list represents the financial and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-financial</div> performance measures that we consider to have been the most important in linking Compensation Actually Paid to our PEO and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO</div> NEOs to company performance. The measures in this list are not ranked. Of these measures, we have identified Net Product Revenue as our most important of our financial performance measures used to link Compensation Actually Paid to our PEO and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO</div> NEOs to company performance: </div><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:nonNumeric name="ecd:CoSelectedMeasureName" contextRef="P01_01_2022To12_31_2022"><ix:nonNumeric name="ecd:MeasureName" contextRef="P01_01_2022To12_31_2022_1TypedMemberecdMeasureAxis">Net Product Revenue</ix:nonNumeric></ix:nonNumeric> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:nonNumeric name="ecd:MeasureName" contextRef="P01_01_2022To12_31_2022_2TypedMemberecdMeasureAxis">Net Income</ix:nonNumeric> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:nonNumeric name="ecd:MeasureName" contextRef="P01_01_2022To12_31_2022_3TypedMemberecdMeasureAxis">Completion of a transformational acquisition</ix:nonNumeric> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"><ix:nonNumeric name="ecd:MeasureName" contextRef="P01_01_2022To12_31_2022_4TypedMemberecdMeasureAxis">Quality and Compliance</ix:nonNumeric> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">38 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><div style="font-weight:bold;display:inline;">Narrative Disclosure to Pay Versus Performance Table </div></div><div style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The graph below compares the compensation actually paid to our PEO and the average of the compensation actually paid to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO</div> NEOs with (i)&#160;our cumulative TSR and our Peer Group TSR, (ii)&#160;our net income, and (iii)&#160;our net product revenue, in each case for the fiscal years ended December&#160;31, 2022, 2021 and 2020. </div><ix:nonNumeric name="ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_83060708"><ix:nonNumeric name="ecd:TotalShareholderRtnVsPeerGroupTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true" continuedAt="TextSelection_83060704"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TSR amounts reported in the graph assume an initial fixed investment of $100 on January&#160;1, 2020 and, with respect to our cumulative TSR, based on the opening trading price on such date. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:0pt;margin-bottom:0pt;text-align:center"><ix:continuation id="TextSelection_83060708"><ix:continuation id="TextSelection_83060704">
<img alt="LOGO" src="g500830g0707050510473.jpg"/></ix:continuation></ix:continuation> </div><div style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</div><div style="margin-top:0pt;margin-bottom:0pt;text-align:center"><ix:nonNumeric name="ecd:CompActuallyPaidVsNetIncomeTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<img alt="LOGO" src="g500830g0707050510771.jpg"/></ix:nonNumeric> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">39 </div></div></div><div style="margin-top:1em; margin-bottom:0em; page-break-before:always"></div><hr style="color:#999999;height:3px;width:100%"/><div style="font-size: .83em;margin-top : 1.67em;margin-bottom : 1.67em;font-weight: bold;"><a href="#toc">Table of Contents</a></div><div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"><div style="margin-top:0pt;margin-bottom:0pt;text-align:center"><ix:nonNumeric name="ecd:CompActuallyPaidVsCoSelectedMeasureTextBlock" contextRef="P01_01_2022To12_31_2022" escape="true">
<img alt="LOGO" src="g500830g0707050511017.jpg"/></ix:nonNumeric> </div><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">40 </div></div></div></div></div></div>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_14">CEO P<small>AY</small> R<small>ATIO</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As required by Item 402(u) of <span style="white-space:nowrap">Regulation&#160;S-K,&#160;the</span> Compensation Committee reviewed a comparison of our CEO&#8217;s annual total compensation in fiscal year 2022 to that of all of our other employees for 2022. Registrants may identify the median employee once every three years unless there has been a change in their employee population or employee compensation arrangements that the registrant reasonably believes would result in a significant change in the pay ratio disclosure. We have elected to utilize the same median employee that we used in 2020 for the CEO Pay Ratio calculation. In 2020, we identified our median employee by reviewing the base salary, on an annualized basis, for all of our employees as of December&#160;31, 2020, for the period from January&#160;1, 2020 through December&#160;31, 2020, excluding our CEO. After identifying our median employee, we calculated total compensation for such employee using the same methodology we use for our named executive officers as set forth in the 2022 Summary Compensation Table above. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The total annual compensation for fiscal year 2022 for our CEO was $6,923,782, as noted in the 2022 Summary Compensation table above. The median of the 2022 annual total compensation of all employees (other than our CEO) was $343,631. The resulting ratio of our CEO&#8217;s pay to the pay of our median employee for fiscal year 2022 was 20 to 1. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">SEC rules for identifying the median of the total annual compensation of our employees and calculating the pay ratio based on that employee&#8217;s total annual compensation allows companies to adopt a variety of methodologies, to apply certain exclusions, and to make reasonable estimates and assumptions that reflect their employee populations and compensation practices. The pay ratio reported by other companies may not be comparable to the pay ratio for our company, as other companies have headquarters offices in different countries, have different employee populations and compensation practices and may utilize different methodologies, exclusions, estimates and assumptions in calculating their pay ratios. We believe that the pay ratio reported above is a reasonable estimate calculated in a manner consistent with SEC rules based on our internal records and the methodology described above. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">41 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We invest in our employees at all levels in our company by rewarding performance that balances risk and reward, empowering professional growth and development and by offering affordable benefits and programs that meet the diverse needs of our employees. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_15">P<small>ROPOSAL</small> F<small>OUR</small> &#8211; R<small>ATIFICATION</small> <small>OF</small> A<small>PPOINTMENT</small> <small>OF</small> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">I<small>NDEPENDENT</small> P<small>UBLIC</small> A<small>CCOUNTING</small> F<small>IRM</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Audit Committee has appointed Grant Thornton, LLP (&#8220;<span style="font-weight:bold">Grant Thornton</span>&#8221;) as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2023. The Board has directed that this appointment be submitted to our stockholders for ratification. Although ratification of our appointment of Grant Thornton is not required, we value the opinions of our stockholders and believe that stockholder ratification of our appointment is a good corporate governance practice. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Grant Thornton also served as our independent registered public accounting firm for the fiscal years ended December&#160;31, 2022, 2021 and 2020. Neither the accounting firm nor any of its members has any direct or indirect financial interest in or any connection with us in any capacity other than as our auditors, providing audit and <span style="white-space:nowrap">non-audit</span> services. A representative of Grant Thornton is expected to attend the Annual Meeting. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the event that the appointment of Grant Thornton is not ratified by the stockholders, the Audit Committee will consider this fact when it appoints the independent registered public accounting firm for the fiscal year ending December&#160;31, 2024. Even if the appointment of Grant Thornton is ratified, the Audit Committee retains the discretion to appoint a different independent registered public accounting firm at any time if it determines that such a change is in the interest of the Company. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Vote Required </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This proposal requires the affirmative vote of the holders of a majority in voting power of the votes cast affirmatively or negatively. Abstentions are not considered to be votes cast and, accordingly, will have no effect on the outcome of the vote on this proposal. Because brokers have discretionary authority to vote on the ratification of the appointment of Grant Thornton, we do not expect any broker <span style="white-space:nowrap">non-votes</span> in connection with this proposal. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">The Board unanimously recommends a vote FOR the Ratification of the Appointment of Grant Thornton as our Independent Registered Public Accounting Firm. </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Independent Auditor Fees </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table represents fees for professional audit and other services rendered by Grant Thornton for the fiscal years ended December&#160;31, 2022 and 2021. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:78%"></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:3%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2022</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><span style="font-weight:bold">2021</span></td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit fees (1)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">415,644</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">361,495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Audit-related fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total audit fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">415,644</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">361,495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tax fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All other fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1px">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&#160;</p></td>
<td>&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total fees</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">415,644</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">361,495</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Footnotes on next page </span></p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">42 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td style="width:100%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:2.00em; text-indent:-2.00em; font-size:10pt; font-family:Times New Roman">(1)&#8194;&#8201;&#8202;Represents aggregate fees billed for professional services rendered by Grant Thornton LLP for the audit of our financial statements included in our 2022 and 2021 Forms <span style="white-space:nowrap">10-K,</span> for their reviews of our quarterly reports during 2022 and 2021, and for their report on the effectiveness of our internal controls over financial reporting as of December&#160;31, 2022 and 2021. Includes, for 2022 and 2021, $10,724 and $9,575, respectively, for the audit of the financial statements of our wholly-owned subsidiary, Catalyst Pharmaceuticals Ireland, Ltd., a corporation organized in the Republic of Ireland.</p></td></tr>
</table> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="white-space:nowrap">Pre-Approval</span> of Audit Functions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to its written charter, the Audit Committee is responsible for <span style="white-space:nowrap">pre-approving</span> all audit and permitted <span style="white-space:nowrap">non-audit</span> services to be performed for us by our independent registered public accounting firm or any other auditing or accounting firm. 100% of the services provided to us by Grant Thornton in 2022 and 2021 were <span style="white-space:nowrap">pre-approved</span> by the Audit Committee. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_16">A<small>UDIT</small> C<small>OMMITTEE</small> R<small>EPORT</small> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Management has the primary responsibility for our internal control over financial reporting, the financial reporting process and preparation of our financial statements. Grant Thornton LLP, our independent registered public accounting firm, is responsible for performing an independent audit of our financial statements in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB) and to issue a report thereon. Grant Thornton LLP is also responsible for auditing our internal control over financial reporting in accordance with the standards of the PCAOB. The Audit Committee&#8217;s responsibility is to select the independent auditors and to monitor and oversee these processes. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has met and held discussions with management and the independent auditors. Management represented to the Audit Committee that our financial statements were prepared in accordance with accounting principles generally accepted in the United States. The Audit Committee reviewed and discussed the audited financial statements with management and the independent auditors. In fulfilling its responsibilities, the Audit Committee discussed with the independent auditors the matters that are required to be discussed by Auditing Standard No.&#160;1301 (Communication with Audit Committees). In addition, the Audit Committee received from the independent auditors the written disclosures and letter required by PCAOB Ethics and Independence Rule 3526, Communications with Audit Committees Concerning Independence, and the Audit Committee discussed with the independent auditors that firm&#8217;s independence. In connection with this discussion, the Audit Committee also considered whether the provision of services by the independent auditors not related to the audit of our financial statements is compatible with maintaining the independent auditors&#8217; independence. During such discussions, the independent auditors confirmed that, as of December&#160;31, 2022, they were independent accountants with respect to our company within the meaning of applicable federal securities laws and the requirements of the PCAOB. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based upon the Audit Committee&#8217;s discussions with management and the independent auditors and the Audit Committee&#8217;s review of the representations of management and the reports and letter of the independent auditors provided to the Audit Committee, the Audit Committee recommended to the Board that our audited financial statements for fiscal 2022 be included in our 2022 Form <span style="white-space:nowrap">10-K.</span> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Audit Committee has also reviewed all <span style="white-space:nowrap">non-audit</span> services being provided by the independent auditors and has concluded that the provision of such services has been compatible with the maintenance of that firm&#8217;s independence in the conduct of its auditing functions. The Audit Committee has discussed these matters with representatives of the independent auditors and our management and will monitor our compliance with any new restrictions as they are put in place to continue to ensure that the services provided by our independent accountants are compatible with the maintenance of that firm&#8217;s independence in the conduct of its auditing functions. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">43 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold"><span style="font-style:italic">The Audit Committee </span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Donald A. Denkhaus (Chair) </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Philip H. Coelho </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Charles B. O&#8217;Keeffe </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><span style="font-style:italic">Notwithstanding anything to the contrary set forth in any of our previous filings under the Securities Act of 1933, or the Securities Exchange Act of 1934 that might incorporate future filings, including this Proxy Statement, in whole or in part, the Audit Committee Report above shall not be incorporated by reference into any such filings </span></p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_17">S<small>ECURITY</small> O<small>WNERSHIP</small> <small>OF</small> C<small>ERTAIN</small> B<small>ENEFICIAL</small> O<small>WNERS</small> <small>AND</small> M<small>ANAGEMENT</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of the Record Date, we had 106,507,108 shares of our common stock outstanding. The following table sets forth, as of such date, certain information regarding the shares of common stock owned of record or beneficially by (i)&#160;each person who owns beneficially more than 5% of our outstanding common stock; (ii)&#160;each of our directors and executive officers; and (iii)&#160;all executive officers and directors as a group. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:76%;border:0;margin:0 auto">


<tr>

<td style="width:75%"></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>

<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="6" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Shares&#160;Beneficially&#160;Owned&#160;(1)</td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman">Name</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Number</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" align="center" style="border-bottom:1.00pt solid #000000;vertical-align:bottom">Percentage</td>
<td style="vertical-align:bottom">&#160;</td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BlackRock, Inc. (2)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">15,690,326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">14.7</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">State Street Corp. (3)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7,873,314</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">7.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">The Vanguard Group (4)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,768,741</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6.4</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Deerfield Mgmt, L.P. (5)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5,884,448</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.5</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick J. McEnany (6)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">6,265,951</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">5.8</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Steven R. Miller (7)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,772,456</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1.6</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Alicia Grande (8)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">1,015,056</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gary Ingenito (9)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">765,700</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Elsbernd (10)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">733,409</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jeffrey Del Carmen (11)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">322,915</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Preethi Sundaram (12)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">108,142</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Charles O&#8217;Keeffe (13)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">830,557</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David Tierney (13)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">543,707</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Philip Coelho (13)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">415,053</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Donald A. Denkhaus (13)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">543,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard Daly (13)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">358,166</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Molly Harper (14)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">50,666</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tamar Thompson (15)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">0</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">*</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">All officers and directors as a group (14 persons) (16)</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">13,724,944</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom" align="right">12.1</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
</table> <p style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">*</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Less than one percent </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(1)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Unless otherwise indicated, each person named in the table has the sole voting and investment power with respect to the shares beneficially owned. Further, unless otherwise indicated, the address for each person named in this table is c/o Catalyst Pharmaceuticals, Inc. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(2)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reported on a Schedule 13G filed by BlackRock on January&#160;26, 2023. According to the Schedule 13G, BlackRock&#8217;s address is 55 East 52<sup style="font-size:75%; vertical-align:top">nd</sup> Street, New York, NY 10055. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(3)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reported in a Schedule 13G filed by State Street on February&#160;8, 2023. According to the Schedule 13G, State Street&#8217;s address is 1 Lincoln Street, Boston, MA 02111. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(4)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reported in a Schedule 13G filed by Vanguard on February&#160;9, 2023. According to the Schedule 13G, Vanguard&#8217;s address is 100 Vanguard Blvd., Malvern, PA 19355. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">44 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(5)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Reported in a Schedule 13G filed by Deerfield on February&#160;10, 2023. According to the Schedule 13G, Deerfield&#8217;s address is 345 Park Avenue South, 12<sup style="font-size:75%; vertical-align:top">th</sup> Floor, New York, NY 10010. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(6)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes options to purchase 2,146,666 shares of our common stock, of which (i) 250,000 shares are exercisable at a price of $1.13 per share, (ii) 300,000 shares are exercisable at a price of $4.01 per share, (iii) 500,000 shares are exercisable at a price of $3.54 per share, (iv) 740,000 shares are exercisable at a price of $4.64 per share, (v) 266,666 shares are exercisable at a price of $3.42 per share, and (vi) 90,000 shares are exercisable at a price of $7.07 per share. Excludes (i)&#160;unvested stock options to purchase 133,334 shares of our common stock at a price of $3.42 per share that will vest on December&#160;30, 2023, (ii) unvested stock options to purchase 180,000 shares of our common stock at a price of $7.07 per share that will vest in two annual tranches beginning on December&#160;28, 2023, (iii) unvested stock options to purchase 272,000 shares of our common stock at a price of $18.59 per share that will vest in three annual tranches beginning on December&#160;27, 2023, (iv) 79,000 restricted stock units that will vest in three annual tranches beginning on December&#160;27, 2023, and (v) 116,667 restricted stock units that will vest in two annual tranches beginning on February&#160;14, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(7)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes options to purchase 1,084,999 shares of our common stock, of which (i) 150,000 shares are exercisable at a price of $1.13 per share, (ii) 285,000 shares are exercisable at a price of $4.01 per share, (iii) 225,000 shares are exercisable at a price of $2.24 per share, (iv) 180,000 shares are exercisable at a price of $4.64 per share, (v) 183,333 shares are exercisable at a price of $3.42 per share, and (vi) 61,666 shares are exercisable at a price of $7.07 per share. Excludes (i)&#160;unvested stock options to purchase 91,667 shares of our common stock at an exercise price of $3.42 per share that will vest on December&#160;30, 2023, (ii) unvested stock options to purchase 123,334 shares of our common stock at a price of $7.07 per share that will vest in two annual tranches beginning on December&#160;28, 2023, (iii) unvested stock options to purchase 146,000 shares of our common stock at an exercise price of $18.59 per share that will vest in three annual tranches beginning on December&#160;27, 2023, (iv) 42,000 restricted stock units that will vest in three annual tranches beginning on December&#160;27, 2023, and (v) 27,334 restricted stock units that will vest in two annual tranches beginning on February&#160;14, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(8)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes options to purchase 964,499 shares of our common stock, of which (i) 100,000 shares are exercisable at a price of $1.13 per share, (ii) 285,000 shares are exercisable at a price of $4.01 per share, (iii) 225,000 shares are exercisable at a price of $2.24 per share, (iv) 132,000 shares are exercisable at a price of $4.64 per share, (v) 166,666 shares are exercisable at a price of $3.42 per share, and (vi) 55,833 shares are exercisable at a price of $7.07 per share. Excludes (i)&#160;unvested stock options to purchase 83,334 shares of our common stock at an exercise price of $3.42 per share that will vest on December&#160;30, 2023, (ii) unvested stock options to purchase 111,667 shares of our common stock at an exercise price of $7.07 per share that will vest in two annual tranches beginning on December&#160;28, 2023, (iii) unvested stock options to purchase 88,000 shares of our common stock at an exercise price of $18.59 per share that will vest in three annual tranches beginning on December&#160;27, 2023, (iv) 26,000 restricted stock units that will vest in three annual tranches beginning on December&#160;27, 2023, and (v) 22,334 restricted stock units that will vest in two annual tranches beginning on February&#160;14, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(9)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes options to purchase 727,333 shares of our common stock, of which (i) 50,000 shares are exercisable at a price of $1.13 per share, (ii) 230,000 shares are exercisable at a price of $4.01 per share, (iii) 225,000 shares are exercisable at a price of $2.24 per share, (iv) 44,000 shares are exercisable at a price of $4.64 per share, (v) 133,333 shares are exercisable at a price of $3.42 per share, and (vi) 45,000 shares are exercisable at a price of $7.07 per share. Excludes (i)&#160;unvested stock options to purchase 66,667 shares of our common stock at an exercise price of $3.42 per share that will vest on December&#160;30, 2023, (ii) unvested stock options to purchase 90,000 shares of our common stock at an exercise price of $7.07 per share that will vest in two annual tranches beginning on December&#160;28, 2023, (iii) unvested stock options to purchase 93,000 shares of our common stock at an exercise price of $18.59 per share that will vest in three annual tranches beginning on December&#160;27, 2023, (iv) 27,000 restricted stock units that will vest in three annual tranches beginning on December&#160;27, 2023, and (v) 20,000 restricted stock units that will vest in two annual tranches beginning on February&#160;14, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(10)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes options to purchase 595,333 shares of our common stock, of which (i) 60,000 shares are exercisable at a price of $4.01 per share, (ii) 225,000 shares are exercisable at a price of $2.24 per share, (iii) 132,000 shares are exercisable at a price of $4.64 per share, (iv) 133,333 shares are exercisable at a price of $3.42 per share, and (v) 45,000 shares are exercisable at a price of $7.07 per share. Excludes (i)&#160;unvested stock options to purchase 66,667 shares of our common stock at an exercise price of $3.42 per share that will vest on December&#160;30, 2023, (ii) unvested stock options to purchase 90,000 shares of our common stock at an exercise price of $7.07 per share that will vest in two annual tranches beginning on December&#160;28, 2023, (iii) unvested stock options to purchase 69,000 shares of our common stock at an exercise price of $18.59 per share that will vest in three annual tranches beginning on December&#160;27, 2023, (iv) 20,000 restricted stock units that will vest in three annual tranches beginning on December&#160;27, 2023, and (v) 19,334 restricted stock units that will vest in two annual tranches beginning on February&#160;14, 2024. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">45 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(11)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes options to purchase 309,316 shares of our common stock, of which (i) 30,000 shares are exercisable at a price of $2.86 per share, (ii) 10,983 shares are exercisable at a price of $4.21 per share, (iii) 90,000 shares are exercisable at a price of $4.70 per share, (iv) 133,333 shares are exercisable at a price of $3.42 per share, and (v) 45,000 shares are exercisable at a price of $7.07 per share. Excludes (i)&#160;unvested stock options to purchase 60,000 shares of our common stock at an exercise price of $4.70 per share that will vest in two annual tranches beginning on June&#160;23, 2024, (ii) unvested stock options to purchase 66,667 shares of our common stock at an exercise price of $3.42 per share that will vest on December&#160;30, 2023, (iii) unvested stock options to purchase 90,000 shares of our common stock at an exercise price of $7.07 per share that will vest in two annual tranches beginning on December&#160;28, 2023 (iv) unvested stock options to purchase 88,000 shares of our common stock at an exercise price of $18.59 per share that will vest in three annual tranches beginning on December&#160;27, 2023, (v) 26,000 restricted stock units that will vest in three annual tranches beginning on December&#160;27, 2023, and (vi) 21,334 restricted stock units that will vest in two annual tranches beginning on February&#160;14, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(12)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes options to purchase 75,000 shares of our common stock which are exercisable at a price of $5.49 per share and options to purchase 22,500 shares of our common stock which are exercisable at a price of $7.07 per share. Excludes (i)&#160;unvested stock options to purchase 150,000 shares of our common stock at an exercise price of $5.49 per share that will vest in two annual tranches beginning on July&#160;6, 2024, (ii) unvested stock options to purchase 45,000 shares of our common stock at an exercise price of $7.07 per share that will vest in two annual tranches beginning on December&#160;28, 2023, (iii) unvested stock options to purchase 68,000 shares of our common stock at an exercise price of $18.59 per share that will vest in three annual tranches beginning on December&#160;27, 2023, (iv) 20,000 restricted stock units that will vest in three annual tranches beginning on December&#160;27, 2023, and (v) 33,334 restricted stock units that will vest in two annual tranches beginning on February&#160;14, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(13)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes options to purchase 210,166 shares of our common stock, of which (i) 60,000 shares are exercisable at a price of $1.13 per share, (ii) 40,000 shares are exercisable at a price of $4.01 per share, (iii) 50,000 shares are exercisable at a price of $2.24 per share, (iv) 33,500 shares are exercisable at a price of $4.64 per share, (v) 20,000 shares are exercisable at a price of $3.42 per share, and (vi) 6,666 shares are exercisable at a price of $7.07 per share. Excludes (i)&#160;unvested stock options to purchase 10,000 shares of our common stock at an exercise price of $3.42 per share that will vest on December&#160;30, 2023, (ii) unvested stock options to purchase 13,334 shares of our common stock at an exercise price of $7.07 per share that will vest in two annual tranches beginning on December&#160;28, 2023, (iii) unvested stock options to purchase 15,000 shares of our common stock at an exercise price of $18.59 per share that will vest in three annual tranches beginning on December&#160;27, 2023, (iv) 4,000 restricted stock units that will vest in three annual tranches beginning on December&#160;27, 2023, and (v) 8,000 restricted stock units that will vest in two annual tranches beginning on February&#160;14, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(14)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes options to purchase 46,666 shares of our common stock, of which (i) 40,000 shares are exercisable at a price of $5.78 per share and (ii) 6,666 shares are exercisable at a price of $7.07 per share. Excludes (i)&#160;unvested stock options to purchase 20,000 shares of our common stock at an exercise price of $5.78 per share that will vest on June&#160;29, 2024, (ii) unvested stock options to purchase 13,334 shares of our common stock at an exercise price of $7.07 per share that will vest in two annual tranches beginning on December&#160;28, 2023, (iii) unvested stock options to purchase 15,000 shares of our common stock at an exercise price of $18.59 per share that will vest in three annual tranches beginning on December&#160;27, 2023, (iv) 4,000 restricted stock units that will vest in three annual tranches beginning on December&#160;27, 2023, and (v) 8,000 restricted stock units that will vest in two annual tranches beginning on February&#160;14, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(15)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Excludes options to purchase 40,000 shares of our common stock at an exercise price of $11.59 per share that will vest in three annual tranches beginning on May&#160;25, 2024. </p></td></tr></table>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">(16)</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Includes options to purchase 7,023,142 shares of our common stock at prices ranging from $1.13 per share to $7.07 per share. Excludes (i)&#160;unvested stock options to purchase 2,552,341 shares of our common stock at prices ranging from $3.42 per share to $18.59 per share, and (ii) 572,337 unvested restricted stock units. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">46 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_18">C<small>ERTAIN</small> R<small>ELATIONSHIPS</small> <small>AND</small> R<small>ELATED</small> P<small>ARTY</small> T<small>RANSACTIONS</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Related Person Transaction Parties and Procedures </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2017, we adopted our Code of Business Conduct and Ethics, including a conflict of interest transaction policy that identifies our procedures for the identification, review, consideration and approval or ratification of conflict of interest transactions. The policy applies where one&#8217;s private life or interest interferes, or even appears to interfere, with the interests of our company. Under the policy, a conflict can arise when any of our personnel (or a member of their family) acts or has interests that make it difficult, or makes it appear difficult, to perform their duties for us objectively and effectively. Conflicts can also arise under the policy when our personnel (or a member of their family) receives significant personal benefits as a result of their position in the Company. Any such determination regarding the approval of such a transaction will be made by the Audit Committee or the Board of Directors, with any interested directors abstaining. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">Certain Related Party Transactions </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Since January&#160;1, 2021, we have had no transactions or proposed transactions in which we were or are to be participants and in which any related person had or will have a direct or indirect material interest. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_19">O<small>THER</small> M<small>ATTERS</small> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Board is not aware of any other business that may come before the meeting. However, if additional matters properly come before the meeting, proxies will be voted at the discretion of proxy holders. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_20">C<small>ONTACTING</small> <small>THE</small> B<small>OARD</small> <small>OF</small> D<small>IRECTORS</small> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholders may communicate with the board of directors by directing their communications in a hard copy <span style="white-space:nowrap">(i.e.&#160;non-electronic)</span> written form to the attention of one or more members of the Board of Directors, or to the Board of Directors collectively, at our principal executive office located at 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134, Attention: Corporate Secretary. A stockholder communication must include a statement that the author of such communication is a beneficial or record owner of shares of our common stock. Our corporate secretary will review all communications meeting the requirements discussed above and will remove any communications relating to (i)&#160;the purchase or sale of our products or services; (ii)&#160;communications from suppliers or vendors relating to our obligations to such supplier or vendor; (iii)&#160;communications from pending or threatened opposing parties in legal or administrative proceedings regarding matters not related to securities law matters or fiduciary duty matters, and (iv)&#160;any other communications that the corporate secretary deems, in his reasonable discretion, to be unrelated to our business. The corporate secretary will compile all communications not removed in accordance with the procedure described above and will distribute such qualifying communications to the intended recipient(s). A copy of any qualifying communications that relate to our accounting and auditing practices will also be automatically sent directly to the chair of the Audit Committee, whether or not it was directed to such person. </p> <p style="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_21">S<small>TOCKHOLDER</small> P<small>ROPOSALS</small> </p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Stockholder proposals intended to be presented at the 2024 Annual Meeting of Stockholders must be received by our corporate secretary not later than March&#160;7, 2024 at our principal executive offices, 355 Alhambra Circle, Suite 801, Coral Gables, Florida 33134, Attention: Corporate Secretary, for inclusion in the proxy statement and proxy relating to the 2024 Annual Meeting of Stockholders. The persons named in the proxies solicited by management may exercise discretionary voting authority with respect to such proposal. </p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">47 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_22">A<small>DDITIONAL</small> I<small>NFORMATION</small> </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We are delivering our Annual Report to our stockholders with this Proxy Statement. We will furnish without charge to any stockholder submitting a written request, our 2022 Annual Report on <span style="white-space:nowrap">Form&#160;10-K&#160;as</span> filed with the Securities and Exchange Commission, including the financial statements and any schedules thereto. Such written requests should be directed to our Corporate Secretary at the address set forth above. </p> <p style="font-size:18pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">48 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center" id="toc500830_23"><span style="text-decoration:underline">ANNEX A </span></p> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">AMENDMENT NO. 3 TO CATALYST PHARMACEUTICALS, INC. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">2018 STOCK INCENTIVE PLAN </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">WHEREAS</span>, the Board of Directors of Catalyst Pharmaceuticals, Inc. (the &#8220;Company&#8221;) has determined that it is in the Company&#8217;s best interests to amend the Company&#8217;s 2018 Stock Incentive Plan (the &#8220;2018 Plan&#8221;). </p> <p style="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><span style="font-weight:bold">NOW, THEREFORE</span>, the 2018 Plan is hereby amended as follows: </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">The first sentence of Section&#160;5(a) of the 2018 Plan is amended in its entirety and restated as follows: </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#160;<span style="text-decoration:underline">Shares Available for Awards</span>. The Common Stock that may be issued pursuant to Awards granted under the 2018 Plan shall be treasury shares or authorized but unissued shares of the Common Stock. The total number of shares of Common Stock that may be issued pursuant to Awards granted under the 2018 Plan shall be Eighteen Million (18,000,000) shares of Common Stock. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%">&#160;</td>
<td style="width:5%;vertical-align:top" align="left">2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">In all other respects, the 2018 Plan shall remain in full force and effect. </p></td></tr></table>
 <p style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center">A-1 </p>

</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">CATALYST PHARMACEUTICALS, INC. </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">355 Alhambra Circle, Suite 801 </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Coral Gables, Florida 33134 </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">THIS PROXY IS SOLICITED ON BEHALF OF THE BOARD OF DIRECTORS </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned hereby appoints Patrick J. McEnany and Alicia Grande, and each of them, with full power of substitution, proxies of the undersigned, to attend and vote all the shares of common stock, $0.001 par value per share, of Catalyst Pharmaceuticals, Inc., a Delaware corporation (the &#8220;Company&#8221;) which the undersigned would be entitled to vote at the 2023 Annual Meeting of Stockholders to be held at 9:00 a.m. local time, on Tuesday, August&#160;22, 2023, or any adjournment thereof, according to the number of votes the undersigned would be entitled to vote if personally present upon the matters referred to in this proxy. </p> <p style="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">THE BOARD OF DIRECTORS RECOMMENDS A VOTE FOR EACH OF THE PROPOSALS. </p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">1.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">PROPOSAL ONE &#8212; Election of Directors </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To elect <span style="font-weight:bold">Patrick J. McEnany</span> as a member of the Board of Directors until the 2024 Annual Meeting of Stockholders, or until his earlier death, disability or resignation: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:80%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#9744;&#160;&#160;FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;AGAINST</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;ABSTAIN</td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To elect <span style="font-weight:bold">Richard J. Daly</span> as a member of the Board of Directors until the 2024 Annual Meeting of Stockholders, or until his earlier death, disability or resignation: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:80%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#9744;&#160;&#160;FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;AGAINST</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;ABSTAIN</td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To elect <span style="font-weight:bold">Donald A. Denkhaus</span> as a member of the Board of Directors until the 2024 Annual Meeting of Stockholders, or until his earlier death, disability or resignation: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:80%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#9744;&#160;&#160;FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;AGAINST</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;ABSTAIN</td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To elect <span style="font-weight:bold">Molly Harper</span> as a member of the Board of Directors until the 2024 Annual Meeting of Stockholders, or until her earlier death, disability or resignation: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:80%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#9744;&#160;&#160;FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;AGAINST</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;ABSTAIN</td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To elect <span style="font-weight:bold">Charles B. O&#8217;Keeffe</span> as a member of the Board of Directors until the 2024 Annual Meeting of Stockholders, or until his earlier death, disability or resignation: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:80%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#9744;&#160;&#160;FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;AGAINST</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;ABSTAIN</td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To elect <span style="font-weight:bold">Tamar Thompson</span> as a member of the Board of Directors until the 2024 Annual Meeting of Stockholders, or until her earlier death, disability or resignation: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:80%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#9744;&#160;&#160;FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;AGAINST</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;ABSTAIN</td></tr>
</table> <p style="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">To elect <span style="font-weight:bold">David S. Tierney, M.D. </span>as a member of the Board of Directors until the 2024 Annual Meeting of Stockholders, or until his earlier death, disability or resignation: </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:80%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#9744;&#160;&#160;FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;AGAINST</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;ABSTAIN</td></tr>
</table>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">2.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">PROPOSAL TWO &#8211; To approve an amendment to our 2018 Stock Incentive Plan to increase the shares available for issuance by 3&#160;million shares. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:80%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#9744;&#160;&#160;FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;AGAINST</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;ABSTAIN</td></tr>
</table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">3.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">PROPOSAL THREE &#8212; To approve, on an advisory basis, the 2022 compensation of our named executive officers. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:80%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#9744;&#160;&#160;FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;AGAINST</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;ABSTAIN</td></tr>
</table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">4.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">PROPOSAL FOUR &#8212; To ratify the selection of Grant Thornton LLP as our independent registered public accounting firm for the fiscal year ending December&#160;31, 2023. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:80%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#9744;&#160;&#160;FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;AGAINST</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;ABSTAIN</td></tr>
</table> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top" align="left">5.</td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">PROPOSAL FIVE &#8212; To transact such other business as may properly come before the meeting. </p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:80%;border:0;margin:0 auto">


<tr>

<td style="width:35%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:31%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">&#9744;&#160;&#160;FOR</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;AGAINST</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom">&#9744;&#160;&#160;ABSTAIN</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This Proxy when properly executed will be voted in the manner directed herein by the undersigned stockholder. If no direction is made, this proxy will be voted FOR the proposals as set forth herein. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The undersigned acknowledges receipt of Notice of Annual Meeting of Stockholders dated July&#160;12, 2023, and the accompanying Proxy Statement. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:40%;border:0">


<tr>

<td style="width:100%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Date: <span style="text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span>, 2023.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Signature</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Name(s) (typed or printed)</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">&#160;</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top">Address(es)</td></tr>
</table> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Please sign exactly as name appears on this Proxy. When shares are held by joint tenants, both should sign. When signing as attorney, executor, administrator, trustee or guardian, please give full title as such. If a corporation, please sign in full corporate name by the President or other authorized officer. If a partnership, please sign in partnership name by authorized person. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PLEASE MARK, SIGN, DATE AND RETURN THE PROXY CARD PROMPTLY USING THE ENCLOSED ENVELOPE. NO POSTAGE IS REQUIRED. </p>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>2
<FILENAME>cprx-20221231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 08-July-2023 [03:46:18] {AM}-->
<schema targetNamespace="http://www.catalystpharma.com/20221231" elementFormDefault="qualified" xmlns:cprx="http://www.catalystpharma.com/20221231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:dei="http://xbrl.sec.gov/dei/2022q4" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:srt="http://fasb.org/srt/2022" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
<annotation>
<appinfo>
<link:linkbaseRef xlink:type="simple" xlink:href="cprx-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="cprx-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
<link:linkbaseRef xlink:type="simple" xlink:href="cprx-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
</appinfo>
</annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
<import namespace="http://xbrl.sec.gov/dei/2022q4" schemaLocation="https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd" />
<import namespace="http://xbrl.sec.gov/dei-sub/2022q4" schemaLocation="https://xbrl.sec.gov/dei/2022q4/dei-sub-2022q4.xsd" />
<import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
<import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
<import namespace="http://fasb.org/srt-types/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd" />
<import namespace="http://xbrl.sec.gov/ecd-sub/2022q4" schemaLocation="https://xbrl.sec.gov/ecd/2022q4/ecd-sub-2022q4.xsd" />
<import namespace="http://xbrl.sec.gov/ecd/2022q4" schemaLocation="https://xbrl.sec.gov/ecd/2022q4/ecd-2022q4.xsd" />
<import namespace="http://www.xbrl.org/2006/ref" schemaLocation="http://www.xbrl.org/2006/ref-2006-02-27.xsd" />
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
<import namespace="http://fasb.org/srt-roles/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd" />
<element name="SCTEquityAwardsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cprx_SCTEquityAwardsMember" substitutionGroup="xbrli:item" />
<element name="ValueOfNewUnvestedAwardsMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cprx_ValueOfNewUnvestedAwardsMember" substitutionGroup="xbrli:item" />
<element name="AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cprx_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember" substitutionGroup="xbrli:item" />
<element name="ChangeInValueOfPriorYearAwardsThatVestDuringYearMember" type="dtr-types:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" id="cprx_ChangeInValueOfPriorYearAwardsThatVestDuringYearMember" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>3
<FILENAME>cprx-20221231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 08-July-2023 [03:46:18] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2022q4/ecd-2022q4.xsd#PvpAdjustmentsOnly" roleURI="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" />
<definitionLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpAdjustmentsOnly">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2022q4/ecd-2022q4.xsd#ecd_AllAdjToCompMember" xlink:label="AllAdjToCompMember" />
<loc xlink:type="locator" xlink:href="cprx-20221231.xsd#cprx_SCTEquityAwardsMember" xlink:label="SCTEquityAwardsMember" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AllAdjToCompMember" xlink:to="SCTEquityAwardsMember" order="100" />
<loc xlink:type="locator" xlink:href="cprx-20221231.xsd#cprx_ValueOfNewUnvestedAwardsMember" xlink:label="ValueOfNewUnvestedAwardsMember" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AllAdjToCompMember" xlink:to="ValueOfNewUnvestedAwardsMember" order="101" />
<loc xlink:type="locator" xlink:href="cprx-20221231.xsd#cprx_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember" xlink:label="AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AllAdjToCompMember" xlink:to="AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember" order="102" />
<loc xlink:type="locator" xlink:href="cprx-20221231.xsd#cprx_ChangeInValueOfPriorYearAwardsThatVestDuringYearMember" xlink:label="ChangeInValueOfPriorYearAwardsThatVestDuringYearMember" />
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="AllAdjToCompMember" xlink:to="ChangeInValueOfPriorYearAwardsThatVestDuringYearMember" order="103" />
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>cprx-20221231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 08-July-2023 [03:46:18] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="cprx-20221231.xsd#cprx_SCTEquityAwardsMember" xlink:label="loc_cprx_SCTEquityAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cprx_SCTEquityAwardsMember" xml:lang="en-US">SCT Equity Awards [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cprx_SCTEquityAwardsMember" xlink:to="lab_cprx_SCTEquityAwardsMember" />
<loc xlink:type="locator" xlink:href="cprx-20221231.xsd#cprx_ValueOfNewUnvestedAwardsMember" xlink:label="loc_cprx_ValueOfNewUnvestedAwardsMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cprx_ValueOfNewUnvestedAwardsMember" xml:lang="en-US">Value of New Unvested Awards [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cprx_ValueOfNewUnvestedAwardsMember" xlink:to="lab_cprx_ValueOfNewUnvestedAwardsMember" />
<loc xlink:type="locator" xlink:href="cprx-20221231.xsd#cprx_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember" xlink:label="loc_cprx_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cprx_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember" xml:lang="en-US">Annual Change in Value of Prior Year Awards that Remain Unvested [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cprx_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember" xlink:to="lab_cprx_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember" />
<loc xlink:type="locator" xlink:href="cprx-20221231.xsd#cprx_ChangeInValueOfPriorYearAwardsThatVestDuringYearMember" xlink:label="loc_cprx_ChangeInValueOfPriorYearAwardsThatVestDuringYearMember" />
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_cprx_ChangeInValueOfPriorYearAwardsThatVestDuringYearMember" xml:lang="en-US">Change in Value of Prior Year Awards that Vest During Year [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_cprx_ChangeInValueOfPriorYearAwardsThatVestDuringYearMember" xlink:to="lab_cprx_ChangeInValueOfPriorYearAwardsThatVestDuringYearMember" />
</labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>cprx-20221231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--Generated by DFIN XBRL Instance Document - http://www.dfinsolutions.com/ - Version R3.0 - on 08-July-2023 [03:46:18] {AM}-->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2022q4/ecd-2022q4.xsd#PvpDisclosure" roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" />
<presentationLink xlink:type="extended" xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure">
<loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/ecd/2022q4/ecd-2022q4.xsd#ecd_AllAdjToCompMember" xlink:label="AllAdjToCompMember" />
<loc xlink:type="locator" xlink:href="cprx-20221231.xsd#cprx_SCTEquityAwardsMember" xlink:label="SCTEquityAwardsMember" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllAdjToCompMember" xlink:to="SCTEquityAwardsMember" order="100" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cprx-20221231.xsd#cprx_ValueOfNewUnvestedAwardsMember" xlink:label="ValueOfNewUnvestedAwardsMember" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllAdjToCompMember" xlink:to="ValueOfNewUnvestedAwardsMember" order="101" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cprx-20221231.xsd#cprx_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember" xlink:label="AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllAdjToCompMember" xlink:to="AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember" order="102" preferredLabel="http://www.xbrl.org/2003/role/label" />
<loc xlink:type="locator" xlink:href="cprx-20221231.xsd#cprx_ChangeInValueOfPriorYearAwardsThatVestDuringYearMember" xlink:label="ChangeInValueOfPriorYearAwardsThatVestDuringYearMember" />
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="AllAdjToCompMember" xlink:to="ChangeInValueOfPriorYearAwardsThatVestDuringYearMember" order="103" preferredLabel="http://www.xbrl.org/2003/role/label" />
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g500830g0707050509901.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g500830g0707050509901.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !. 2$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#WZJFHZC;:
M5:?:KMRD(=5+!20N3@$XZ#WHU'48-+LGN[GS/)0C<40L0"<9P.P[UAN\D<TT
M\LXU/P]J(^8D[OL^1CMU0_I0D#9>?49U\1?V9.%6UNK;?:S)D'</O@GUP016
M%F[F\,::MQ([7=AJD<<KN<D[9"N2?H16G#I\D-K'8ES(]DPFL9B<ED'\)/KC
MCZ8JS-!$\=V5_P!7/LN /<$9_D*HDJ%VM/$?B#4G)*06<04=N S8_P ^M1VE
M[J-AIN@Z=N^T:C>$/.TQ+;(_O.3SVR *TKBU2=KN/_GYG1']P "?T%12K)Y\
M]Y;@&\G'V>UST1!U;Z9Y_ 4#-&VU*UN[VZM()"\MJ0LV%.%)&<9Z9JW7)_8K
MA(5T319F@B1B]]J)^]N/+!3W<]SV%;NFZM9ZFTZ6<K3+;L$>7;\K'V;H??%2
MT-,OT450U;5[+1+![R^E\N-> !RS'T [FA)MV0-I*[+]%>0:AX]U_7+O[+H\
M3VRMPD<"[Y6]R>WX4B>#O&E]^^FFE1B/^6UX=WZ$UT?5[+WVD8>WN_=5SV"B
MO')/#_CG10TT$EVZKR3;W)DS_P !)R?RKU?21=C2;3[=)YEWY2F9MH&6QSP*
MSJ4U!73N:0J.3LU8N4445D:!1110 451N-9TVTN8[:>^@2>5PB1;P6+'@# Y
MJ]3::%=!1112&%%%% #7=(HVD=@J*"S,>@ [U1LM=TG49_(LM0MYY=N[9&X)
MQZU)JO\ R![[_KWD_P#037DWPP_Y&L?]>K_S6MJ=)2A*78RG4<9J/<]EHHHK
M$U"BBB@ HHHH **** "BJ=_JVGZ9%YE]>06ZXS^\< GZ#J:M1R++$DB'*.H9
M3Z@T[/<5T.HHHI#,?4'U@77GZ6]G=6Z#9+:2':V<\D/V/L:J6$4$,SM91/82
MR',UA.,1N>Y7L#[C\JS2-%GU!I_[&UFPNV;<TL4+H6)ZD[20?QK<@E5H=OVQ
MIT':ZA(/YX%62*[I!&47,:QG< W6 ^ONE9UUJ 4.N-IPXV9Z;AROX/M(]G%)
MJ-R$4;9%^4_)ME#8/^R>&'TP1[5C:?I]SKEX\:2".&,#?)MZ>B@?YQ^0 (V1
MJJR2.V[R]Q<YS]W)P6_!4;\QZUH13[P3DQ?P$]XQVC'JWKZ5SNK:)=:,L=RM
MQY\18!WV[64]C^8'XXJSI=UG:=X4@8'SJI ] 6/ ^@)/<F@#4OH('MUM[HO%
M9]K.#)>7_>QS^'YFDM#JQEA*6UII.DP'F)\&1U]..$'ZU9\U5B)2XBAR.6B0
MR,?Q-8-ZFBR2>9>VNLZJW8-%(R?EP* .T!R 0<@]Z\3\5ZM<^*?%(M;4EX4E
M^SVJ \$YP6_$_H*]7O+X0^%;F]CAEMQ':.R12+M9,*< CM7E?PWMEG\80,XS
MY$+R#ZX _K71ADHJ53L8UWS-0[GJ/AWPY9^'=/6"!0TS >=.1\TC?X>@K9HH
MKEDW)W9T))*R"BBBD,P]2\8:%I,C17-_&95ZQQ NP^N.GXUF)\2_#CN%,MR@
M/\30' _*HK7X::+%=33W)FN \K.L>[8J G('')_.K%[\._#US;-'!:M:R$?+
M+'(Q(/T)((KH2H+1W,&ZW2QT=CJ%IJ5JMS97$<\+=&0Y_ ^AJKJ_B#3-"\G^
MT;CR?.SL^0MG&,]![BO*?"5]<^&_&@L)GQ').;6X4'Y2<X5OSQ^!KT_7O#&G
M^)/LXO\ SOW!;9Y3[>N,Y_*E.E&G-*3T'&I*<;K<\=COK9?&PU$O_HO]H>>7
MP?N;\YQUZ5ZQ'X]\-RRI&FH9=V"J/*?DDX':O)4TVW;Q@-+._P"S&^^S_>^;
M9OV]?7%>G1?#70(9XY4-YNC<.N9NX.1VKIQ'L].:^QA1=37E.N9E1"SL%4#)
M). *YR^\>^';%RC7WG.#@BW0O^HX_6MK4K&/4],NK&7[D\31D^F1UKF=.^&V
M@VD*BY26\EQ\S2.5'X!>E<</9VO,Z9N?V26W^(WARXE$9N98<_Q2Q$+^==3%
M+'/$LL4BR1N,JZG((]C7#>(_AWI;Z7-/I4+6UU"A=5#EEDQS@@YY]ZR?A;K,
MHO)]'D<F!XS-"#_ 01N ]CG/X5JZ4)0<Z?0S52<9*,^IZ-JO_('OO^O>3_T$
MUY-\,/\ D:Q_UZO_ #6O6=5_Y ]]_P!>\G_H)KR;X8?\C6/^O5_YK54?X4Q5
M?XD3T[5O$VE:'/'#J-R87D7<G[MCD=.H%7=/U"UU2RCO+.42V\F=K 8S@X-<
MO\2-(^W^'/MD:YFL6\SCNAX;^A_"LKX5ZKN@O-)=N4/GQ#V/#?K@_C6?LDZ7
M.MT7[1JIRO8]'K(U;Q/I&B7"0:A=B*5UWJNPMQG&>!6O7A^NR2>*O'DD,#96
M6<6T1'9%X)_]"-*A34V[[(=6HX+3<]HL;V#4;**\M6+P2KN1BI&1ZX-8NI^-
M]!TJ=H)KSS)E.&2!2^WZD<54\;WSZ#X.\FQ)B+E+6,KU1<<X]\#'XURG@#PC
MIVM64^H:BIF5)3$D(8@< $DXY/6JA3ARN<MB95)<RA'<Z^T^(7AR[E$?VMX"
M3@&>,J/SZ?G6YJ6JV6D6)O;V;R[<$#> 6Z].E<]=_#CP_.T;00R6Q1@2(W)#
M ')!!SUK=UG1K37-.-A>>8("RM^[;:<@Y%1+V5URWL5'VEG<\>\=ZG9:UXA-
MU82^;%]G5-VTCD9XY^M>B67CSPY#86\;ZAATB56'E/P0![5YOXTT:UT#7#9V
M7F>4(%D_>-N.3G_"N]M/AMH$]E!,YO-TD:L<3=R,^E==7V7)'FO8YZ;J<\K;
MFE_PL#PS_P!!'_R$_P#A15/_ (5CX>];S_O]_P#6HK"V'\S:];R+KMJMHV=2
M\3V, )^XMNJG'MDYJ_:SF>/]W=W5R/[ZQA ?Q(K.O+6UL-78:9X<%WJ$^97N
M9 !&F2>2YS^0JXLLGGBWN[@75X1DVUN-L<8_VN^/K^58FI1U4/(C$NS;!SF4
ML%^IX4?F3[5F:)JPT6]G6YC<PS8W,HRR,/4?C]:Z2XB#@DMGR^"T8X0_W4']
MX^O:L6ZTL8<[54J&X'W054L0/8':ON2Q[T"&Z_K]OJEHMI:([(6#R2.N, <\
M _SI=)1X_P!X6*D?*6+LH!]">0#]0*%TGRI6+978S9*]0%;!(]P"C?\  ?>M
M:WM_LXRW[OR_E9D_Y9_XQGJ >E'D!:>1XH<O-=1#'WPHD'Y@5FF:^NWVZ=XG
MLRX/^KD@4M^/(/Z5<FD$$BQ^?]AF?_5R8S#(?Y9]N*SKFW2]OH[+7_#R2M*V
MV.]MEW*3[GADH&:FIVUU/X4O;:YD22Y>TD5FB7:&;:>@KRWX;7*P^+X58X\Z
M!T'UP&_H:]G2-8XEC4?(J[0/:O"]>T^Y\)^*R8,J(Y?M%JYZ%<Y _#H:Z,-:
M490[G/7]UQGV/=J*R/#_ (AL_$.GK<VS@2 8EA)^:-O0^WH:UZY6G%V9TIIJ
MZ"@D 9/2BN:\>WDMEX.O7A8J\FV+<#@@,P!_3-.,>:20I.RN8FN_$R"UN&M=
M(MA=R*=IF<G9G_9 Y:LY=5^(NH@/!:/"C<C$"I_Z%S2?"O3[:>YO[V1%>>WV
M)%D?<SG)'OQ7J5=-24*4N6,;^IA!2J+F;L>!_P"G#QE%_:7_ !_?;8_.Z?>W
M+Z<?E7OG>O#=2GBN?B+)-"X>-M13:PZ'#*/Z5[E3Q6T?06'^T>&1?\E(7_L+
M?^U:]SKPW'D_$G$GR[=5YSV_>5[E2Q7V?0>'^UZD-U=065K)<W,JQ01+N=V/
M %>=:A\3;JYNOLV@Z<9"3A7E4LS>X0?UJS\5KN6/3M/M%)$<TK._OM P/US^
M%7OAKIUK!X:2^14-S<NWF28Y !P%^G&?QJ80C&G[22N.4I2GR1=C"-U\2+Q&
M;R'B0KR#'&G'X\UA_#OCQM9@?W)1_P".&O9KV>.UL9YYG"1QQLS,>P KQGX>
M'/C:S/JDI_\ '#6M.?-3GI8SG#EG'6Y[#JO_ "![[_KWD_\ 037DWPP_Y&L?
M]>K_ ,UKUG5?^0/??]>\G_H)KR;X8?\ (UC_ *]7_FM11_A3+J_Q(GL4T23P
M20RJ&CD4HRGN#P:\1TYY/!_CM8Y20EO.89#_ 'HFXS^1!_"O<:\O^*FD;+BU
MU=%^60>1,1ZCE3^61^ J<-)<S@]F/$1T4ET.Y\3:F-(\-WUX#AUC*Q\]7;A?
MU->?_"W2?/U.YU20$K;+Y49/=VZG\!_.J'B7Q(=3\':':;\RX9K@=\I\HS]>
MM>D^#])_L;PQ9V[+B9U\V7_>;G].!^%4TZ5)KJV2G[2HGT1-XET-/$.B36#/
ML<D/$YZ*XZ9]NWXUY-:WGB'P'J#QM$8E<_/'(NZ*7'<'^HYKW"HI[>&YA:&X
MB26-NJ.H(/X&LZ5;D7*U=&E2ES/F3LSDO#_Q#T[5YDM;J,V5TYPNYLHY] W8
M_6NRKQCX@>'K/0]3MWL1Y<-TC,80?N,".GL<UZ?X5NYK[PMIMS.VZ5X%W-ZD
M<9_2G6IQ45.&S%2G)R<);H\Q^)__ "-;?]>J?^S5Z[IW_(,M/^N*?^@BO(_B
M@#_PE9][5,?FU>M:8P?2;-E(*F!""._RBJK?PH$TOXDBW1117*=)4U*UN+RQ
M>"VO'M)'('G(H+ 9YQGH<=ZYZS6-;F71M%5H;:W;_3[]SEBW=0QZMZGM765G
MZOIG]J:=)9K</;I*P\UHP,LO\2^V1QFFF)HH07T3VOVNW4"T1O)LU_YZN3C=
M^?3\34\OEHEPA((A18F/JSD$_P!*KFUD/B"'=!Y&DZ7;[HNFUY",9'LJC]:R
MHKV63PU9WK E]3U-& ']QI.!_P!\J*H1T,CQQ2RNV,1W #_1U _J*ADG>!9O
M+3S)[+[\7>6$\C\<?RJG-NN]3\2::A^=K:*2/UW%2/Y@5%;W-U?1Z#K]E$TI
ME06]Y&O7:>I_X"P/YT %Y>6UK:)--&+WPY>#EL;OLQ/<]]N?Q!K8T;39-,BD
MB%]+<VI(-NLO+1+CINZL/3-&FZ,FF37HBE+6MS)YBVQ4;8B?O8]B><5IU+8T
M@K)U_P /V7B*P^S7:D,O,4J_>C;U'^%:U%";3N@:35F>,7G@OQ-X>O/M&GB6
M8*?EGLV.['NO7^8J1/&OC&U412+(Y' ,MF=W\A7K%S?+;7EC;,C,UW(T:D=%
MPC/S_P!\U;KI^LW^.*9A["WPNQX\^L^/-;4Q0QWB*W!\FW\K_P >/3\Z]'DT
MJ75_"*Z;J8\NXEME24@[ML@ YSWY&:VJ*SG5YK65K%QIVO=W/$H+?Q-X(U1Y
M(K63D;698S)%*OX?_6(K;.M^-?%2&SM++[%#(-LDRQL@ [_,W].:]2HJWB+Z
MN*N0J%M%+0\4O_"6I:-XC@BL[2ZNH87A?STA)4G@MT]#FO:Z**SJ574M?H:4
MZ:A>QY-X\\)W\6M3:M86\DUO.1(_E#+1OWX'..,YI^B>+O%MUJ5C:20O)"94
M25S:G=MR,DGMQWKU:BK]O>/+)7(]C[UXNQSGC+PV?$>CB&%E6[@;S(2W0G'*
MGZ_X5YQI.J^)_!SR6@L)?*9LF&:%F7=ZJ1Z^U>SB2,RM$'4R*H9ESR <X/XX
M/Y5%972WMJLZ131*Q("31E&&"1R#]/RI4ZSC'E:NASI<TN9.S/-UA\6^.7CA
MOHSI^E;@9,1E P]@>6/Z53\(Z+J.F>.X6ET^[2UC>:,2M$=N,, 2>GI7KE5-
M2OUTVU6=T9U,L<6%/.7<(#^&ZG]8=G%+1B]BKIMZBZDK2:5>(BEF:!PJ@<D[
M37F'PZTC4K+Q,);O3[J"/[,Z[Y8BHSE>,FO6:*B%5QBX]RY4U*2EV"L;Q780
MZCX8U""9E51"9%<_PLO(/Z5LUYQ\2O$JI#_85J^7?#73 _=7J$_'J?;ZT48N
M4TD%62C%W.-\'Z2=:\2V<#+F&,^=-Z;5YQ^)P/QKWFN(^&VAG3]%;49DQ/>X
M*Y'*QC[OY\G\J[>KQ-3GG9=",/#EAKU.8\;#7CIEN=!64RI-OE:%@'"@'  [
M@D\CVKC5\>>+;4>3<:<KR#C,EJX8G\.*]9HJ858I6<;E2IMNZ=CQR+0?$WC7
M55N]122"' 4S2IL")Z(O4_YR:]=M+6*RLX;6!=L,*!$'H ,5-12J57.RV2'3
MIJ&O4X'XB^%[O5?(U+3XC--"ACEB7[S+G((]2.>/>N3TWQ/XMTNS73[6&5UB
M&$22U9F4>GTKVJBKC7M'EDKD2HWES)V./_M3Q'_S[R_^ _\ ]:BNPHK/G78O
MD?<****S- P",$57ELK:985D@0K XDB&.$8="*L44 0+:6Z7DEVL2BXD4(\@
M'+*.@/YU*B)&@1$55'0*, 4ZB@ HHHH *Y>WL$U;Q#KJ7UQ/+;P3Q)#;B9D6
M/,*$GY2.23^';J:ZBN5M=)AOO$?B"8S7-O,+B)#);S&,LOD(<''7J<=QFFA,
MHH)]0FTNRN+J<K;:K<VPG#XDEC2.3 +=<X^4D<\'O5TW%MH&I:K:233IIBV,
M=R$\QF:-V=T(0DY&["X&>O3K6[%I%C MDD,/EK9,S0@,>"5*DGU)#'D]SFFW
MFBV&H2W$EU"9#<0"WDRQ *!BPQZ$$DY'-.XK&#IHN++Q&ENMG/96MS92R&&6
MZ\TED9,-C)VG#'."<\>E4_LUQ;>$-(G&H7?VV_GLEN+GS26(9@"!G@<,1P/?
MK72VN@6=M>+>&2YGNEC:(33SL[;&QE>>,9 J9](LY+&SLV1O)M'B>$;CD&,@
MKSWZ"BX6,0Z- GB1-.6>Z&GRVC3R6WVAR'D5E4$DG=T8Y&<$@$U';W$<6FW.
MF7/VJ\V:B]K:Q),1)(  X4OD< $Y)/0<YKIS9PF_6](/GK$8@<\;203Q]0*I
M3Z!8SHXQ+'(UR;H2QRE720C:2I[<<8Z<FE<+'*PZC?V8U32U62T47UK!$?.\
MYK9)@NXAC^.!S@M6UK%I'X>T*^O=-$RW118][W#/RS!=QWDC(SG)_E5Z'PYI
MD4%Y$T+3+>A1<F:0N92!@$D\Y]QTP,=*=;Z';11312SW=W#+&8FBNIVE7:>H
MP?YGFG<+,R;"QU&VU>SDM]/N+:$EEO&GOA*)5VG#$9/S;MO(QP34-I>7/_"L
M8+I[B7[0;=<RLYWYWXZ]<]JWK'1HK"8/'=WTBJI5(YKEG51]#U_'-59/">ER
MB2-Q<&V>0RBV\]O*5RV[<JYX.[GTR>E%PL0P:9:MXUO[@^=YBV]O(,3OC=NE
M[9QC@<=*SM+EGU2VT>PN;R98IDNIIB)"KS;)0H3<.<?-DX/8#IFNFETR"35(
M]1#S1W"((V\N0A9%!) 8=#@DX^M5W\.Z>]A!9A)$6V<R021R%9(F)))5AS_$
M?;!I7"Q4U"VT_3K6'3H[:ZG-U*3%:QW##>0N3EBW" #)&<>QS6.QN(]&O;2=
M7C6WU>U6*)YO-,:EX6V[NI&6/TSCM70OX?M98(DDN+UI8I#)'<&X;S4)&#AN
MP(XQTI8O#NG0V\L*I*5FG2YD+RLS/(A4AB3SG*+FG<+&=,GV'Q&USJD5P\4U
MPBV=W',VR'("B-T!&,MGG!!+#.*Z>LR31+::^%U--=2A9!*L#SL8E<="%]CR
M!TSS6G28T<)XX\:7FA7']G65N$EDB#BY<Y !R/E'J,=ZY3PEX0N_$-\M_J"R
M"PW[W>3.ZX.>@]0>YKUB\T?3=0NH;F\LH;B:$$1M(N[:*NJ H    X ':MXU
MU"'+!:]S%TG*5Y/0%554*H 4#  ' I:**YS<**** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>g500830g0707050510098.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g500830g0707050510098.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] .8# 2(  A$! Q$!_\0
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MM4VH#N9B<L['JS'N3ZU@W5MXA99[S5/$D.D64)9@FGVZ,0G8O),K@GV"C\:
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0!6[110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>g500830g0707050510473.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g500830g0707050510473.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %/ C\# 2(  A$! Q$!_\0
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MS1;W5K+;NR?WE$BJ2/I6[0 4444 %%%% !1110 4444 %%%% !1110 4444
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M*C('R] 1M&<\UZE10!XQH&JZW<ZUI$;7U]+J\]W<QZQ9M.^V&$9VGR^D7;#
M GU-97A_7;U]5\(V5UK.HF<WU[;WT4EY+DK\VQ7RW7D8SST]J]\IKJ7C90S(
M6! 9<9'N,T >%>#M9U&6[\,?9M:U"[U&:_NH[VVFNY)5^S@G#,K$@ 8&&ZYX
MS7;?&B[MX/AEJ4,L\:2S[%B1F +D.I( [\5TWA;PQ;>$]+;3K.[NYX#*TJ_:
M2A*ECD@%57C.3SGK6W0!Y]KPTS7?!.A@7\\4;R(8-1L7)-LZHWSG'\(P0<X
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M_P!\?_7H EHJ+;/_ ,]4_P"^/_KT;9_^>J?]\?\ UZ ):*BVS_\ /5/^^/\
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MV32Q0A'NM3%X) "_ /\ #C/3/<?B >@4444 %%%% &#XC\7:7X7-N-1^TDW
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MR=H9CT&>P&!^%:-%% $7D1_[?_?9_P :/L\?^W_WV?\ &I:* (OL\?\ M_\
M?9_QH^SQ_P"W_P!]G_&I:* (OL\?^W_WV?\ &C[/'_M_]]G_ !J6B@"+[/'_
M +?_ 'V?\:/L\?\ M_\ ?9_QJ6B@"+[/'_M_]]G_ !H^SQ_[?_?9_P :EHH
MB^SQ_P"W_P!]G_&C[/'_ +?_ 'V?\:EHH B^SQ_[?_?9_P :/L\?^W_WV?\
M&I:* (OL\?\ M_\ ?9_QH^SQ_P"W_P!]G_&I:* (OL\?^W_WV?\ &C[/'_M_
M]]G_ !J6B@"+[/'_ +?_ 'V?\:/L\?\ M_\ ?9_QJ6B@"+[/'_M_]]G_ !H^
MSQ_[?_?9_P :EHH B^SQ_P"W_P!]G_&C[/'_ +?_ 'V?\:EHH B^SQ_[?_?9
M_P :/L\?^W_WV?\ &I:* (OL\?\ M_\ ?9_QH^SQ_P"W_P!]G_&I:* (OL\?
M^W_WV?\ &C[/'_M_]]G_ !J6B@"+[/'_ +?_ 'V?\:/L\?\ M_\ ?9_QJ6B@
M"+[/'_M_]]G_ !H^SQ_[?_?9_P :EHH JW)M[2W>>9G6-!ECN8UF?\)#HO\
MS\2_D]6O$'_(!N_]T?S%><T =Y_PD.B_\_$OY/1_PD.B_P#/Q+^3UP=% 'IM
MI):WUNL]NSM&Q(!+,.E3_9X_]O\ [[/^->:M\4?#W@VVM].U9KA9V4R+Y<18
M$$GTKTBRNDOK&"[B!$<R!U!ZX(S0 [[/'_M_]]G_ !H^SQ_[?_?9_P :EHH
MB^SQ_P"W_P!]G_&C[/'_ +?_ 'V?\:EHH B^SQ_[?_?9_P :/L\?^W_WV?\
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MFK(H>6(XRC_+@@X'0 \=:6;PZ;M9DGO)XD24/9M ZAK=0FTA25X!Y&#GKU]
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M -V/\S_A0!+1469_[L?YG_"C,_\ =C_,_P"% $M%19G_ +L?YG_"C,_]V/\
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MI:BBMXH9)7C7#2MN<Y)R<8_I6-J7B4Z=I<&I?V;<36;1+//*A7]PAP<D'[V
M<D#TJYJNK?V=' (;9[NYN'VPP(P4M@%B<G@  $T :51SPQW,#PR@F-QM8 D9
M'U%87_"76C2P&&"22U9(WGN 0!!O.%# \DY!SCICFK&G^(8K_46MA;R1QOO^
MSSLPVS[#A\#J,'UZT ;  50J@  8 ':EK#?Q-;QZI);/ ZVR2&$W98;/-"[M
MF.O3OTSQ5>/Q?$]J[M83I.P1K: LNZX60X0CL,GUZ=Z .DHJGIFH)J5F)U1H
MV#,DD;$$HZG!4XJY0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9%]J4TMR=.TP*]U_
MRTE/*0#U/J?04RZOKC4+E[#2VV[3B>[ZB+V7U;^5:-C86^G6P@MTPN<LQY+'
MN2>YH R;_38=.\-WBH6>5P&EF?EI&R.2:X6O1O$'_(!N_P#='\Q7G- !1110
M!Z!X6_Y ,/\ O-_,ULUC>%O^0##_ +S?S-;- !1110 4444 %%%% !1110!Q
M6H+>0^.HWTBQGBN)4(NI70_9Y4VG#%N@8$*..>M9\>C^((+N^FN[.W=8I+6X
M_P!&9V,Y1B7QE1EN2?KBO1:* //C9ZA!/<ZJ--N9%U)+F)+<1G?$7(V;Q_"#
MC)/;O7;Z;;-9Z9:VSMN:&)4)]2!BK5% 'G7Q+L[4207]^^DSVPB\L6FIW#1)
MNSG<NWJ3D Y]!5SX;6<,=C<WEI+IRVL^Q4M=.F:2*(KG)RW1CD=..!4_B[2(
MKG4([R+5]/L[T0>5LOX4E1ER2" QRO)/(Z\>E/\ !ME:V=Y?'^U;.]U"2.(S
M+91+%&B L%^5>Y.[D\\#TH S?B+I_A.\#_VI=:7;ZTT""W>^;C8KDXQZ'Y@2
M/6H?AC#IZ7NKRV4VBAG2$-;Z4Q94 WX9F/<Y/'^S71>,-)CN=&O+VWTRWNM2
M6)41WMUF=4#<[0W4@%B!W.*POAG:26LFIGRYC"RQ!)KFS2VE8_/D%5ZJ,C!Q
MW([4 >A4444 %%%% %#6H9;C0K^*&"*XF>W<1PRC*.VTX!'H37)>#]3\[6X[
M.+P__9P2QS<SO:+;F64,H^4#DCEL]NE;7BRW\3W-K!'X:O+2U8OBX>9-S[3C
M[G;(Y//M7+>!]%33O%'VG5=5U*[\0RV]TCK=C@P+,H5P.BY 0X'7)]* /2FW
M;#M +8XSTKB-,TS688/$+C3!;1W*$060F7#R?,"Z]E!!7ZXS7<44 <E<C7%T
M72]/30_M$/D*EZOVF,8P,;.3R#CD^E2WKZC>7<5W:Z?ON-,E,;1>:H64/'SM
M)Z8)'7T]ZZBB@#A8_"VI6T!TY$26WODB^U3AP/)96+/@=2#G ^G-6(+'4-)=
M9[BU#6NDI.T#+*N;C>21Q_#@$@Y[UV5% '&3:!?WUQ)9O"(]/FN3?&<N-RDI
MCR]O7(;G/3%1+H.LR^1>S6T:W6G)#%!")01<"-LL<_P[@!C/3O7<44 9>@V4
M]G8R-=*$N+B=YY(P<A"QX7/?  K4HHH B^SQ_P!T_P#?1H^SQ?W3_P!]&I:*
M (OL\7]T_P#?1H^SQ?W3_P!]&I:* (OL\7]T_P#?1H^SQ?W3_P!]&I:* (OL
M\7]T_P#?1H^SQ?W3_P!]&I:* (OL\7]T_P#?1H^SQ?W3_P!]&I:* (OL\7]T
M_P#?1H^SQ?W3_P!]&I:* (OL\7]T_P#?1H^SQ?W3_P!]&I:* (OL\7]T_P#?
M1H^SQ?W3_P!]&I:* (OL\7]T_P#?1H^SQ?W3_P!]&I:* (OL\7]T_P#?1H^S
MQ?W3_P!]&I:* (OL\7]T_P#?1H^SQ?W3_P!]&I:* (OL\7]T_P#?1H^SQ?W3
M_P!]&I:* (OL\7]T_P#?1H^SQ?W3_P!]&I:* (OL\7]T_P#?1H^SQ?W3_P!]
M&I:* (OL\7]T_P#?1H^SQ?W3_P!]&I:1G5$+NP55&22>!0!&8(@,D''^\:PY
M6?6YFM=/9XK)#MFNU8Y;U5/ZFGEYO$3E(F>'2@<-(.&N/8>B^_>MN&&."%8H
M45(T&%51@ 4 06VFVEG;K!;Q;(UZ $U+]GB_NG_OHU+10!DZ_#&NAW1 .0H[
MGU%>>5Z-X@_Y -W_ +H_F*\YH **** .\\,0H^A1%@<[F[GUK8^SQ?W3_P!]
M&LOPM_R 8?\ >;^9K9H B^SQ?W3_ -]&C[/%_=/_ 'T:EHH B^SQ?W3_ -]&
MC[/%_=/_ 'T:EHH B^SQ?W3_ -]&C[/%_=/_ 'T:EHH :D:IG:,9]Z=110 4
M444 %%%% 'GWC&Y\&1>(9)?$%A'=2P60::67[L,8+%0!W9B3P/:CX=W?ANYO
M;R71]'DTBZGMH7DMFQAH\OM; Z')(/X5U&L>&=%URY@GU.T2=X2"H9B <'(!
M&<, >>:N6MA96]_=7,(!NK@+YK;LG:,[1[ <_K0!RWCV7Q+<6TVFZ1I<<ME)
M"CS7;7HMRIWDE0?HHR?]JJ7PUTJ[T^\U*:YTTVJS0P&.3^T3="09<\'MUS[Y
MKH_&XB;P??B8,4PGW<<'>N"<\$9QD'J,BLSP'HL6CK/&-?359EMX(56/:%AB
M0,$& >I^;GVH [.BBB@ HHHH *:8T,@D*+O (#8Y /49_ 51UZ]ET[P]J5]#
MM$MO:R2IN&1E5)&1WZ5P7@#Q1J>N>)/)O=8EN4%F\GV=M.:W .Y.<GKC)&/>
M@#TJ4.8G$9 D*G:3T![5PNB3ZBGA_7;6XU.Y36($9Y/.Q)Y;8/SQGH5)!P.V
M*[QE#J5/0C!K M?"-G;0:@GVN]D>^7RWF>7+HG.%4XX')H S+R^O[FWLTCOI
M;=H=*^WLZ$?O9 %P&]5Y.1[BK^HWESJ":+;13RV8OU,LDD)PZ@1[]H)]\?@#
M5B;PK87%E9VLDMT5M8_)#B7#21\91SCE3@9'M2S^'Q>_:%NKN=5,PDMC#)M:
M !=I"G'&><CWH YB'7]2N[235&NG0Z<D(,"'"3EF(<L/<#CT-:FB:A>R:E93
MS74DJ:F;C,+'Y8?+8[=OIP,'U)K5;POIK7%K*J21K;HB")'PD@0Y3>/XL'D5
M&_AF"$WD]C--%<S(XB)D^6 L<L4&/ER>30!BWFLWUK=7&J"XD:-+UK(6F?DV
MA,[L==VXYSZ57&I:E"UIIQU&>1M3CMY3<$C="9&PX3C@8/'I73IX<LAJ(OI&
MEDDQED9OW;/MVF3;_>(XS447A+38K2>W#7!\W;MD:3+PA3E A_A"GI0!-X=N
M9I[&:*>1I7MKB2 2MU<*>"??!Y^E:]5M/L(=-LTM8-Q1<DLYRS$G))/<DU9H
M B^T1?W_ -*/M$7]_P#2I:* (OM$7]_]*/M$7]_]*EHH B^T1?W_ -*/M$7]
M_P#2I:* (OM$7]_]*/M$7]_]*EHH B^T1?W_ -*/M$7]_P#2I:* (OM$7]_]
M*/M$7]_]*EHH B^T1?W_ -*/M$7]_P#2I:* (OM$7]_]*/M$7]_]*EHH B^T
M1?W_ -*/M$7]_P#2I:* (OM$7]_]*/M$7]_]*EHH B^T1?W_ -*/M$7]_P#2
MI:* (OM$7]_]*/M$7]_]*EHH B^T1?W_ -*/M$7]_P#2I:* (OM$7]_]*/M$
M7]_]*EJ"[NX+&V>XN) D:]2?Y#WH 2:^M;>%I9IE2-!EF;@"L0.?$,@><M#I
M:G*1$$-/[MZ+[=ZGAM9]:F2[U",QVB'=!:-W]&?W]!6YT&!0!"LT"*%4@*!@
M #I2_:(O[_Z5+10!%]HB_O\ Z4?:(O[_ .E2T4 9.OS1MH=T V25';W%>>5Z
M-X@_Y -W_NC^8KSF@ HHHH [SPQ-&FA1!FP=S?SK8^T1?W_TK+\+?\@&'_>;
M^9K9H B^T1?W_P!*/M$7]_\ 2I:* (OM$7]_]*/M$7]_]*EHH B^T1?W_P!*
M/M$7]_\ 2I:* &I(DF=ISBG444 <>\M]:_$#%]>SQVUPNVS52#"_R\JP[-D$
M@]ZI_P!I7D%SJFG+?W_F-=6\(:Z3:T8D)#/&<8VG!"^A%=%<^&;6ZUR/5);B
MZ+1C*0B3]VKX(W@>N":5?#=I]CN()I[JX>?;NGFEW2KM.5PV.,'D4 <T=0U*
M>XN=+749X_[-2XE%P&&^8H1L#G'(Y^;UKM=.N3>:;:W3+M::)7*^F1FLN7PE
MITMG!;%[D>66W2K+AY0YRX<]PQZUN(JHBHH 51@ =A0!Q?CSPC%K5I-J:2S"
M\@A5(X_M;0QE0^6R1P"02,GVJI\.-'DL;G4KW[&UK!<QPK$DEY]H=L;CNSV4
M[AC\:Z'QJ(#X2O1<EQ"3&&9<?)^\7YB#P0.I'< BN3^%DUHU[J=M::G<ZG':
MVUM#'<M%Y<)C7>%5!WQSD^XH ZCQX(SX,OQ+8QWJ'R\P2YV']XO+8YP/O''I
M7+_"^!+?5M=B_LRQT^6-84DCM(W7D&3J6Z_A_6M?QSKNKVL4NE:-H^JW%Q+"
MDGVNR53Y0+G(^;^(A3^8JE\.4U(:EJK:E'KB2&*';_:FWD9D^[M_7\* /0:*
M** "BBB@#/UDE])N[:*YAM[F:"186D(P&VGG!Z@=37#?#ZPN+/79V;=#&UNP
M>*741=-*^Y?G7^Z!SGUW#TKH_'&DR:CX=NY;2UM)K^*VF2!KEB @="K8/;(]
M:X[X=6ULOBPRQ:9H6GNMC(I73[LS/)EX^3Z 8_6@#U>HYYX;6!Y[B5(HD&6=
MVP /<U)6%XOM+:]\.7$5U="V0%761@"H93D!@>""1C!H U?M]F(89C=P".?
MB<R !\],'O4D]Q#;1&6>6.*,=7D8*!^)KRC5+RWO-"TN9(+:-H[>YB>$D"-D
M#*KO 3QOSRH],BNRU^XL9;S2?M<D+:>DKB<2$%5?RB4#YZ>V>^* .D:Y@26.
M)IHUDESY:%P"^/0=Z5+B"2:2*.:-Y(\;T5@2N>F1VKS&W,@LF^TY_M,Q6O\
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M]YOYFMFL+PQYO]A1;=F-S=<^M;'[_P#Z9_K0!+147[__ *9_K1^__P"F?ZT
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M=[DY]\4 >K5'/!#<P/!/$DL3C#(ZY!'N*DK*\0ZR-!T>2^,/FD,J*I;:-S$
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ME;^$=J +4NOW_P"_RR6_RKGS$S]E_P!M_4-VQ1+K]_\ O\LEO\JY\Q,_9?\
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M2BVT.[TU9186VCQX5?*)@?.[^+<=W3KC%7I&UU?.*1V+X5?*&6&3WSSTZXH
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ML[N\5[>)PZJHVL09D+'[N1N'OQS6YKM_ISWFE37%U ^GPRN)V=QMC<Q'9O\
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M.V:/]1_T[?9_G^?Y_LF[^-_^>@?L.V:/]1_T[?9_G^?Y_LF[^-_^>@?L.V:
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M 'V:EHH B\A?[\G_ 'V:/(7^_)_WV:EHH B\A?[\G_?9H\A?[\G_ 'V:EHH
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M;MV!DC&:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1DXRK;5.0>Q%=#7+:7H.H3>+)?$FL+;0W M_LT%M;2M(J+G)8L57)/T%=30
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MJRH<$ D M]!FBT\.Q6UW'(TF^&$^9%'@C;(?O-G/.?0\"L[Q1X>O/$C7-K-
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M<UH;>..!FD,DD3KSN"F, 9SV/:@#0\5^)KWP[HK:M;:2E[:Q1B24O=>25R0
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M^V#]VR.%.P;<OUSDA1[YJS-\0YK?Q*^DR:.@1;V.S6<7?5I%+*=NSVP>?SH
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M"<97\: /;Z*!TYHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *RM:\-Z-XBCBCUC3H+U(B2B
MS+D*3WQ6K10!2TK2;#1+%;+3+6.UM5)*Q1C"@GK@5=HHH I:KI%AK=D;34;9
M)X20P#9!4CH01R"/4<U1?PEHTNGR64T$T\<A5FDGNI9)<J<J1(S%P0>F#Q6W
M10!S,W@#PW<1PQO8RA88I(4V7<R?+)]_.&&2>Y.3[UC>(/AQ:R:2]OH%ND<\
M\UNTYN;Z;#)$1@ _-@X&!@#ZUW]% ',2?#[PQ/;Q13:9E8T91_I$F3N8,V6W
M98[@#D\TLW@+P_-?MJ!MKAKPS+<!VO9\>:HPK8WXXKIJ* ,C0M.N+075W?PV
M::A=ONG:TW;&"\+][G.*6Z\-Z9>:];:W-'.;^V7;"ZW4JJH/4; VWGOD<UK4
M4 8EUX3T:\EDDFM7_>OYDJ)/(B2MZNJL _0?>!JJG@'PY';"W%I.46Y^UJ6O
M9BR2_P!Y6+Y4GO@C/>NEHH 0#  ]/4TM%% !1110 4444 %%%% !1110 444
M4 <KXB^''A7Q7J O]:TU[JX5 @;[3*@ 'H%8#]*Z'3["WTO3X+&T1DMX$"1J
MSER /=B2?Q-6:* "LJX\.:;=:];ZU,EP;ZW4K$ZW4JJH/4; VTY[\5JT4 9<
MGAW2Y=:_M=K=A>E C.LKJK@=-R@[6QVR#BL]O 7AQQM^Q2A!<"Y5%NY55) <
MY50V%Y[# KI** *FHZ99ZM8265_;K/;N/F1_T.>H/N.:H6WA32+2WNX8X9V^
MUQ^5/)-=2R2.F,;?,9BP&.P-;5% &!/X+T&XTRST^6S=K>S4I /M$@95/5=^
M[<5/<$D&H]0\!^'-3N4GN;!MZ",*(KB2-?W?W/E5@,CL<5T=% '%^%_!1TS6
MM1U74H('NI+N2:U>.YDD"(^,Y5@%#<=0"?>M[4O#>F:OJ=EJ-Y'.US9'=;LE
MU+&$/<[58 Y]QTXK6HH Q[WPOI&H3337%O)OG(,WESR1B; P X5@'7'8Y%4?
M^%?^&_LUU;FRF:*YF6>0->3'$B]&4E\H1ZKBNFHH ;&@CC6-=Q51@;F)/YGD
KTZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g500830g0707050510771.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g500830g0707050510771.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %/ C\# 2(  A$! Q$!_\0
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M&FZO=WMK93N\]DX2=&A="A(R/O 9_"KMU<QV=K)<RB0QQKN;RXV=L>RJ"3^
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M\1R0/*UQ*"D0^[EMV[Z$G/O7T+10!XG?ZYJD-WXNM])U.\DBANK8$?:7D>"
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M'@D60$H5(8#J17G7A_Q#HNBVVII-=P7&F6!06]XP!<$[@(6. "PQQT.#SZD
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MO0!+146V?_GJG_?'_P!>C;/_ ,]4_P"^/_KT 2T5%MG_ .>J?]\?_7HVS_\
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M  JW7ET"R6ME)9W(=+V_@MAIJ/\ >(65F"KZ%,AB.PY->H#.T9ZXH 6BBB@
MHHHH **** "BBB@ I%14SM4+DY.!U-#NL:,[D!5&23V%8=GXNTF\TR\U$22P
MVMH-TDD\+)E,9#+D<J>Q'6@#=J**WBADED12'E;<Y+$Y.,=^@XZ#C\ZS;[Q-
MI>G0VLMQ+)LNH_-CV1,^(P 2[8'RJ,C). ,U:U+5;72K=)KDR$.P1$AC:1W/
M7 502>,GCL#0!=J.>!+F!X90Q1QM;:Q4X^HY%9S^(M,2ZM8//9FN55T=(V9
M&X4LP&%W'@9QD]*DL];L;Z_FLH)',L6<EHV57P<-M8C#8)P<9P>M &@JA5"J
M % P .U+6;_;MA_:K::97$ZCD^6VS.,[=^-N['.W.<<U!'XITJ6SN+I99?+@
M(R# X9\G"E%QEPQX!&<]J -FBJ]E>0:A:)<V[$QOG&Y2I!!P00>00>"#5B@
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MW < 0,K%GX/+ YP,>G-6+>SU#2'2:YM,VND).\3K*F;G>21@$_+@$@YQSTH
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ME6']Z ZPC!.0IX'3ZDD4[PM;V%_(^HPZ.-(N;>5HVCAVJ)%*@C<%X/4>X(H
MZVBBB@ HHHH \Z^)EM<ZA?Z/9I8:I>VYCGE:+3I?+8.OEA&)R.!N;CUJ_P"$
M/$6NW5S8:/K&AWEF\=@6ENK@C]](GEJ<8]=Q/-==?W+6>GW-RD1F>&)G6,$
MN0,XR?6L_3_%&D:E=RV4-[";R #SH=X)3CUZ&@#8HIDDBQ1/(V=J*6.!Z5SN
MF^+?M^@7FL/IES'! IDC5")#,F,C&T]?4'I0!TM%9%_XAM=/T.'5)4D*3",I
M&HRQWX_EG)^AJ;5M5_LQ(5CMI+JYG?9%!&P!; ))R>   30!HT5SW_"76C2P
M&&"62V9(WGN 0%@WG"!@><D@YQTQS5C3_$,5_J#6PMY(XVW_ &>=B-L^PX?
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M 5A@3>(WRP>'20>%Z-<_7T3^?TIT=O-KTJW%XC1:>IW0VS<&7T9_;T7\ZW
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MJ1JF=HQGWIU !16=_;FF_P!L_P!D?:D^W;-_E=\?X^U(NOZ4_P!LQ>QXLO\
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M^S=G/) ;K0!Z#17F4%W<75E+?3SR-=:?!;FQ.XC=ND9=V/XMX %>F#[HSZ4
M8.L>'[N\O!>Z9JDEC<8PX*"2-L=#M/0^XIND>'[VUO?MNJ:M)>SJ#L54$<:Y
M&"<#J<=S4GBWQ*GA71&U%[9I\-M"AMH'!.2>W3^53:!XAM/$,-S+9L'CMYO)
M+J<JQV@\'OUQ^% &O1110 4444 <OXYEN[#0Y]4M;N_C-K;S_N;1 V]F0A6/
M^Z>:YCP!?37GBAMFLZYJ%N+.1I%O[/R$1RZ;<<<G&ZO0M8ANKC1+Z"RD$=W)
M;NL+GHKE2%/YUQ?@[0=;TKQ3))J%Q//;_8>#+>^;M9F4XV^V",^WO0!Z#6-X
MIN-1M?#]Q-I:L;A2N2BAF5,C<R@\$@9.*V:IZI9S7VG36]O=-:RN,+*JAL?4
M'J* .-U/Q+J-II&CS0:E ZW$3D77D@K/*,;(S_<W<@GL1BNDUN[O5GL+"QF6
MWN+MFS,4#[%52QP#P2>!^-93>!$;3;>U_M*8,%E6X8QJPF$C!F^4\*<@8(Y%
M:%SHM[?/(7OFMWMY@UE,B*S1ILVL#ZYR>M &-'XJU"Y@;449([>Q2+[3!L!\
MYF8JV#V QD>N:T-(UF^N-1MGN9%:UU$S>1$$ ,/EG Y[Y )/H:E/@^U62!8;
MB6.U5(UG@P"+CRSE2QZ@Y)SCKFC_ (1N:R:XN+&\=I423[%$RKMMV<[FQGKD
M^O0<4 4[KQ%>VMY/?,ZG3X[HV?V<(-V0N=^[K][C'I5==?U>(064MQ&UWJ*0
MRP2B( 0"1L$8_BV@C&>M; \+QR7_ -HGN7>!F\Y[7:-AF*[2^>O3MTSS4,?@
M]$MG5]0F>X41K:SE!NMUC.4 '?!ZYZT :6A7LU[8R"Y8-/;S/!(X& Y4_>QV
MR"*TZI:7IRZ99"W$C2N6:225A@R.QR2:NT ,\V/^^OYT>;'_ ,]%_.E\M/[B
M_E1Y:?W%_*@!/-C_ .>B_G1YL?\ ST7\Z7RT_N+^5'EI_<7\J $\V/\ YZ+^
M='FQ_P#/1?SI?+3^XOY4>6G]Q?RH 3S8_P#GHOYT>;'_ ,]%_.E\M/[B_E1Y
M:?W%_*@!/-C_ .>B_G1YL?\ ST7\Z7RT_N+^5'EI_<7\J $\V/\ YZ+^='FQ
M_P#/1?SI?+3^XOY4>6G]Q?RH 3S8_P#GHOYT>;'_ ,]%_.E\M/[B_E1Y:?W%
M_*@!/-C_ .>B_G1YL?\ ST7\Z7RT_N+^5'EI_<7\J $\V/\ YZ+^='FQ_P#/
M1?SI?+3^XOY4>6G]Q?RH 3S8_P#GHOYT>;'_ ,]%_.E\M/[B_E1Y:?W%_*@!
M/-C_ .>B_G1YL?\ ST7\Z7RT_N+^5'EI_<7\J *][!:ZA936EP5:&92CKNZ@
MUA:!X(\,>%[Q[O1[**VF==C,K]172^6G]Q?RH\M/[B_E0 GFQ_\ /1?SH\V/
M_GHOYTOEI_<7\J/+3^XOY4 )YL?_ #T7\Z/-C_YZ+^=+Y:?W%_*CRT_N+^5
M">;'_P ]%_.CS8_^>B_G2^6G]Q?RH\M/[B_E0 GFQ_\ /1?SH\V/_GHOYTOE
MI_<7\J/+3^XOY4 )YL?_ #T7\Z/-C_YZ+^=+Y:?W%_*CRT_N+^5 &9K\B'0K
ML!U)VCH?<5YW7HNOHHT*[(4 [1V]Q7G5 !1110!WWA=T70H064'<W4^YK8\V
M/_GHOYUC^%T4Z%"2H)W-U'N:NS:AIUNUPLLT2&V56FR/N ],_6@"WYL?_/1?
MSH\V/_GHOYU3EU+38?/\R:)?LZJ\N1]T-T)^M$NI:;#Y_F31+]G56ER/N!NA
M/UH N>;'_P ]%_.CS8_^>B_G4,5Q:37,EO&T;31!6= .5!Z5/Y:?W%_*@!/-
MC_YZ+^='FQ_\]%_.E\M/[B_E1Y:?W%_*@!0RM]U@?H:6D"JO0 ?04M &:V@Z
M8^M+J[6B&^5=JRDGCWQTS[U//IEE<BY$ULC_ &E0DV1]\#IGZ5;HH RTT&QB
MFM##&(X;:)XEA ^4AL9SZ]._K0/#FCC2VTT6$?V-GWF/G[WKG.<UJ44 4)-%
MTV:>TGDLXC):#$!Q]P=L5?HHH X[XDSR1>&XHDD=%GN5CD$=N)G9<$X53WXS
MGVJK\+FE&D:C"[W+117>V+[3 (F"[%/W1[DU)\488Y_#=NDFX-]K3RV\\PHK
M;6P7<<@?UQ3/A;$D.A7J@LTGVL^8WV@S(QV+]QSU']<T =U1110 4444 9OB
M%87\-:HMS+)% ;24221#+*NTY(]\5PG@":W?Q"NRTU7[2UG(9;N\@,2N-Z84
M#..!@ =@#ZFNZ\1)%)X9U1)A*8FM)0XA^^1M.=OOZ5Y[\-?^$>.MQMI<MW]K
M-G.LD#WS7*1*LRJ,D\ G (]1F@#U6BBL;Q3/J5MX?N)=+#&X4KDHH9E3(W%0
M>"0,G!H V:*X+4/%MU;:/IL=K=O<O+ ;BYOX;<.8X5(!;8<#=V/I@\5T&K7U
MTYTVSTZ[$4E[EOM6P-A%3=D \<\#\: -VBN&C\4ZC<P-J*.D5O8I%]I@" ^<
MS,5;!/( QD8]>:T-'UF_N-1M7N95>UU$S>3$$ \GRS@<]3D DY[T =317'W7
MB*^M;R>_:0-I\=V;,6P09R%SOW=<[N,=,57&O:Q$+>REN4:ZU%(98)A$H%OY
MC888_BV@C&>O>@#N**R]"O9KRRD6Y8//;SO \@&-Y4\-CMD$5J4 %%1?:(_[
MQ_[Y-'VB+^\?^^30!+147VB+^\?^^31]HB_O'_ODT 2T5%]HB_O'_ODT?:(O
M[Q_[Y- $M%1?:(O[Q_[Y-'VB+^\?^^30!+147VB+^\?^^31]HB_O'_ODT 2T
M5%]HB_O'_ODT?:(O[Q_[Y- $M%1?:(O[Q_[Y-'VB+^\?^^30!+147VB+^\?^
M^31]HB_O'_ODT 2T5%]HB_O'_ODT?:(O[Q_[Y- $M%1?:(O[Q_[Y-'VB+^\?
M^^30!+147VB+^\?^^31]HB_O'_ODT 2T5%]HB_O'_ODT?:(O[Q_[Y- $M%1?
M:(O[Q_[Y-'VB+^\?^^30!+147VB+^\?^^31]HB_O'_ODT 2T5%]HB_O'_ODT
M?:(O[Q_[Y- $M%1?:(O[Q_[Y-'VB+^\?^^30!+147VB+^\?^^31]HB_O'_OD
MT 4?$'_(!N_]T?S%><UZ'K\T;:'= $Y*CL?45YY0 4444 >@>%O^0##_ +S?
MS-86I-LU*Y;>L?DR%MSC(M\_Q2#^)6[#M6SX8F1-"B#$YW-V/K6+J+@:C<.'
M6,12%]SKD6^[^.0?Q*W8=J *W^J_Z8>3\W[WYOLV[^*3^^K?PCM1_JO^F'D?
M-^^^;[-N_BD_OAOX1VH_U7_3#R/F_>_/]FW?Q2?WPW8=J/\ 5?\ 3#R/F_>_
M/]FW?Q2?WPW8=J -;PZNW4FCV,GEQD^4QR\62#ES_%NZCT KJJY30"L6HE&1
MT$<9_=,<O%N(.6/\6[J/0"NF^T1?WC_WR: ):*B^T1?WC_WR:/M$7]X_]\F@
M"6BFI(KYVG./:G4 <H-1U1?'CV5S="WM&C_T6!HQLG&!DANNX'/'I51/$%^D
MFIV:ZE%<W"W4-M&Q@V&!I#@\8^91S@]R*U[WPW+?>((-1DU*7R(#OCMMBX63
M! .[KCD\4'PR9H+DWE_)<7LVPK=>4J-'L)9, <<$GZYH B36[JU\.ZG/.5GN
M]/D>'?MVB5A]TD#IG(SCWJC_ &KJZWZ^'S?*;YY5_P!.\E>(S&7/R=,Y&WZ<
MUHCP]*L L'N&FL[A)C?.X4--(^,-P.#UZ<#%-'A1O(\PZG.=3$HE6^\M=PPN
MP#;TQMXQ^/6@#)C\4ZE=0->HZ11:?'$;J'8#Y[,Y5L'JH &1CN:[@'(!]:YT
M^#[56MTAN98K=4C2XA !%R$;<NXGD').<=<XKHZ .>\9/=QZ/$]M:"[A6X0W
M4/EART7< 'C.<5'X+O9KW3[IFTT:=;I<%;>W^4,$P#E@.A))_#%<K\3O$6GW
M%L-%BNK<7MO>1F>"XG:%6386SN'..1^-7/A)+#)H^JK#!!$$O<$P3M,CGRT.
M0S?7'X4 >AT444 %%%% &9XCDN8O#&JR68<W2VDIA"#YM^PXQ[YKQOPM=7OA
M/4[F?0_"&IL)[5WN8)+Z*4M+E2'P#D <@X_O5[#XI9$\):PT@R@LIBPWE>-A
M[CD?6O+_ (7R6$WC)7LWT+<-.EW#33)O;+Q<MN^GZT >RJ25!(P2.E5-4LY;
M_3I;>"Z>UE<865 #M_ \$5<HH Y2/P2D5E;Q1:E<1S*LJ7$JJO[]9&W.I&,+
MR.,=*M3:#=709/MK6OV:4?8)(T4M$FS:1R,$')'.?Y5T-% '.GPA:+);B&XE
MCM42-)[< $7'EG*EB><Y)SCKGFD_X1N6R:YN+&\D,JI)]BB8+MMV<[FQD<Y/
MKG'2NCHH P!X7B?4/M,]R\D+-YKVNT>69BNTOZ].W3O4,?@^)+:1&OYWG41K
M;3LJ[K=8SE .QP?7KWKI:* *6EZ<FF60MUD:5BS/)*PYD=CDL<5=HHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *I7.K6-G-Y5Q<K')
MC.T@U=K@O%G_ "'&_P"N:T =7_PD&E?\_L?Y'_"C_A(-*_Y_8_R/^%><44 >
ME0ZUIUQ,L45TC2.<*H!YJ_7F^A?\ARS_ .NE>D4 %%%% !1110 4444 %%%%
M !1110!F>(/^0#=_[H_F*\YKT;Q!_P @&[_W1_,5YS0 4444 >@>%O\ D P_
M[S?S-86I-LU*Y;>L?DR%]SC(M]W\;C^-6[#M6[X6_P"0##_O-_,UA:DVS4[E
MMZQ^3(7W.,BVW?QN/XU;L.U %7_4_P#3OY'S?O?G^S;OXI/[X;L.U'^I_P"G
M?R/F_>_/]EW?Q2?WPW8=J/\ 4_\ 3OY'S?O?G^R[OXI/[X;L.U'^I_Z=_(^;
M][\_V7=_%)_?#=AVH UO#J[=2:/8R>7&3Y+'+Q;B#EC_ !;NH] *ZJN5\.KM
MU)H_+9/+C)\ECEH=Q!RS?Q;NH] *ZJ@ HHHH **** "BN>C\233^*;K28; O
M#:J/-E$@WAB,CY/[IZ9SUJ/_ (2N6%[VVO=+>"^@\HPPB8.)A(2J8;''S @\
M<8[T =+161#KT1T6YU"YB,#6F];B$-N*.O50>_MZY%4O^$IG\L6YTS&K-*(U
ML_/&#E=^[?CIMSVZ\4 =)17-?\)A"YAD@M'DMA'&]W*7VFWWMM48Q\QR#GI@
M#-=+0!S>I6?A2QU)I]56Q6ZOY!S<D98A<#&>@PM6] AT.+[<=#:W*/.#.(""
MH?8OIQTQ6#\3H+<^&UNY-&@U*2"7*K+&7"<'G Y/I^-7/ 4UA+I%U_9>D_V?
M9+<$1#RC'YORC+8//7(_"@#JZ*** "BBB@#-UUP='N[:-[?[5<021P1SL-LC
ME< 8/49(KB/A]I^HV^NW$L\.IB$6Y61M26,.LA92!'L_AP#D=.%Q6[XPOY-$
MO=+UJ73[B^T^U\U9X[:/S)(F8*$D"]\88?\  L]JK>'/$#>*_%+:C8Z??6NF
MV]H\,DMW$8C-(74KM4]0H#<_[5 ':UB^*X+^X\.W*:=*4G&&;;(8RR Y90P^
MZ2,\UM54U+3XM4L)+29Y45Q]^)RCJ?4$=#0!P^H^*;>T\'VL-IK!@N=@9GNY
M5690K@%#DY+9XSSP"<UTFNRR75UI>GPW4L$-VSL\MO(58A4+ *PZ9..G85+'
MX5TA-'72VMA) .2TAW.Q)W$ECSDGFB?P]%>_:5O+B=D>82P>5,R-!A=N%.?E
MSSD# P?K0!RD.MZC=V<NJ/=RK)IR0!8D8A)RSD,67ON X].U:NAWUVVIV-Q+
M=2RC4S<>9"[DI%L8[=H_AP!@^I-;+^&M,>YM9Q"R?9E5$C1R$8+RNY>C;3R,
M]*CD\-6L9O9K)Y8;JY1E5_-;$18Y)0 _+D\G&,F@#!O-6O;6ZN-56XE;9?-9
M"UWGR]@3.=O][)SGTXJL+Z_A:ST[^T;F0:I%;RR3F0EHC(V'V'^$$'  Z8XK
MK$\/6"ZB+]A(\^W!#2$H6V[2^WIN(XSUQ447A32XK.XME2;9,5^8S,6C"G*A
M&ZJ%/0#I0 _PY<2S6$T4TC2FVN9(%D<Y9U4\$GN<'&?:MBJUC8P:=9QVMNI$
M:9Y9B223DDD]23SFK- $7G'_ )Y2?D/\:/./_/&3\A_C4M% $7G'_GC)^0_Q
MH\X_\\9/R'^-2T4 1><?^>,GY#_&CSC_ ,\9/R'^-2T4 1><?^>,GY#_ !H\
MX_\ /&3\A_C4M% $7G'_ )XR?D/\:/./_/&3\A_C4M% $7G'_GC)^0_QH\X_
M\\9/R'^-2T4 1><?^>,GY#_&CSC_ ,\9/R'^-2T4 1><?^>,GY#_ !H\X_\
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M[9SU<^H/]WI5K3]&GL;M9=R-$H+!,D'S3]YL^A].@K<HH BW3?\ /)/^^_\
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MG# DXQZCK0!V\VNZ1;7ZV$^JV,5X_P!VW>X19#]%)S5V21(8VDE=411EF8X
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M WOBW/&A:-C_ +#$G_R-7BUMXK^(3?$T632W[:5]L9 C1D0E><#S-F=N<#-
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g500830g0707050511017.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g500830g0707050511017.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %/ C\# 2(  A$! Q$!_\0
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M7-S!9VTEQ<RK%#&,N['  H EHJ@NLV#ZN-*6<F],'V@1[&^YG&<XQ^&<U?H
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M=I+*&8]%RBGGVZT ;5%96B^)-)\0"?\ LVZ\Q[=MDT3QM')&?1D<!A^(K5H
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M_P#SU3_OC_Z]&V?_ )ZI_P!\?_7H EHJ+;/_ ,]4_P"^/_KT;9_^>J?]\?\
MUZ ):*BVS_\ /5/^^/\ Z]&V?_GJG_?'_P!>@"6BHML__/5/^^/_ *]&V?\
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M&V?_ )ZI_P!\?_7H EHJ+;/_ ,]4_P"^/_KT;9_^>J?]\?\ UZ ):*BVS_\
M/5/^^/\ Z]&V?_GJG_?'_P!>@"6BHML__/5/^^/_ *]&V?\ YZI_WQ_]>@"6
MBHML_P#SU3_OC_Z]&V?_ )ZI_P!\?_7H EHJ+;/_ ,]4_P"^/_KT;9_^>J?]
M\?\ UZ ):*BVS_\ /5/^^/\ Z].590WS.I'H$Q_6@!]4=1UG3=(\C^T+V"V\
M]Q'%YKA=[>@J]7%>/YK.P2SU)[E(;Z'<L,<HS'<J<%HB,<DX&,<Y]1P0#J5U
M;3GU,Z:M];F^5/,-L)1Y@7UV]<<BHTUW29&O%34[1FLL_:@)E_<=?O\ /R]#
MU]*YN?6?#]_XBTVS:YM[>^LI/M#0AE#B1D*E,=3PQ+>FT9JB[6HM;I]+U!K[
M08;FWN)&,QF6(B0F0!SG*C"L02<<]N* .\M[NVN[1+NVGCFMW7>DJ,"K#U!]
M*J#7]'.EMJ8U2S^P*=IN?.7RP<XQNSCKQ7+FYCNO#&LPVTRLVH27$]E"K_-/
M%D;B@ZD'D\==P]:I_P!H69UQ->6>/^P([E T^?W0D$!3=Z8!PF?7B@#NI=4T
M^&XM;>6]MTFNL_9XVD :7')VCO\ A5NO+H%DM;*2SN0Z7M_!;#34?[Q"RLP5
M?0ID,1V')KU 9VC/7% "T444 %%%% !1110 4444 %(J*F=JA<G)P.IH=UC1
MG<@*HR2>PK#L_%VDWFF7FHB26&UM!NDDGA9,IC(9<CE3V(ZT ;M116\4,DLB
M*0\K;G)8G)QCOT''0<?G6;?>)M+TZ&UEN)9-EU'YL>R)GQ& "7; ^51D9)P!
MFK6I:K:Z5;I-<F0AV"(D,;2.YZX"J"3QD\=@: +M1SP)<P/#*&*.-K;6*G'U
M'(K.?Q%IB75K!Y[,URJNCI&S( W"EF PNX\#.,GI4EGK=C?7\UE!(YEBSDM&
MRJ^#AMK$8;!.#C.#UH T%4*H50 H& !VI:S?[=L/[5;33*XG4<GRVV9QG;OQ
MMW8YVYSCFH(_%.E2V=Q=+++Y<!&08'#/DX4HN,N&/ (SGM0!LT57LKR#4+1+
MFW8F-\XW*5((.""#R"#P0:L4 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4C(KXW*&P<C(Z&EHH **** (GMXGN(YV
M4F2,$(=QP,XSQTSQU_QJ6BB@ HHHH **P-9N_$,D[6NA6ELK( 6NKUF$>3V4
M*,L?R%-T>]\117$=MKMK:2>86"75@S,@([.",K]>10!T-%%% !1110 45#/=
M6]KM^T3QQ;NF]@,_G4<.I6-Q<"WANX))BI<(D@)VC )QZ<C\Z +$@!B8%-X(
M.5]?:N!T5YX-,\0VUM8:@FE1QL+:"6W?S$D.X,B _,R_=/?&>#C@>@44 ><Z
M];7ESHVAM;V5^DJV1C)2V=BS80&"5,95&P<L<8VCFMW5;TMJ%G>QVEU-_9LC
M1W,,4#,P+QD H /F ) R/4^AKJ:8D4<9<QQJA=MSE5QN.,9/J< ?E0!YW#HV
MHVEG)I<EG,TNI) 4E1"R0%7)8.PX7:#QZ]JOZ<L]A<VWVFSNHX]'6Y:>40,1
M*'8E=F!\^0<G&<$<\UW%,EBCGB:*6-9(V&&1QD$>XH X6YT^\OIIM-BMIU\Z
M]-\MV8R(_+,8Q\W][/R[>N.>E0K:7T[V>H_V;=1II<5O%+"T+!Y2C9?8N/F
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M:* (O*;_ )[2?I_A1Y3?\]I/T_PJ6B@"+RF_Y[2?I_A1Y3?\]I/T_P *EHH
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M* (O*;_GM)^G^%'E-_SVD_3_  J6B@"+RF_Y[2?I_A3EC*MDRNWL<?X4^B@
MHHHH **** "BBB@ HHHH \S^(FOZK]HCTW3=+U1)8;E#'=PJ-DK%"=H&X9P#
MGZK6M\-I)&TW4XY+.ZL_+O"HBNI=[_<4Y/7&<YZ]\T_XF7-K;>&H1=6MO/YM
MTB1F>Y,"QM@D-O'(/&/QJ'X8.C:)?".&RC479YM;K[1N.U<EG/);^F* .YHH
MHH **** .3\;Z-X=UFU6/67M$NUMY_L;W)XC.T%GQGG;M!/L*Y3X;V6FP>*'
M>T?P['*EBT?E:5,TCRC<F78GH!@<?[5>@>);5)]"OG6R@NKM+65;=)4!W,R$
M;1W^;H<=:X;P'IVI6GC%S?6,<"C3V*O#I8ME.YD(!8=3@=.Q#4 >FR2+%$\C
M9VHI8X'85SVF^+1?:#>:N^F7<<$"&2-5Q(TR8R"NTGGV/(KHVW;#M +8X!Z5
MP^EZ=K$-OXA*Z2UK#<(1!8B9,-*=VYEYVJI!7TR1G'7(!O7_ (EMK*RL)E@E
MGN+\*;>V0@.V0"<DD   \DG%6=4U?^S8;?;:2W%U<-MCMHV4,2 6/)(' !/6
MN3U3PU>7]EIK3:,ES)_9K6,D4DJ9MG.W$@.<<;3]W)Z8K2N!J$DMM+:V;W5Q
MI#^0ZF5%^T!HL%@2< @D'!Q_*@"X?%UFTL'DPRRVSI&\UP,!8-YP@8$YR2".
M <8YQ5C3_$,-_J+6JV\L:-O^SSN5VS[#M?;@Y&#Z@9[5SD?A?4[6W.FK$LL%
M^D7VFX#@"!E8L_!Y8'.!CTYJQ;V>H:0Z37-IFUTA)WB=94S<[R2, GY< D'.
M.>E &P_B6VCU1[5X9%MT<PF[)7R_-"[MG7.<=\8[9S5>/Q? ]J\C6-PDQ"-;
M0,5WW"N<(5YP,GUQCOBLZ;0=0OIY+)H/+L)KDWWV@NN02F/+VYSG=WZ8]ZB7
M0]9E\B^ELU2YTU(8H8!*I^T>6V6(.<*& &,X]Z .NTW4$U*S%PB-&P8I)&Y&
MZ-P<%3CC@^E6ZRM LI[2QD:Z01W%S.\[Q@@^7N/"Y'!P /QK5H **B\H_P#/
M:3\Q_A1Y)_Y[2?F/\* ):*B\D_\ /:3\Q_A1Y)_Y[2?F/\* ):*B\D_\]I/S
M'^%'DG_GM)^8_P * ):*B\D_\]I/S'^%'DG_ )[2?F/\* ):*B\D_P#/:3\Q
M_A1Y)_Y[2?F/\* ):*B\D_\ /:3\Q_A1Y)_Y[2?F/\* ):*B\D_\]I/S'^%'
MDG_GM)^8_P * ):*B\D_\]I/S'^%'DG_ )[2?F/\* ):*B\D_P#/:3\Q_A1Y
M)_Y[2?F/\* ):*B\D_\ /:3\Q_A1Y)_Y[2?F/\* ):*B\D_\]I/S'^%'DG_G
MM)^8_P * ):*B\D_\]I/S'^%'DG_ )[2?F/\* ):*B\D_P#/:3\Q_A1Y)_Y[
M2?F/\* ):*B\D_\ /:3\Q_A1Y)_Y[2?F/\* ):*B\D_\]I/S'^%'DG_GM)^8
M_P * ):*B\D_\]I/S'^%'DG_ )[2?F/\* ):*B\D_P#/:3\Q_A08\ DSR #J
M21_A0!POBK_D/2_[B_RK!FGBMXFDFD5$49+,<"K/BG5OM&OS0Z8/M;J%5I2?
MW:''=N_T%9,.EAI5GOI/M4XY4,,(G^ZO]30!']KO-1XL4\B _P#+Q*O)_P!U
M>_U/ZUTO@K2;.+66+QB>5HFW2S .S<CUZ?05GUN>$UW:R0&*_NFY'X4 =Q%;
MP0$F&&.//78H&:EJ+R3_ ,]I/S'^%'DG_GM)^8_PH EHJ+R3_P ]I/S'^%'D
MG_GM)^8_PH EHJ+R3_SVD_,?X4>2?^>TGYC_  H EHJ+R3_SVD_,?X4Y8RK9
M\QS[''^% #ZP]<\1?V/>65I'937<]T20D;*-J#&3R1D\C@<UN5R_C:ROK[3X
M8K#33=3B3,4R2*CV[]GR>@]<?3!H O3^(EM=8@LKFPN88+@LD5V^WRV<*6*X
MSN' ;DC'!JM'XPMGMI97L[B-BJ/;1L5W7*NVU"O/&3V.,=\57G36;[4X[2\T
M<M9QIM2[\Z/&\J5:3;G<."0!CO6>- UB>."::U6.?2XHHK=/,4BY*/N8@Y^4
M$  9QSUH Z>#7+=]'GU&='MUMMXN(GP6C9?O*<9!/TZU2_X2H?9]ITVY&HF4
M1+8%T\PDKO!SNVXV\YS[=:SVL[R73KO3)[8PWFKF:Y^^K+ 1MVJV#S_#DC(_
M2F?V9K#:@/$)T[%XDH L/.3<T8C*?>SMSDYZ]/>@#3/BZS+VYA@FE@=$DGF7
M 6W#MM7>"<Y)!'&<8R:Z&N$C\,:I:V[6*1)+'J,<0NI@X MV5RS\'E@0<#'<
M<UW0& !Z4 <I\0+.]OM'M(;&R@NI6NU!\^#SEC&UANV_7 SVS53X:6US;Z3J
M/VNU^S2M>'*"T%NO"J.%'TZU=\>ZA<Z9HUO=6NJ6^GNMRH+7#;4D&UOE)P?8
MX]J;X#O8;W3KWR-8?5(X[DKYS'.#M4D ^F3GVSB@#K**** "BBB@#SKXF6US
MJ%_H]FEAJE[;F.>5HM.E\M@Z^6$8G(X&YN/6K_A#Q%KMU<V&CZQH=Y9O'8%I
M;JX(_?2)Y:G&/7<3S777]RUGI]S<I$9GAB9UC! +D#.,GUK/T_Q1I&I7<ME#
M>PF\@ \Z'>"4X]>AH V**9)(L43R-G:BEC@>E<[IOBW[?H%YK#Z9<QP0*9(U
M0B0S)C(QM/7U!Z4 =+161?\ B&UT_0X=4E20I,(RD:C+'?C^6<GZ&IM6U7^S
M$A6.VDNKF=]D4$; %L DG)X  !- &C17/?\ "76C2P&&"62V9(WGN 0%@WG"
M!@><D@YQTQS5C3_$,5_J#6PMY(XVW_9YV(VS[#A\ <C!]>O:@#9HK#?Q-;QZ
MI);/!(MLCF$W9(V>:%W;,=>G?IVJO'XOA>U>1K&=)F"-;0%EW7"N<(5YP,GU
MQCO0!TE%4],U!-2LQ.J-&P8I)&Q!*.IP5..*N4 %%%% !1110 4444 %%%%
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MM% $7V>/T/\ WT:/L\?H?^^C4M% 'G_BA0FN2!>FU>_M6-6UXJ_Y#TO^XO\
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M>+^Z?^^C0!+147V>+^Z?^^C1]GB_NG_OHT 2T5%]GB_NG_OHT?9XO[I_[Z-
M$M%1?9XO[I_[Z-'V>+^Z?^^C0!POBK_D/2_[B_RK%K9\4*$UR4+TVKW]JQJ
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M$MN]K%9?9SO+>8S9!SZ8XJM-H6HWZ3W=Y):1ZCF(P>3N,8\MBR[LC/)8@^U
M%J+7S'H5[?7<($]BSQSQQ$D%U[*3V/&,^M4?^$CU(2#3#:6HUEI0BIYC>3M*
M;]Q.,] 1TZTO]C7S6<NF7'EM_:(FFN[B,-B*0XV[<]AQUY.*9_PCNJF7^U6G
ML_[964,H^;R=@0IM/?H2WUH 0>,)9E2XM[5/LL$<;WQ=CNC+L5PHZ':02<]N
ME=:.1FN/'@^X@1+:WNHC:W$<:7Y<'>Q1BV4[?-D@YZ"NP' Q0!Y]XON+JVU.
M2.;7;O2X)7CDAG^SB2- JL&53V))'6K'@;43YUS:)J=QK?FR^:]ZT'EK&NT
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MFL[A)C?.R@-+(^,,,=#UQC@8I@\*/Y'FG5)CJ@E$JWWEKN&%V ;>F-O'UYH
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MB+^\?^^30!+147VB+^\?^^31]HB_O'_ODT 2T5%]HB_O'_ODT?:(O[Q_[Y-
M$M%1?:(O[Q_[Y-'VB+^\?^^30!+147VB+^\?^^31]HB_O'_ODT 2T5%]HB_O
M'_ODT?:(O[Q_[Y- $M%1?:(O[Q_[Y-'VB+^\?^^30!+147VB+^\?^^31]HB_
MO'_ODT 2T5%]HB_O'_ODT?:(O[Q_[Y- $M%1?:(O[Q_[Y-'VB+^\?^^30!+1
M47VB+^\?^^31]HB_O'_ODT <+XJ_Y#TO^XO\JQ:V?%#!]<D*]-J]O:L:@ K>
M\(_\AH_]<F_F*P:W/";JFLDL>/*;M]* -_Q,-L5O-@IY98_:&YCAZ<NO\0/2
MN=_U7_3#R?F_>_-]FS_%)_?5NP[5T'B.13';S+E/*+$W#<QPYQRZ_P 0/2N?
M_P!5_P!,/(^;][\WV;=_%)_?5NP[4 '^J_Z8>3\W[WYOLV[^*3^^K?PCM1_J
MO^F'D?-^^^;[-N_BD_OAOX1VH_U7_3#R/F_>_/\ 9MW\4G]\-V':C_5?],/(
M^;][\_V;=_%)_?#=AVH [Y.8U.0>!R.].J%+B/8OS9X'(4TOVB+^\?\ ODT
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MKG\<9K5J*UMH;.UBMK= D,2A$4=@*EH XSQQ>2SR:=I>E7%@VL"Y6=+:ZF*
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MW_/&3]/\:/-;_GC)^G^- $M%1>:W_/&3]/\ &CS6_P">,GZ?XT 2T5%YK?\
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MV* -VBBB@ HHHH **** (KG_ (]9O]QOY5Y77JES_P >LW^XW\J\KH ****
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M2?\ ??\ ]:C=-_SR3_OO_P"M4M% $6Z;_GDG_??_ -:C=-_SR3_OO_ZU2T4
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MT(7WQB5 VUO44 )8:O9WTS6]O]HWHBL=]O(JX(XPY7:WX$UH4@    P!TI:
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M1$VKLYY(8#( SGOVJ[;7=AHWC+Q<_BB6&!KL1_8GNF&)H-A!2//4[LY4<\T
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MG\* /1/[9TO[9-:?VE9_:8%WRP^>N^-?5ESD#W-9Y\:^%!C/B;1AGIF_B_\
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M!G.!FC SG SZTM% ";5SG:,_2@@'J :6B@ HHHH ****  @'J*3 SG S2T4
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:\E5)R0/3.!G'7 ]*LT4 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139736512411904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">DEF 14A<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Catalyst Pharmaceuticals, Inc.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001369568<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.2</span><table class="report" border="0" cellspacing="2" id="idm139736507848496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTableTextBlock', window );">Pay vs Performance [Table Text Block]</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table sets forth information concerning the compensation of our PEO and <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO</div> NEOs for the fiscal years ended December&#160;31, 2022, 2021 and 2020, and our financial performance for each such fiscal year: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:30%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Value of Initial $100 Fixed<br/>Investment Based on (3)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Year</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Summary<br/>Compensation<br/>Table Total<br/>for PEO ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Compensation<br/>Actually Paid<br/>to PEO ($)<br/>(1)(2)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/>Summary<br/>Compensation<br/>Table&#160;Total&#160;for<br/><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO&#160;NEOs</div><br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Average<br/>Compensation<br/>Actually Paid<br/>to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO</div><br/>NEOs ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total<br/>Shareholder<br/>Return ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Peer Group<br/>Total<br/>Shareholder<br/>Return ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net<br/>Income (in<br/>thousands)<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Net&#160;Product<br/>Revenue (in<br/>thousands)<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,923,782</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,549,684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,674,788</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,393,846</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">496</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">69</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">83,079</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">213,938</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,089,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,369,277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,361,793</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,328,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">181</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">94</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">39,482</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">137,997</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,762,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,544,344</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,245,629</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,099,682</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">89</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">113</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">74,983</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">118,790</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(1)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Amounts represent &#8220;compensation actually paid&#8221; (&#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">CAP</div></div>&#8221;) to our PEO and the average compensation actually paid to our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO</div> NEOs for the relevant fiscal year, as determined under SEC rules (and described below). </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(2)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">Fair value or change in fair value, as applicable, of stock options in the &#8220;Compensation <div style="display:inline;">Actually </div>Paid&#8221; columns was estimated using a Black-Scholes option pricing model for the purposes of this disclosure in accordance with SEC rules and do not reflect compensation actually earned, realized or received during each applicable year. The calculation of CAP for purposes of this table includes <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">point-in-time</div></div> fair values of equity awards and those values will fluctuate based on our stock price and various accounting valuation assumptions. See the Summary Compensation Table for certain other compensation of our PEO and our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO</div> NEOs for each applicable fiscal year. </div></td></tr></table>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top;text-align:left;">(3)</td>
<td style="vertical-align:top;text-align:left;"><div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-align: left; line-height: normal;">For the relevant fiscal year, represents our cumulative &#8220;total shareholder return&#8221; (&#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">TSR</div></div>&#8221;) or the cumulative TSR of the Nasdaq Biotechnology Index, in each case assuming an initial investment of $100 as described under the Narrative Disclosure to Pay Versus Performance heading below. We have never declared or paid a dividend on our common stock and do not anticipate doing so in the foreseeable future. </div></td></tr></table><div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&#160;</div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"> </div><div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In the table immediately above, the columns &#8220;Compensation Actually Paid to PEO&#8221; and &#8220;Average Compensation Actually Paid to <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO</div> NEOs&#8221; reflect the Total Compensation reported in the 2022 Summary Compensation Table (&#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SCT</div></div>&#8221;), as adjusted based on the following: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:39%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">SCT&#160;Total&#160;($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Minus SCT<br/>Equity<br/>Awards ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Plus&#160;Value&#160;of<br/>New&#160;Unvested<br/>Awards as of<br/>12/31 ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Plus&#160;Annual<br/>Change in<br/>Value&#160;of&#160;Prior<br/>Year Awards<br/>that Remain<br/>Unvested ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Plus&#160;Value&#160;of<br/>Awards<br/>Vested and<br/>Granted<br/>During Year<br/>($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Plus&#160;Change<br/>in Value of<br/>Prior Year<br/>Awards that<br/>Vest During<br/>Year ($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Total&#160;CAP&#160;($)</div></div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">PEO</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">6,923,782</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,727,859</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,659,348</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,460,212</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,234,201</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">17,549,684</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,089,432</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,041,324</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">978,593</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,424,326</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,918,250</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">5,369,277</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,762,272</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">834,093</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">808,368</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(264,158</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">71,955</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,544,344</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="font-size:1pt">
<td colspan="9" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td>
<td colspan="4" style="height:6pt"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td colspan="8" style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">Average <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-PEO</div> NEOs</div></div></td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="font-weight:bold;display:inline;">&#160;</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2022</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,674,788</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,939,664</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,316,864</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,394,265</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,947,593</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">7,393,846</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2021</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,361,793</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">767,761</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">804,173</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">456,388</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">473,572</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">2,328,165</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">2020</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,245,629</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">652,457</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">574,265</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">(70,986</td>
<td style="white-space:nowrap;vertical-align:bottom">)&#160;</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">&#8212;&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">3,231</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">1,099,682</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following tables illustrate the valuation assumptions as of the vesting date for awards that vested in each of 2022, 2021 and 2020. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:55%"></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td>
<td style="vertical-align:bottom;width:2%"></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="5" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">For Stock Options Vesting in</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Risk-free interest rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">1.30%&#160;-&#160;4.00%</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.35%&#160;-&#160;1.17%</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">0.24%&#160;-&#160;1.53%</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected term</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">4.5 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">4.5 years</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">4.5 years</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected volatility</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">68.4% - 69.5%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">68.6% - 72.8%</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">80.5% - 83.7%</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected dividend yield</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">&#8212;&#160;&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Expected forfeiture rate</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">&#8212;&#160;&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap;text-align:center;">&#8212;&#160;&#160;</td></tr></table><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td style="width:73%"></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td>
<td style="vertical-align:bottom;width:5%"></td>
<td></td>
<td></td>
<td></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="10" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">Weighted&#160;Average&#160;Fair&#160;Value&#160;of&#160;Full&#160;Value<br/>Awards&#160;Vesting in</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2022</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2021</div></div></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td colspan="2" style="vertical-align:bottom;text-align:center;"><div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">2020</div></div></td>
<td style="vertical-align:bottom">&#160;</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff">
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">For Restricted Stock Units</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.65</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="white-space:nowrap;vertical-align:bottom">$</td>
<td style="white-space:nowrap;vertical-align:bottom;text-align:right;">4.64</td>
<td style="white-space:nowrap;vertical-align:bottom">&#160;</td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CoSelectedMeasureName', window );">Company Selected Measure Name</a></td>
<td class="text">Net Product Revenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NamedExecutiveOfficersFnTextBlock', window );">Named Executive Officers, Footnote [Text Block]</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Company&#8217;s principal executive officer (&#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">PEO</div></div>&#8221;) and our <div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">non-PEO</div> named executive officers (&#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">NEO</div></div>s&#8221;) were as follows for the fiscal years ended December&#160;31, 2022, 2021 and 2020: </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr style="font-size: 0px;">
<td></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:15%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:79%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align: bottom; padding-bottom: 0.5pt;"><div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Year</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">PEO</div></td>
<td style="vertical-align: bottom; padding-bottom: 0.5pt;">&#160;&#160;</td>
<td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"><div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &quot;Times New Roman&quot;; line-height: normal;"><div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;">Non-PEO</div> NEOs</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">2022</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Patrick J. McEnany</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Alicia Grande, Steven Miller, Gary Ingenito, Jeffrey Del Carmen</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">2021</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Patrick J. McEnany</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Alicia Grande, Steven Miller, Gary Ingenito, Preethi Sundaram</div></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">2020</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Patrick J. McEnany</div></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &quot;Times New Roman&quot;; line-height: normal;">Alicia Grande, Steven Miller, Gary Ingenito, Jeffrey Del Carmen</div></td></tr></table><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeerGroupIssuersFnTextBlock', window );">Peer Group Issuers, Footnote [Text Block]</a></td>
<td class="text">For the relevant fiscal year, represents our cumulative &#8220;total shareholder return&#8221; (&#8220;<div style="letter-spacing: 0px; top: 0px;;display:inline;"><div style="font-weight:bold;display:inline;">TSR</div></div>&#8221;) or the cumulative TSR of the Nasdaq Biotechnology Index, in each case assuming an initial investment of $100 as described under the Narrative Disclosure to Pay Versus Performance heading below. We have never declared or paid a dividend on our common stock and do not anticipate doing so in the foreseeable future.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoTotalCompAmt', window );">PEO Total Compensation Amount</a></td>
<td class="nump">$ 6,923,782<span></span>
</td>
<td class="nump">$ 2,089,432<span></span>
</td>
<td class="nump">$ 1,762,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoActuallyPaidCompAmt', window );">PEO Actually Paid Compensation Amount</a></td>
<td class="nump">17,549,684<span></span>
</td>
<td class="nump">5,369,277<span></span>
</td>
<td class="nump">1,544,344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgTotalCompAmt', window );">Non-PEO NEO Average Total Compensation Amount</a></td>
<td class="nump">2,674,788<span></span>
</td>
<td class="nump">1,361,793<span></span>
</td>
<td class="nump">1,245,629<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt', window );">Non-PEO NEO Average Compensation Actually Paid Amount</a></td>
<td class="nump">$ 7,393,846<span></span>
</td>
<td class="nump">2,328,165<span></span>
</td>
<td class="nump">1,099,682<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock', window );">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TSR amounts reported in the graph assume an initial fixed investment of $100 on January&#160;1, 2020 and, with respect to our cumulative TSR, based on the opening trading price on such date. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<img alt="LOGO" src="g500830g0707050510473.jpg"/><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsNetIncomeTextBlock', window );">Compensation Actually Paid vs. Net Income [Text Block]</a></td>
<td class="text">
<img alt="LOGO" src="g500830g0707050510771.jpg"/><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock', window );">Compensation Actually Paid vs. Company Selected Measure [Text Block]</a></td>
<td class="text">
<img alt="LOGO" src="g500830g0707050511017.jpg"/><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnVsPeerGroupTextBlock', window );">Total Shareholder Return Vs Peer Group [Text Block]</a></td>
<td class="text"><div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">TSR amounts reported in the graph assume an initial fixed investment of $100 on January&#160;1, 2020 and, with respect to our cumulative TSR, based on the opening trading price on such date. </div><div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</div>
<img alt="LOGO" src="g500830g0707050510473.jpg"/><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TotalShareholderRtnAmt', window );">Total Shareholder Return Amount</a></td>
<td class="nump">$ 496<span></span>
</td>
<td class="nump">181<span></span>
</td>
<td class="nump">89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeerGroupTotalShareholderRtnAmt', window );">Peer Group Total Shareholder Return Amount</a></td>
<td class="nump">69<span></span>
</td>
<td class="nump">94<span></span>
</td>
<td class="nump">113<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net Income (Loss)</a></td>
<td class="nump">$ 83,079,000<span></span>
</td>
<td class="nump">$ 39,482,000<span></span>
</td>
<td class="nump">$ 74,983,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_CoSelectedMeasureAmt', window );">Company Selected Measure Amount</a></td>
<td class="nump">213,938,000<span></span>
</td>
<td class="nump">137,997,000<span></span>
</td>
<td class="nump">118,790,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PeoName', window );">PEO Name</a></td>
<td class="text">Patrick J. McEnany<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureAxis=1', window );">Measure [Axis]: 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureName', window );">Measure Name</a></td>
<td class="text">Net Product Revenue<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureAxis=2', window );">Measure [Axis]: 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureName', window );">Measure Name</a></td>
<td class="text">Net Income<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureAxis=3', window );">Measure [Axis]: 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureName', window );">Measure Name</a></td>
<td class="text">Completion of a transformational acquisition<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureAxis=4', window );">Measure [Axis]: 4</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_MeasureName', window );">Measure Name</a></td>
<td class="text">Quality and Compliance<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO [Member] | SCT Equity Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="num">$ (5,727,859)<span></span>
</td>
<td class="num">$ (1,041,324)<span></span>
</td>
<td class="num">$ (834,093)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO [Member] | Value of New Unvested Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">7,659,348<span></span>
</td>
<td class="nump">978,593<span></span>
</td>
<td class="nump">808,368<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO [Member] | Annual Change in Value of Prior Year Awards that Remain Unvested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">3,460,212<span></span>
</td>
<td class="nump">1,424,326<span></span>
</td>
<td class="num">(264,158)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember', window );">PEO [Member] | Change in Value of Prior Year Awards that Vest During Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">5,234,201<span></span>
</td>
<td class="nump">1,918,250<span></span>
</td>
<td class="nump">71,955<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | SCT Equity Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="num">(1,939,664)<span></span>
</td>
<td class="num">(767,761)<span></span>
</td>
<td class="num">(652,457)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Value of New Unvested Awards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">2,316,864<span></span>
</td>
<td class="nump">804,173<span></span>
</td>
<td class="nump">574,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Annual Change in Value of Prior Year Awards that Remain Unvested [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">2,394,265<span></span>
</td>
<td class="nump">456,388<span></span>
</td>
<td class="num">(70,986)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember', window );">Non-PEO NEO [Member] | Change in Value of Prior Year Awards that Vest During Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure [Table]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_AdjToCompAmt', window );">Adjustment to Compensation Amount</a></td>
<td class="nump">$ 1,947,593<span></span>
</td>
<td class="nump">$ 473,572<span></span>
</td>
<td class="nump">$ 3,231<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CoSelectedMeasureAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph vi<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CoSelectedMeasureAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CoSelectedMeasureName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph vi<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CoSelectedMeasureName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsNetIncomeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsNetIncomeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph vi<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NamedExecutiveOfficersFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NamedExecutiveOfficersFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgCompActuallyPaidAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgCompActuallyPaidAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonPeoNeoAvgTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonPeoNeoAvgTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeerGroupIssuersFnTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeerGroupIssuersFnTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeerGroupTotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeerGroupTotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoActuallyPaidCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoActuallyPaidCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PeoTotalCompAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PeoTotalCompAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnAmt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 2<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnAmt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TotalShareholderRtnVsPeerGroupTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 5<br> -Subparagraph iv<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TotalShareholderRtnVsPeerGroupTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureAxis=1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureAxis=1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureAxis=2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureAxis=2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureAxis=3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureAxis=3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_MeasureAxis=4">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_MeasureAxis=4</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ExecutiveCategoryAxis=ecd_PeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ExecutiveCategoryAxis=ecd_PeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=cprx_SCTEquityAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=cprx_SCTEquityAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=cprx_ValueOfNewUnvestedAwardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=cprx_ValueOfNewUnvestedAwardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=cprx_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=cprx_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_AdjToCompAxis=cprx_ChangeInValueOfPriorYearAwardsThatVestDuringYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_AdjToCompAxis=cprx_ChangeInValueOfPriorYearAwardsThatVestDuringYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_ExecutiveCategoryAxis=ecd_NonPeoNeoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>d500830ddef14a_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:cprx="http://www.catalystpharma.com/20221231"
  xmlns:dei="http://xbrl.sec.gov/dei/2022q4"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2022q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="cprx-20221231.xsd" xlink:type="simple"/>
    <context id="P01_01_2022To12_31_2022">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:ChangeInValueOfPriorYearAwardsThatVestDuringYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NonPeoNeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:ValueOfNewUnvestedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_NonPeoNeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:SCTEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:ChangeInValueOfPriorYearAwardsThatVestDuringYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:ValueOfNewUnvestedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2020To12_31_2020_PeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:SCTEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:ChangeInValueOfPriorYearAwardsThatVestDuringYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NonPeoNeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:ValueOfNewUnvestedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_NonPeoNeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:SCTEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:ChangeInValueOfPriorYearAwardsThatVestDuringYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:ValueOfNewUnvestedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2021To12_31_2021_PeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:SCTEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:ChangeInValueOfPriorYearAwardsThatVestDuringYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NonPeoNeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:ValueOfNewUnvestedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_NonPeoNeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:SCTEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:NonPeoNeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:ChangeInValueOfPriorYearAwardsThatVestDuringYearMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:ValueOfNewUnvestedAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_PeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ecd:AdjToCompAxis">cprx:SCTEquityAwardsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ecd:ExecutiveCategoryAxis">ecd:PeoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_4TypedMemberecdMeasureAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:MeasureAxis">
                    <ecd:MeasureAxis.domain>4</ecd:MeasureAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_3TypedMemberecdMeasureAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:MeasureAxis">
                    <ecd:MeasureAxis.domain>3</ecd:MeasureAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_2TypedMemberecdMeasureAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:MeasureAxis">
                    <ecd:MeasureAxis.domain>2</ecd:MeasureAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="P01_01_2022To12_31_2022_1TypedMemberecdMeasureAxis">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001369568</identifier>
            <segment>
                <xbrldi:typedMember dimension="ecd:MeasureAxis">
                    <ecd:MeasureAxis.domain>1</ecd:MeasureAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <dei:DocumentType contextRef="P01_01_2022To12_31_2022" id="hidden83060743">DEF 14A</dei:DocumentType>
    <dei:AmendmentFlag contextRef="P01_01_2022To12_31_2022">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="P01_01_2022To12_31_2022">0001369568</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName contextRef="P01_01_2022To12_31_2022">Catalyst Pharmaceuticals, Inc.</dei:EntityRegistrantName>
    <ecd:NamedExecutiveOfficersFnTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The Company&#x2019;s principal executive officer (&#x201c;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PEO&lt;/div&gt;&lt;/div&gt;&#x201d;) and our &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-PEO&lt;/div&gt; named executive officers (&#x201c;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;NEO&lt;/div&gt;&lt;/div&gt;s&#x201d;) were as follows for the fiscal years ended December&#160;31, 2022, 2021 and 2020: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&lt;/td&gt;
&lt;td style="width:15%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:1%"&gt;&lt;/td&gt;
&lt;td style="width:79%"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; border-bottom: 1pt solid rgb(0, 0, 0); display: table-cell; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Year&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;PEO&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="border-bottom:1.00pt solid #000000;vertical-align:bottom"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 1pt; font-size: 8pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-PEO&lt;/div&gt; NEOs&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;2022&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Patrick J. McEnany&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Alicia Grande, Steven Miller, Gary Ingenito, Jeffrey Del Carmen&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;2021&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Patrick J. McEnany&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Alicia Grande, Steven Miller, Gary Ingenito, Preethi Sundaram&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:bottom"&gt;2020&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Patrick J. McEnany&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Alicia Grande, Steven Miller, Gary Ingenito, Jeffrey Del Carmen&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ecd:NamedExecutiveOfficersFnTextBlock>
    <ecd:PeoName contextRef="P01_01_2022To12_31_2022">Patrick J. McEnany</ecd:PeoName>
    <ecd:PvpTableTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following table sets forth information concerning the compensation of our PEO and &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-PEO&lt;/div&gt; NEOs for the fiscal years ended December&#160;31, 2022, 2021 and 2020, and our financial performance for each such fiscal year: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:30%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="6" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Value of Initial $100 Fixed&lt;br/&gt;Investment Based on (3)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; white-space: nowrap; padding-bottom: 0.5pt;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Year&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Summary&lt;br/&gt;Compensation&lt;br/&gt;Table Total&lt;br/&gt;for PEO ($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Compensation&lt;br/&gt;Actually Paid&lt;br/&gt;to PEO ($)&lt;br/&gt;(1)(2)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;br/&gt;Summary&lt;br/&gt;Compensation&lt;br/&gt;Table&#160;Total&#160;for&lt;br/&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-PEO&#160;NEOs&lt;/div&gt;&lt;br/&gt;($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average&lt;br/&gt;Compensation&lt;br/&gt;Actually Paid&lt;br/&gt;to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-PEO&lt;/div&gt;&lt;br/&gt;NEOs ($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&lt;br/&gt;Shareholder&lt;br/&gt;Return ($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Peer Group&lt;br/&gt;Total&lt;br/&gt;Shareholder&lt;br/&gt;Return ($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&lt;br/&gt;Income (in&lt;br/&gt;thousands)&lt;br/&gt;($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Net&#160;Product&lt;br/&gt;Revenue (in&lt;br/&gt;thousands)&lt;br/&gt;($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,923,782&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,549,684&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,674,788&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,393,846&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;496&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;69&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;83,079&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;213,938&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,089,432&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,369,277&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,361,793&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,328,165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;181&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;94&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;39,482&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;137,997&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,762,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,544,344&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,245,629&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,099,682&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;89&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;113&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;74,983&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;118,790&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:11%"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(1)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Amounts represent &#x201c;compensation actually paid&#x201d; (&#x201c;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;CAP&lt;/div&gt;&lt;/div&gt;&#x201d;) to our PEO and the average compensation actually paid to our &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-PEO&lt;/div&gt; NEOs for the relevant fiscal year, as determined under SEC rules (and described below). &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(2)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;Fair value or change in fair value, as applicable, of stock options in the &#x201c;Compensation &lt;div style="display:inline;"&gt;Actually &lt;/div&gt;Paid&#x201d; columns was estimated using a Black-Scholes option pricing model for the purposes of this disclosure in accordance with SEC rules and do not reflect compensation actually earned, realized or received during each applicable year. The calculation of CAP for purposes of this table includes &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;point-in-time&lt;/div&gt;&lt;/div&gt; fair values of equity awards and those values will fluctuate based on our stock price and various accounting valuation assumptions. See the Summary Compensation Table for certain other compensation of our PEO and our &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-PEO&lt;/div&gt; NEOs for each applicable fiscal year. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%"&gt;
&lt;tr style="page-break-inside:avoid"&gt;
&lt;td style="width:4%;vertical-align:top;text-align:left;"&gt;(3)&lt;/td&gt;
&lt;td style="vertical-align:top;text-align:left;"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; text-align: left; line-height: normal;"&gt;For the relevant fiscal year, represents our cumulative &#x201c;total shareholder return&#x201d; (&#x201c;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;TSR&lt;/div&gt;&lt;/div&gt;&#x201d;) or the cumulative TSR of the Nasdaq Biotechnology Index, in each case assuming an initial investment of $100 as described under the Narrative Disclosure to Pay Versus Performance heading below. We have never declared or paid a dividend on our common stock and do not anticipate doing so in the foreseeable future. &lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:0pt;margin-bottom:0pt ; font-size:8pt"&gt;&#160;&lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:center"&gt; &lt;/div&gt;&lt;div style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;In the table immediately above, the columns &#x201c;Compensation Actually Paid to PEO&#x201d; and &#x201c;Average Compensation Actually Paid to &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;non-PEO&lt;/div&gt; NEOs&#x201d; reflect the Total Compensation reported in the 2022 Summary Compensation Table (&#x201c;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SCT&lt;/div&gt;&lt;/div&gt;&#x201d;), as adjusted based on the following: &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:39%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;SCT&#160;Total&#160;($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Minus SCT&lt;br/&gt;Equity&lt;br/&gt;Awards ($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Plus&#160;Value&#160;of&lt;br/&gt;New&#160;Unvested&lt;br/&gt;Awards as of&lt;br/&gt;12/31 ($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Plus&#160;Annual&lt;br/&gt;Change in&lt;br/&gt;Value&#160;of&#160;Prior&lt;br/&gt;Year Awards&lt;br/&gt;that Remain&lt;br/&gt;Unvested ($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Plus&#160;Value&#160;of&lt;br/&gt;Awards&lt;br/&gt;Vested and&lt;br/&gt;Granted&lt;br/&gt;During Year&lt;br/&gt;($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Plus&#160;Change&lt;br/&gt;in Value of&lt;br/&gt;Prior Year&lt;br/&gt;Awards that&lt;br/&gt;Vest During&lt;br/&gt;Year ($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="border-bottom:1.00pt solid #000000;vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Total&#160;CAP&#160;($)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align: bottom; padding-bottom: 0.5pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;PEO&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;6,923,782&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,727,859&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,659,348&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,460,212&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,234,201&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;17,549,684&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,089,432&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,041,324&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;978,593&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,424,326&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,918,250&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;5,369,277&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,762,272&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;834,093&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;808,368&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(264,158&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;71,955&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,544,344&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="font-size:1pt"&gt;
&lt;td colspan="9" style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;
&lt;td colspan="4" style="height:6pt"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td colspan="8" style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Average &lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;Non-PEO&lt;/div&gt; NEOs&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 0em; text-indent: 0em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;&#160;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2022&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,674,788&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,939,664&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,316,864&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,394,265&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,947,593&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;7,393,846&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2021&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,361,793&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;767,761&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;804,173&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;456,388&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;473,572&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;2,328,165&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;2020&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,245,629&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;652,457&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;574,265&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;(70,986&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;)&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;3,231&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;1,099,682&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;The following tables illustrate the valuation assumptions as of the vesting date for awards that vested in each of 2022, 2021 and 2020. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:55%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:2%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="5" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;For Stock Options Vesting in&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Risk-free interest rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;1.30%&#160;-&#160;4.00%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.35%&#160;-&#160;1.17%&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&lt;div style="white-space: nowrap; letter-spacing: 0px; top: 0px;;display:inline;"&gt;0.24%&#160;-&#160;1.53%&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected term&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;4.5 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;4.5 years&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;4.5 years&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected volatility&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;68.4% - 69.5%&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;68.6% - 72.8%&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;80.5% - 83.7%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected dividend yield&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;Expected forfeiture rate&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom;white-space:nowrap;text-align:center;"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;table cellpadding="0" cellspacing="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt;width:84%;border:0;margin:0 auto"&gt;
&lt;tr style="font-size: 0px;"&gt;
&lt;td style="width:73%"&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom;width:5%"&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;
&lt;td&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="10" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;Weighted&#160;Average&#160;Fair&#160;Value&#160;of&#160;Full&#160;Value&lt;br/&gt;Awards&#160;Vesting in&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt"&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2022&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2021&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td colspan="2" style="vertical-align:bottom;text-align:center;"&gt;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;2020&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt;background-color:#cceeff"&gt;
&lt;td style="vertical-align:top"&gt;&lt;div style="margin-top: 0pt; margin-bottom: 0pt; margin-left: 1em; text-indent: -1em; font-size: 10pt; font-family: &amp;quot;Times New Roman&amp;quot;; line-height: normal;"&gt;For Restricted Stock Units&lt;/div&gt;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.65&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;
&lt;td style="vertical-align:bottom"&gt;&#160;&#160;&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;$&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom;text-align:right;"&gt;4.64&lt;/td&gt;
&lt;td style="white-space:nowrap;vertical-align:bottom"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</ecd:PvpTableTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD">6923782</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD">17549684</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD">2674788</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD">7393846</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD">496</ecd:TotalShareholderRtnAmt>
    <ecd:PeerGroupTotalShareholderRtnAmt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD">69</ecd:PeerGroupTotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">83079000</us-gaap:NetIncomeLoss>
    <ecd:CoSelectedMeasureAmt
      contextRef="P01_01_2022To12_31_2022"
      decimals="-3"
      unitRef="Unit_USD">213938000</ecd:CoSelectedMeasureAmt>
    <ecd:PeoTotalCompAmt
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">2089432</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">5369277</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">1361793</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">2328165</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">181</ecd:TotalShareholderRtnAmt>
    <ecd:PeerGroupTotalShareholderRtnAmt
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">94</ecd:PeerGroupTotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">39482000</us-gaap:NetIncomeLoss>
    <ecd:CoSelectedMeasureAmt
      contextRef="P01_01_2021To12_31_2021"
      decimals="-3"
      unitRef="Unit_USD">137997000</ecd:CoSelectedMeasureAmt>
    <ecd:PeoTotalCompAmt
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1762272</ecd:PeoTotalCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1544344</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1245629</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1099682</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:TotalShareholderRtnAmt
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">89</ecd:TotalShareholderRtnAmt>
    <ecd:PeerGroupTotalShareholderRtnAmt
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">113</ecd:PeerGroupTotalShareholderRtnAmt>
    <us-gaap:NetIncomeLoss
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">74983000</us-gaap:NetIncomeLoss>
    <ecd:CoSelectedMeasureAmt
      contextRef="P01_01_2020To12_31_2020"
      decimals="-3"
      unitRef="Unit_USD">118790000</ecd:CoSelectedMeasureAmt>
    <ecd:PeerGroupIssuersFnTextBlock contextRef="P01_01_2022To12_31_2022">For the relevant fiscal year, represents our cumulative &#x201c;total shareholder return&#x201d; (&#x201c;&lt;div style="letter-spacing: 0px; top: 0px;;display:inline;"&gt;&lt;div style="font-weight:bold;display:inline;"&gt;TSR&lt;/div&gt;&lt;/div&gt;&#x201d;) or the cumulative TSR of the Nasdaq Biotechnology Index, in each case assuming an initial investment of $100 as described under the Narrative Disclosure to Pay Versus Performance heading below. We have never declared or paid a dividend on our common stock and do not anticipate doing so in the foreseeable future.</ecd:PeerGroupIssuersFnTextBlock>
    <ecd:PeoTotalCompAmt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD">6923782</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2022To12_31_2022_PeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis"
      decimals="0"
      unitRef="Unit_USD">-5727859</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2022To12_31_2022_PeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis"
      decimals="0"
      unitRef="Unit_USD">7659348</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2022To12_31_2022_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis"
      decimals="0"
      unitRef="Unit_USD">3460212</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2022To12_31_2022_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis"
      decimals="0"
      unitRef="Unit_USD">5234201</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD">17549684</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">2089432</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2021To12_31_2021_PeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis"
      decimals="0"
      unitRef="Unit_USD">-1041324</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2021To12_31_2021_PeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis"
      decimals="0"
      unitRef="Unit_USD">978593</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2021To12_31_2021_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis"
      decimals="0"
      unitRef="Unit_USD">1424326</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2021To12_31_2021_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis"
      decimals="0"
      unitRef="Unit_USD">1918250</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">5369277</ecd:PeoActuallyPaidCompAmt>
    <ecd:PeoTotalCompAmt
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1762272</ecd:PeoTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2020To12_31_2020_PeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis"
      decimals="0"
      unitRef="Unit_USD">-834093</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2020To12_31_2020_PeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis"
      decimals="0"
      unitRef="Unit_USD">808368</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2020To12_31_2020_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis"
      decimals="0"
      unitRef="Unit_USD">-264158</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2020To12_31_2020_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_PeoMemberecdExecutiveCategoryAxis"
      decimals="0"
      unitRef="Unit_USD">71955</ecd:AdjToCompAmt>
    <ecd:PeoActuallyPaidCompAmt
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1544344</ecd:PeoActuallyPaidCompAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD">2674788</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2022To12_31_2022_NonPeoNeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis"
      decimals="0"
      unitRef="Unit_USD">-1939664</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2022To12_31_2022_NonPeoNeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis"
      decimals="0"
      unitRef="Unit_USD">2316864</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2022To12_31_2022_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis"
      decimals="0"
      unitRef="Unit_USD">2394265</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2022To12_31_2022_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis"
      decimals="0"
      unitRef="Unit_USD">1947593</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="P01_01_2022To12_31_2022"
      decimals="0"
      unitRef="Unit_USD">7393846</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">1361793</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2021To12_31_2021_NonPeoNeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis"
      decimals="0"
      unitRef="Unit_USD">-767761</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2021To12_31_2021_NonPeoNeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis"
      decimals="0"
      unitRef="Unit_USD">804173</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2021To12_31_2021_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis"
      decimals="0"
      unitRef="Unit_USD">456388</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2021To12_31_2021_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis"
      decimals="0"
      unitRef="Unit_USD">473572</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="P01_01_2021To12_31_2021"
      decimals="0"
      unitRef="Unit_USD">2328165</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:NonPeoNeoAvgTotalCompAmt
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1245629</ecd:NonPeoNeoAvgTotalCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2020To12_31_2020_NonPeoNeoMemberecdExecutiveCategoryAxis_SCTEquityAwardsMemberecdAdjToCompAxis"
      decimals="0"
      unitRef="Unit_USD">-652457</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2020To12_31_2020_NonPeoNeoMemberecdExecutiveCategoryAxis_ValueOfNewUnvestedAwardsMemberecdAdjToCompAxis"
      decimals="0"
      unitRef="Unit_USD">574265</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2020To12_31_2020_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis"
      decimals="0"
      unitRef="Unit_USD">-70986</ecd:AdjToCompAmt>
    <ecd:AdjToCompAmt
      contextRef="P01_01_2020To12_31_2020_ChangeInValueOfPriorYearAwardsThatVestDuringYearMemberecdAdjToCompAxis_NonPeoNeoMemberecdExecutiveCategoryAxis"
      decimals="0"
      unitRef="Unit_USD">3231</ecd:AdjToCompAmt>
    <ecd:NonPeoNeoAvgCompActuallyPaidAmt
      contextRef="P01_01_2020To12_31_2020"
      decimals="0"
      unitRef="Unit_USD">1099682</ecd:NonPeoNeoAvgCompActuallyPaidAmt>
    <ecd:CoSelectedMeasureName contextRef="P01_01_2022To12_31_2022">Net Product Revenue</ecd:CoSelectedMeasureName>
    <ecd:MeasureName contextRef="P01_01_2022To12_31_2022_1TypedMemberecdMeasureAxis">Net Product Revenue</ecd:MeasureName>
    <ecd:MeasureName contextRef="P01_01_2022To12_31_2022_2TypedMemberecdMeasureAxis">Net Income</ecd:MeasureName>
    <ecd:MeasureName contextRef="P01_01_2022To12_31_2022_3TypedMemberecdMeasureAxis">Completion of a transformational acquisition</ecd:MeasureName>
    <ecd:MeasureName contextRef="P01_01_2022To12_31_2022_4TypedMemberecdMeasureAxis">Quality and Compliance</ecd:MeasureName>
    <ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;TSR amounts reported in the graph assume an initial fixed investment of $100 on January&#160;1, 2020 and, with respect to our cumulative TSR, based on the opening trading price on such date. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;img alt="LOGO" src="g500830g0707050510473.jpg"/&gt;</ecd:CompActuallyPaidVsTotalShareholderRtnTextBlock>
    <ecd:TotalShareholderRtnVsPeerGroupTextBlock contextRef="P01_01_2022To12_31_2022">&lt;div style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"&gt;TSR amounts reported in the graph assume an initial fixed investment of $100 on January&#160;1, 2020 and, with respect to our cumulative TSR, based on the opening trading price on such date. &lt;/div&gt;&lt;div style="font-size:12pt;margin-top:0pt;margin-bottom:0pt"&gt;&#160;&lt;/div&gt;
&lt;img alt="LOGO" src="g500830g0707050510473.jpg"/&gt;</ecd:TotalShareholderRtnVsPeerGroupTextBlock>
    <ecd:CompActuallyPaidVsNetIncomeTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;img alt="LOGO" src="g500830g0707050510771.jpg"/&gt;</ecd:CompActuallyPaidVsNetIncomeTextBlock>
    <ecd:CompActuallyPaidVsCoSelectedMeasureTextBlock contextRef="P01_01_2022To12_31_2022">
&lt;img alt="LOGO" src="g500830g0707050511017.jpg"/&gt;</ecd:CompActuallyPaidVsCoSelectedMeasureTextBlock>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>31</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>7</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>1</UnitCount>
  <MyReports>
    <Report instance="d500830ddef14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>995100 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/dei/role/document/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="d500830ddef14a.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="DEF 14A" original="d500830ddef14a.htm">d500830ddef14a.htm</File>
    <File>cprx-20221231.xsd</File>
    <File>cprx-20221231_def.xml</File>
    <File>cprx-20221231_lab.xml</File>
    <File>cprx-20221231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>g500830g0707050509901.jpg</File>
    <File>g500830g0707050510098.jpg</File>
    <File>g500830g0707050510473.jpg</File>
    <File>g500830g0707050510771.jpg</File>
    <File>g500830g0707050511017.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="3">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="4">http://xbrl.sec.gov/dei/2022q4</BaseTaxonomy>
    <BaseTaxonomy items="70">http://xbrl.sec.gov/ecd/2022q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "d500830ddef14a.htm": {
   "axisCustom": 0,
   "axisStandard": 3,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 3,
    "http://xbrl.sec.gov/dei/2022q4": 4,
    "http://xbrl.sec.gov/ecd/2022q4": 70
   },
   "contextCount": 31,
   "dts": {
    "definitionLink": {
     "local": [
      "cprx-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "d500830ddef14a.htm"
     ]
    },
    "labelLink": {
     "local": [
      "cprx-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "cprx-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "cprx-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022q4/dei-2022q4.xsd",
      "https://xbrl.sec.gov/dei/2022q4/dei-2022q4_def.xsd",
      "https://xbrl.sec.gov/dei/2022q4/dei-2022q4_lab.xsd",
      "https://xbrl.sec.gov/dei/2022q4/dei-2022q4_pre.xsd",
      "https://xbrl.sec.gov/dei/2022q4/dei-sub-2022q4.xsd",
      "https://xbrl.sec.gov/ecd/2022q4/ecd-2022q4.xsd",
      "https://xbrl.sec.gov/ecd/2022q4/ecd-sub-2022q4.xsd"
     ]
    }
   },
   "elementCount": 217,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2022q4": 3,
    "total": 3
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 4,
   "memberStandard": 3,
   "nsprefix": "cprx",
   "nsuri": "http://www.catalystpharma.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d500830ddef14a.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "995100 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://xbrl.sec.gov/dei/role/document/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d500830ddef14a.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:EntityRegistrantName",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d500830ddef14a.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ecd:PvpTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "menuCat": "Notes",
     "order": "2",
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "shortName": "Pay vs Performance Disclosure",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "d500830ddef14a.htm",
      "contextRef": "P01_01_2022To12_31_2022",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "ecd:PvpTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 7,
   "tag": {
    "cprx_AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Change in Value of Prior Year Awards that Remain Unvested [Member]"
       }
      }
     },
     "localname": "AnnualChangeInValueOfPriorYearAwardsThatRemainUnvestedMember",
     "nsuri": "http://www.catalystpharma.com/20221231",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "cprx_ChangeInValueOfPriorYearAwardsThatVestDuringYearMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Change in Value of Prior Year Awards that Vest During Year [Member]"
       }
      }
     },
     "localname": "ChangeInValueOfPriorYearAwardsThatVestDuringYearMember",
     "nsuri": "http://www.catalystpharma.com/20221231",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "cprx_SCTEquityAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "SCT Equity Awards [Member]"
       }
      }
     },
     "localname": "SCTEquityAwardsMember",
     "nsuri": "http://www.catalystpharma.com/20221231",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "cprx_ValueOfNewUnvestedAwardsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Value of New Unvested Awards [Member]"
       }
      }
     },
     "localname": "ValueOfNewUnvestedAwardsMember",
     "nsuri": "http://www.catalystpharma.com/20221231",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AdditionalSecurities462b": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities. 462(b)"
       }
      }
     },
     "localname": "AdditionalSecurities462b",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AdditionalSecurities462bFileNumber": {
     "auth_ref": [
      "r121"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities, 462(b), File Number"
       }
      }
     },
     "localname": "AdditionalSecurities462bFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_AdditionalSecuritiesEffective413b": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional Securities Effective, 413(b)"
       }
      }
     },
     "localname": "AdditionalSecuritiesEffective413b",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AddressTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An entity may have several addresses for different purposes and this domain represents all such types.",
        "label": "Address Type [Domain]"
       }
      }
     },
     "localname": "AddressTypeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_ApproximateDateOfCommencementOfProposedSaleToThePublic": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The approximate date of a commencement of a proposed sale of securities to the public. This element is disclosed in S-1, S-3, S-4, S-11, F-1, F-3 and F-10 filings.",
        "label": "Approximate Date of Commencement of Proposed Sale to Public"
       }
      }
     },
     "localname": "ApproximateDateOfCommencementOfProposedSaleToThePublic",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateOrAsapItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r46",
      "r49",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Line Items]"
       }
      }
     },
     "localname": "AuditorLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "xbrltype": "stringItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r46",
      "r49",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r46",
      "r49",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor [Table]"
       }
      }
     },
     "localname": "AuditorTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_BusinessContactMember": {
     "auth_ref": [
      "r49",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business contact for the entity",
        "label": "Business Contact [Member]"
       }
      }
     },
     "localname": "BusinessContactMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelEmailAddress": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Email address of contact personnel.",
        "label": "Contact Personnel Email Address"
       }
      }
     },
     "localname": "ContactPersonnelEmailAddress",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelFaxNumber": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fax Number of contact personnel.",
        "label": "Contact Personnel Fax Number"
       }
      }
     },
     "localname": "ContactPersonnelFaxNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContactPersonnelName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of contact personnel",
        "label": "Contact Personnel Name"
       }
      }
     },
     "localname": "ContactPersonnelName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContainedFileInformationFileDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the contained file.",
        "label": "Contained File Information, File Description"
       }
      }
     },
     "localname": "ContainedFileInformationFileDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_ContainedFileInformationFileName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the contained file.",
        "label": "Contained File Information, File Name"
       }
      }
     },
     "localname": "ContainedFileInformationFileName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_ContainedFileInformationFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The SEC Document Number of the contained file.",
        "label": "Contained File Information, File Number"
       }
      }
     },
     "localname": "ContainedFileInformationFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_ContainedFileInformationFileType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type or format of the contained file (usually XBRL but may be used for other types such as HTML, Word, PDF, GIF/JPG, etc.).",
        "label": "Contained File Information, File Type"
       }
      }
     },
     "localname": "ContainedFileInformationFileType",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DelayedOrContinuousOffering": {
     "auth_ref": [
      "r73",
      "r74",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Delayed or Continuous Offering"
       }
      }
     },
     "localname": "DelayedOrContinuousOffering",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DividendOrInterestReinvestmentPlanOnly": {
     "auth_ref": [
      "r73",
      "r74",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Dividend or Interest Reinvestment Plan Only"
       }
      }
     },
     "localname": "DividendOrInterestReinvestmentPlanOnly",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r46",
      "r49",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentCopyrightInformation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The copyright information for the document.",
        "label": "Document Copyright Information"
       }
      }
     },
     "localname": "DocumentCopyrightInformation",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentCreationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The date the document was made available and submitted, in YYYY-MM-DD format. The date of submission, date of acceptance by the recipient, and the document effective date are all potentially different.",
        "label": "Document Creation Date"
       }
      }
     },
     "localname": "DocumentCreationDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The description of the document.",
        "label": "Document Description"
       }
      }
     },
     "localname": "DocumentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of the document as assigned by the filer, corresponding to SEC document naming convention standards.",
        "label": "Document [Domain]"
       }
      }
     },
     "localname": "DocumentDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_DocumentEffectiveDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The date when a document, upon receipt and acceptance, becomes officially effective, in YYYY-MM-DD format. Usually it is a system-assigned date time value, but it may be declared by the submitter in some cases.",
        "label": "Document Effective Date"
       }
      }
     },
     "localname": "DocumentEffectiveDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "auth_ref": [
      "r46",
      "r49",
      "r61",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement",
        "label": "Document Financial Statement Error Correction [Flag]"
       }
      }
     },
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFinStmtRestatementRecoveryAnalysisFlag": {
     "auth_ref": [
      "r46",
      "r49",
      "r61",
      "r105"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates whether any of the financial statement periods include restatements that required a recovery analysis of incentive-based compensation received by any of the registrant's executive officers during the relevant recovery period pursuant to \u00a7240.10D-1(b).",
        "label": "Document Financial Statement Restatement Recovery Analysis [Flag]"
       }
      }
     },
     "localname": "DocumentFinStmtRestatementRecoveryAnalysisFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationDocumentAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Document Information, Document [Axis]"
       }
      }
     },
     "localname": "DocumentInformationDocumentAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Text Block]"
       }
      }
     },
     "localname": "DocumentInformationTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_DocumentName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the document as assigned by the filer, corresponding to SEC document naming convention standards. Examples appear in the &lt;FILENAME> field of EDGAR filings, such as 'htm_25911.htm', 'exhibit1.htm', 'v105727_8k.txt'.",
        "label": "Document Name"
       }
      }
     },
     "localname": "DocumentName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentSubtitle": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The subtitle given to the document resource by the creator or publisher. An example is 'A New Period of Growth'.",
        "label": "Document Subtitle"
       }
      }
     },
     "localname": "DocumentSubtitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentSynopsis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A synopsis or description of the document provided by the creator or publisher. Examples are 'This is the 2006 annual report for Company. During this period we saw revenue grow by 10% and earnings per share grow by 15% over the prior period'",
        "label": "Document Synopsis"
       }
      }
     },
     "localname": "DocumentSynopsis",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentTitle": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name or title given to the document resource by the creator or publisher. An example is '2002 Annual Report'.",
        "label": "Document Title"
       }
      }
     },
     "localname": "DocumentTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentVersion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The version identifier of the document.",
        "label": "Document Version"
       }
      }
     },
     "localname": "DocumentVersion",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r38"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EffectiveAfter60Days486a": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective after 60 Days, 486(a)"
       }
      }
     },
     "localname": "EffectiveAfter60Days486a",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveOnDate486a": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(a)"
       }
      }
     },
     "localname": "EffectiveOnDate486a",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EffectiveOnDate486b": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Date, 486(b)"
       }
      }
     },
     "localname": "EffectiveOnDate486b",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EffectiveOnSetDate486a": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(a)"
       }
      }
     },
     "localname": "EffectiveOnSetDate486a",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveOnSetDate486b": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective on Set Date, 486(b)"
       }
      }
     },
     "localname": "EffectiveOnSetDate486b",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveUponFiling462e": {
     "auth_ref": [
      "r124"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective Upon Filing, 462(e)"
       }
      }
     },
     "localname": "EffectiveUponFiling462e",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveUponFiling486b": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective upon Filing, 486(b)"
       }
      }
     },
     "localname": "EffectiveUponFiling486b",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EffectiveWhenDeclaredSection8c": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effective when Declared, Section 8(c)"
       }
      }
     },
     "localname": "EffectiveWhenDeclaredSection8c",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAccountingStandard": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The standardized abbreviation of the accounting standard used by the entity. This can either be US GAAP as promulgated by the FASB or IFRS as promulgated by the IASB. Example: 'US GAAP', 'IFRS'.  This is distinct from the Document Accounting Standard element.",
        "label": "Entity Accounting Standard"
       }
      }
     },
     "localname": "EntityAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the kind of address for the entity, if needed to distinguish more finely among mailing, principal, legal, accounting, contact or other addresses.",
        "label": "Entity Address, Address Description"
       }
      }
     },
     "localname": "EntityAddressAddressDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityAddressesAddressTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Addresses, Address Type [Axis]"
       }
      }
     },
     "localname": "EntityAddressesAddressTypeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Addresses [Line Items]"
       }
      }
     },
     "localname": "EntityAddressesLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressesTable": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container of address information for the entity",
        "label": "Entity Addresses [Table]"
       }
      }
     },
     "localname": "EntityAddressesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r41"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityContactPersonnelLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Contact Personnel [Line Items]"
       }
      }
     },
     "localname": "EntityContactPersonnelLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityHomeCountryISOCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code for the Entity's home country. If home country is different from country of legal incorporation, then also provide country of legal incorporation in the 'Entity Incorporation, State Country Code' element.",
        "label": "Entity Home Country ISO Code"
       }
      }
     },
     "localname": "EntityHomeCountryISOCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation, Date of Incorporation"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationFormerLegalOrRegisteredName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former Legal or Registered Name of an entity",
        "label": "Entity Information, Former Legal or Registered Name"
       }
      }
     },
     "localname": "EntityInformationFormerLegalOrRegisteredName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityInvCompanyType": {
     "auth_ref": [
      "r116"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "One of: N-1A (Mutual Fund), N-1 (Open-End Separate Account with No Variable Annuities), N-2 (Closed-End Investment Company), N-3 (Separate Account Registered as Open-End Management Investment Company), N-4 (Variable Annuity UIT Separate Account), N-5 (Small Business Investment Company), N-6 (Variable Life UIT Separate Account), S-1 or S-3 (Face Amount Certificate Company), S-6 (UIT, Non-Insurance Product).",
        "label": "Entity Inv Company Type"
       }
      }
     },
     "localname": "EntityInvCompanyType",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "invCompanyType"
    },
    "dei_EntityLegalForm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The details of the entity's legal form. Examples are partnership, limited liability company, trust, etc.",
        "label": "Entity Legal Form"
       }
      }
     },
     "localname": "EntityLegalForm",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityListingDepositoryReceiptRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of underlying shares represented by one American Depository Receipt (ADR) or Global Depository Receipt (GDR). A value of '3' means that one ADR represents 3 underlying shares. If one underlying share represents 2 ADR's then the value would be represented as '0.5'.",
        "label": "Entity Listing, Depository Receipt Ratio"
       }
      }
     },
     "localname": "EntityListingDepositoryReceiptRatio",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "pureItemType"
    },
    "dei_EntityListingDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the kind of listing the entity has on the exchange, if necessary to further describe different instruments that are already distinguished by Entity, Exchange and Security.",
        "label": "Entity Listing, Description"
       }
      }
     },
     "localname": "EntityListingDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityListingForeign": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yes or No value indicating whether this is a listing that is a foreign listing or depository receipt.",
        "label": "Entity Listing, Foreign"
       }
      }
     },
     "localname": "EntityListingForeign",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingParValuePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The par value per share of security quoted in same currency as Trading currency. Example: '0.01'.",
        "label": "Entity Listing, Par Value Per Share"
       }
      }
     },
     "localname": "EntityListingParValuePerShare",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "perShareItemType"
    },
    "dei_EntityListingPrimary": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Yes or No value indicating whether a listing of an instrument on an exchange is primary for the entity.",
        "label": "Entity Listing, Primary"
       }
      }
     },
     "localname": "EntityListingPrimary",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityListingSecurityTradingCurrency": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The three character ISO 4217 code for the currency in which the security is quoted. Example: 'USD'",
        "label": "Entity Listing, Security Trading Currency"
       }
      }
     },
     "localname": "EntityListingSecurityTradingCurrency",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityListingsExchangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the domain members or categories in the table and the line items or concepts that complete the table.",
        "label": "Entity Listings, Exchange [Axis]"
       }
      }
     },
     "localname": "EntityListingsExchangeAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityListingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Listings [Line Items]"
       }
      }
     },
     "localname": "EntityListingsLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityListingsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container for exchange listing information for an entity",
        "label": "Entity Listings [Table]"
       }
      }
     },
     "localname": "EntityListingsTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityNumberOfEmployees": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of persons employed by the Entity",
        "label": "Entity Number of Employees"
       }
      }
     },
     "localname": "EntityNumberOfEmployees",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "decimalItemType"
    },
    "dei_EntityPhoneFaxNumbersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Phone Fax Numbers [Line Items]"
       }
      }
     },
     "localname": "EntityPhoneFaxNumbersLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityReportingCurrencyISOCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The three character ISO 4217 code for the currency used for reporting purposes. Example: 'USD'.",
        "label": "Entity Reporting Currency ISO Code"
       }
      }
     },
     "localname": "EntityReportingCurrencyISOCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "currencyItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r37"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to serve as parent of six Entity related Table concepts.",
        "label": "Entity [Text Block]"
       }
      }
     },
     "localname": "EntityTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r118"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_ExchangeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of all exchanges. MIC exchange codes are drawn from ISO 10383.",
        "label": "Exchange [Domain]"
       }
      }
     },
     "localname": "ExchangeDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_ExhibitsOnly462d": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d)"
       }
      }
     },
     "localname": "ExhibitsOnly462d",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_ExhibitsOnly462dFileNumber": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Exhibits Only, 462(d), File Number"
       }
      }
     },
     "localname": "ExhibitsOnly462dFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_FormerAddressMember": {
     "auth_ref": [
      "r48",
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former address for entity",
        "label": "Former Address [Member]"
       }
      }
     },
     "localname": "FormerAddressMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_FormerFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Former end date of previous fiscal years",
        "label": "Former Fiscal Year End Date"
       }
      }
     },
     "localname": "FormerFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r46",
      "r49",
      "r61"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_InvestmentCompanyActFileNumber": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act File Number"
       }
      }
     },
     "localname": "InvestmentCompanyActFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_InvestmentCompanyActRegistration": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Act Registration"
       }
      }
     },
     "localname": "InvestmentCompanyActRegistration",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_InvestmentCompanyRegistrationAmendment": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment"
       }
      }
     },
     "localname": "InvestmentCompanyRegistrationAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_InvestmentCompanyRegistrationAmendmentNumber": {
     "auth_ref": [
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investment Company Registration Amendment Number"
       }
      }
     },
     "localname": "InvestmentCompanyRegistrationAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/AuditInformation",
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LegalEntityIdentifier": {
     "auth_ref": [
      "r34"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A globally unique ISO 17442 value to identify entities, commonly abbreviated as LEI.",
        "label": "Legal Entity Identifier"
       }
      }
     },
     "localname": "LegalEntityIdentifier",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "legalEntityIdentifierItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NameChangeEventDateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a sequence of name change event related facts, use this typed dimension to distinguish them.  The axis members are restricted to be a valid for xml schema 'date' or 'datetime' data type.",
        "label": "Name Change Event Date [Axis]"
       }
      }
     },
     "localname": "NameChangeEventDateAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_NameChangeEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent concepts included in a table. Name change event line item concepts are used for information qualified by domain members of axes in the Name Change Event table.",
        "label": "Name Change Event [Line Items]"
       }
      }
     },
     "localname": "NameChangeEventLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_NameChangeEventTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For a set of related facts in a sequence of name change events, use this table when the events occurred within a single reporting period.",
        "label": "Name Change Event [Table]"
       }
      }
     },
     "localname": "NameChangeEventTable",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_NewEffectiveDateForPreviousFiling": {
     "auth_ref": [
      "r74",
      "r75",
      "r76",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New Effective Date for Previous Filing"
       }
      }
     },
     "localname": "NewEffectiveDateForPreviousFiling",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_NoSubstantiveChanges462c": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c)"
       }
      }
     },
     "localname": "NoSubstantiveChanges462c",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_NoSubstantiveChanges462cFileNumber": {
     "auth_ref": [
      "r122"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Substantive Changes, 462(c), File Number"
       }
      }
     },
     "localname": "NoSubstantiveChanges462cFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherAddressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other address for entity",
        "label": "Other Address [Member]"
       }
      }
     },
     "localname": "OtherAddressMember",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r49"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_ParentEntityLegalName": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "If the entity which the financial information concerns is a subsidiary of another company, then provide to full legal name of the parent entity",
        "label": "Parent Entity Legal Name"
       }
      }
     },
     "localname": "ParentEntityLegalName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_PhoneFaxNumberDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of Phone or Fax Number",
        "label": "Phone Fax Number Description"
       }
      }
     },
     "localname": "PhoneFaxNumberDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_PostEffectiveAmendment": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Post-Effective Amendment"
       }
      }
     },
     "localname": "PostEffectiveAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PostEffectiveAmendmentNumber": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 after the registration becomes effective.",
        "label": "Post-Effective Amendment Number"
       }
      }
     },
     "localname": "PostEffectiveAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreEffectiveAmendment": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-Effective Amendment"
       }
      }
     },
     "localname": "PreEffectiveAmendment",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreEffectiveAmendmentNumber": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment number to registration statement under the Securities Act of 1933 before the registration becomes effective.",
        "label": "Pre-Effective Amendment Number"
       }
      }
     },
     "localname": "PreEffectiveAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_RegistrationStatementAmendmentNumber": {
     "auth_ref": [
      "r35"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment number to registration statement under the Investment Company Act of 1940.",
        "label": "Registration Statement Amendment Number"
       }
      }
     },
     "localname": "RegistrationStatementAmendmentNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "sequenceNumberItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r36"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r39"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/dei/role/document/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "auth_ref": [
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "localname": "Additional402vDisclosureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AdjToCompAmt": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "localname": "AdjToCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AdjToCompAxis": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "localname": "AdjToCompAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "localname": "AdjToPeoCompFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AggtErrCompAmt": {
     "auth_ref": [
      "r53",
      "r65",
      "r81",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "localname": "AggtErrCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "auth_ref": [
      "r56",
      "r68",
      "r84",
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_AllAdjToCompMember": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "localname": "AllAdjToCompMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AllExecutiveCategoriesMember": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "localname": "AllExecutiveCategoriesMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_AllIndividualsMember": {
     "auth_ref": [
      "r60",
      "r69",
      "r85",
      "r104",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All Individuals [Member]"
       }
      }
     },
     "localname": "AllIndividualsMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "localname": "ChangedPeerGroupFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CoSelectedMeasureAmt": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "localname": "CoSelectedMeasureAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "decimalItemType"
    },
    "ecd_CoSelectedMeasureName": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Company Selected Measure Name"
       }
      }
     },
     "localname": "CoSelectedMeasureName",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "auth_ref": [
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "auth_ref": [
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "auth_ref": [
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "auth_ref": [
      "r98"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "auth_ref": [
      "r53",
      "r65",
      "r81",
      "r109"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "localname": "ErrCompAnalysisTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ErrCompRecoveryTable": {
     "auth_ref": [
      "r50",
      "r62",
      "r78",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "localname": "ErrCompRecoveryTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_ExecutiveCategoryAxis": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Executive Category [Axis]"
       }
      }
     },
     "localname": "ExecutiveCategoryAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "auth_ref": [
      "r57",
      "r69",
      "r85",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "auth_ref": [
      "r57",
      "r69",
      "r85",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "auth_ref": [
      "r57",
      "r69",
      "r85",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "auth_ref": [
      "r57",
      "r69",
      "r85",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_ForgoneRecoveryIndName": {
     "auth_ref": [
      "r57",
      "r69",
      "r85",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "localname": "ForgoneRecoveryIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_IndividualAxis": {
     "auth_ref": [
      "r60",
      "r69",
      "r85",
      "r104",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Individual [Axis]"
       }
      }
     },
     "localname": "IndividualAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_MeasureAxis": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure [Axis]"
       }
      }
     },
     "localname": "MeasureAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_MeasureName": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measure Name"
       }
      }
     },
     "localname": "MeasureName",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_NonNeosMember": {
     "auth_ref": [
      "r57",
      "r69",
      "r85",
      "r104",
      "r113"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "localname": "NonNeosMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_NonPeoNeoMember": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "localname": "NonPeoNeoMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_OtherPerfMeasureAmt": {
     "auth_ref": [
      "r96"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Performance Measure Amount"
       }
      }
     },
     "localname": "OtherPerfMeasureAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "decimalItemType"
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "auth_ref": [
      "r55",
      "r67",
      "r83",
      "r111"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "localname": "OutstandingAggtErrCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "auth_ref": [
      "r58",
      "r70",
      "r86",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "localname": "OutstandingRecoveryCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_OutstandingRecoveryIndName": {
     "auth_ref": [
      "r58",
      "r70",
      "r86",
      "r114"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "localname": "OutstandingRecoveryIndName",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "localname": "PayVsPerformanceDisclosureLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "xbrltype": "stringItemType"
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "localname": "PeerGroupIssuersFnTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "auth_ref": [
      "r94"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "localname": "PeoActuallyPaidCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PeoMember": {
     "auth_ref": [
      "r104"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO [Member]"
       }
      }
     },
     "localname": "PeoMember",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "domainItemType"
    },
    "ecd_PeoName": {
     "auth_ref": [
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Name"
       }
      }
     },
     "localname": "PeoName",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "ecd_PeoTotalCompAmt": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "localname": "PeoTotalCompAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_PvpTable": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "localname": "PvpTable",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_PvpTableTextBlock": {
     "auth_ref": [
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "localname": "PvpTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "auth_ref": [
      "r50",
      "r62",
      "r78",
      "r106"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "xbrltype": "stringItemType"
    },
    "ecd_RestatementDateAxis": {
     "auth_ref": [
      "r51",
      "r63",
      "r79",
      "r107"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "localname": "RestatementDateAxis",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "stringItemType"
    },
    "ecd_RestatementDeterminationDate": {
     "auth_ref": [
      "r52",
      "r64",
      "r80",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Determination Date"
       }
      }
     },
     "localname": "RestatementDeterminationDate",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "dateItemType"
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "auth_ref": [
      "r59",
      "r71",
      "r87",
      "r115"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "auth_ref": [
      "r54",
      "r66",
      "r82",
      "r110"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TabularListTableTextBlock": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "localname": "TabularListTableTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "ecd_TotalShareholderRtnAmt": {
     "auth_ref": [
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "localname": "TotalShareholderRtnAmt",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "auth_ref": [
      "r102"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "nsuri": "http://xbrl.sec.gov/ecd/2022q4",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r7",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r14",
      "r15",
      "r16",
      "r17",
      "r18",
      "r19",
      "r20",
      "r21",
      "r22",
      "r23",
      "r24",
      "r25",
      "r26",
      "r27",
      "r28",
      "r29",
      "r30",
      "r31",
      "r32",
      "r33",
      "r129"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "xbrltype": "monetaryItemType"
    }
   },
   "unitCount": 1
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r100": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r101": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r102": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iv",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r103": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "6",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r104": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "6",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r105": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r106": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r107": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r108": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "A",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r109": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "B",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r110": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "C",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r111": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "D",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r112": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Sentence": "E",
   "Subparagraph": "i",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r113": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r114": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r115": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "w",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r116": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "313",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r117": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r118": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r119": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "413",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r120": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r121": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r122": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r123": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r124": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "462",
   "Subsection": "e",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r125": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "486",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r126": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "486",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r127": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r128": {
   "Name": "Securities Act",
   "Publisher": "SEC",
   "Section": "8",
   "Subsection": "c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r34": {
   "Publisher": "Global LEI Foundation",
   "URI": "www.leiroc.org",
   "URIDate": "2013-08-21",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r35": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r36": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r37": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r38": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r39": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r40": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r41": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r42": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r43": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r44": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r45": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r46": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r47": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r48": {
   "Name": "Form 10-Q",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r49": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r50": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r51": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r52": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "A",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r53": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "B",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r54": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "C",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r55": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "D",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r56": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Sentence": "E",
   "Subparagraph": "i",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r57": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "ii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r58": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "iii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r59": {
   "Name": "Form 20-F",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "6",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r60": {
   "Name": "Form 20-F",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "6",
   "Subparagraph": "ii",
   "Subsection": "F",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r61": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r62": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r63": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r64": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "i",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r65": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "ii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r66": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "iii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r67": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "iv",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r68": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Sentence": "v",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r69": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r70": {
   "Name": "Form 40-F",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "19",
   "Subparagraph": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r71": {
   "Name": "Form 40-F",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "19",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r72": {
   "Name": "Form 8-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "308",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r73": {
   "Name": "Form F-3",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r74": {
   "Name": "Form N-2",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r75": {
   "Name": "Form N-3",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r76": {
   "Name": "Form N-4",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r77": {
   "Name": "Form N-6",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r78": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r79": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r80": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "i",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r81": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "ii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r82": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "iii",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r83": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "iv",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r84": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Sentence": "v",
   "Subparagraph": "1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r85": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r86": {
   "Name": "Form N-CSR",
   "Paragraph": "a",
   "Publisher": "SEC",
   "Section": "18",
   "Subparagraph": "3",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r87": {
   "Name": "Form N-CSR",
   "Paragraph": "b",
   "Publisher": "SEC",
   "Section": "18",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r88": {
   "Name": "Form S-3",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r89": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r90": {
   "Name": "Investment Company Act",
   "Number": "270",
   "Publisher": "SEC",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r91": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r92": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "1",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r93": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "ii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r94": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iii",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r95": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "iv",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r96": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "2",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "vi",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r97": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "3",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r98": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "4",
   "Publisher": "SEC",
   "Section": "402",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r99": {
   "Name": "Regulation S-K",
   "Number": "229",
   "Paragraph": "5",
   "Publisher": "SEC",
   "Section": "402",
   "Subparagraph": "i",
   "Subsection": "v",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-23-185962-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-185962-xbrl.zip
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M=(T,)X7"_V#[_I<68U]QNY3!+V? Z[\!4$L#!!0    ( .6#[%:E/R3NP (
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MK2H[;UWMJI$W=[ F1(;1/'QW"Y<;><Z\I>9M+[[WS%WZ+WOP%U!+ P04
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MEK]CEK[HOG^A?-6_Z4+!)T$4_%C+%+J]FRX3?*+")[1"&Y5C3'^F<9[07R3
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M@@ [<6(85@)C [9!Y\'J?(KBZD?/HZ8Y;"^8P^;V7<QA;Z"\;S1:=X1 FTD
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MF30WKMV2!5F>F0$AWC&LLIM5 *UU%7;^ V%["<@(1YHH/_<4 OH[N"H6*+-
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MUK$."!KBIE:L8M_#GJ9*&<@R30>8SEBIWU B<6?DT;@+UZAE%LD$F;?;+.O
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MRP4L7O+2T/&L(@(RUD4%:?3@Y!4M__3:%*WJ1<*!2Y NEE@08&["'UA,[0_
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MU!DD1*8PUA#S-AX(%91P"/[$2:AX#S2BP3K6-,U9JV0O'@%X:" EU\N'*GH
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M$ *"RMH=%(RG58$,3+V<\0!=0J(M5Z(K5T !?G;EAKDNY]@2\*[A,(]$P"!
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M>MP+0+Y2[O*CF^H%Z(Z!$<O"O.R\XC5XN?GJ^<W_(@;A\];3^KFI+C\7:&4
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MIEEQ ="R TN(.+Z:N?T07N=T"0\V,PT*>4YS62].@+N3-@4B=^J:MJ[BT$
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M8PHR+(@(JW?3)(X_@'S?H9,G,[EJF@XUU2P4X?FJJ#J4JU4N<QYS+"6M\U#
M'+O4D[2;Z &R$I&L<R@V/D79@M+UDWG4(O7R7);'H<2A)S*#<K@J7LP3E)@(
M\GHBCE1K>$8JG*@@53S]%W(*\EWR7$2YOT[(3TE0_"3S)ODX^6X*# T-S!V'
M 9%4A/KLH4SMQ_QHR.2.2,[>SZFI:65NU<<N"N1.8LFZO)A::T:M>3&-.0F]
MY7(9TQ)3&]&IT78:.730I4A4B5K0F2>?R.:0LF6>6'W(7'ZL+^">,R%%XF%"
MYDIR8U(/7TQ*DC.F.?*@IHS4)\S(GN2<_'1=6K7 .,3Z35P6O<W8IJ+V5:'
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MF(YG=5-_$ZHA!7M<L.Z9.TR'-'$;@<5)K!*M\RCEZQZH M4!5 )E+:+C(!H
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M^WW109#?H_W-3$+D-@"_(GZ:ANR+=U'XVI-"[ K'PGHL@</UTGL^.>G929S
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M(B&.^WN=0%3(E+&,*1Z_HC,J(WLLPQ5XKR!2XG@3_M_4>54R/E/H50;_E6Q
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M8Y$]R 6,TLI::'ZSGZ <]02"17Y$G8O(L2-C&=AQR%9K_! *%_K&,3>XYX_
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M"/V0 1K'H$MR5DC(?@V<TXN01U[;8WXY'@$.WY%B([AP8)P,;" 1Y)7 8:/
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M;[QZ*CP'+@"JLHW<P FZ\3",D+6'!1P0J4IA0:D8 &9$+!LV/3.&])L8AXX
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M/#:/6OR7/8EAG3&_-H%5_-<)]VGA3XE+-TJV8'HM<@)*+]M+U#(2K(I36 H
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MV> E1?'NL+X?@.+M/MKC$-L;P6=@M$&BI N=NDW_^3!@N&/OJZ.?'QZ=7C2
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M(2Q,E,N/'_W,)<>+HD!83%C.8',5BI*R1$J'C[G\!X6UB6IO\K &,$W4UC_
M\Z)/DDSQFPL[$Y947Y\^/ZU.VM"/O0A;A(E>(8:H1IXIWV7+LW4CT!=%M? -
MU"T_.;XNK. >^9GJ8ECUR^9'!8WIRY!OK;,660"LZ,$&("OEPDPLN-YC\(DA
MO-\3S9!NSTY$1[5#ZHS&PF[@=+")$'/]Q[<E0W'W9!C JR+%RCZ1XA=LF/;
M*Z,$ANANY7A&/[E.J&*/1BZL#[;8Q HJ8>1W?QC^B+?;HY9U3-)PIEW5C,85
M!^GA68Y6UPJ9=WTW'F(G/_@V"R,0:=C+*@ZI]9?QV;6[/XYNN]@N*Q33P+X/
MB&;&T.\Q-T'^41R,_!"?ZO.^6]CNS_51)E.#L&X7D(A*ZU'3P)0"B !\:JD5
ML#X*\RED#=0$%&3"4P#N_V+9F ";!3+G 7[WX@#G1"7[4A@2"98,+',(.-.5
MO1!ABL!L:.H3T^;D);H$ALOG'TL?<.0['KJ@CV#SF,I %=2BY6&;R&ALV(]V
MT L%*X6ERR<>'1=VTXT1W!%+VS@B%^5HB!O/Z,4'.Z 6;[BK,1:QO*=1Q(:%
M83SD&%LR;AGCO=WX\?]LCS5>8 .WH0MD;0.:^/!L,+.XY#J9>AZ;%+ZN632Q
MZ.H^L>@9)=F%?7\.J+V$5CU?9BH,B;(6$K)WXR'QK8>$\4?H9<!.A-+- *_@
M$>O-J6YWMS>%JIM8I[($>%*VE[VTPY[]'^.SXT>L._!\U[_'LKT]]I-Z-!+Q
M=8$+<8;">U$:CB@IYJ0UQ& X*C!&BI94I-*FDY=V$/!OGZ82":O$V&/C#]A,
M8&/72N%7;""&WR)-K&3\B=UYX5V/ 5JC@>C: 1<]I&7:(.8>@):\A%5B\UIL
M?DL<4Y%ML,T.=DL"UMKS\0.A+^4Y]@H+&>,LAII9EO*5B*=RFRETM& 3R7Q!
MV]7WD41:8S])R'ZJ\IBS_#-9:W$? ]E:2U1/YD(".YU-J: \H\SR\0C$3"]Y
M]"\K.Z]E]W]3%TE_J$N88TV3TUU@;97<VA9KK?EN^;.O+#+[ZO2=401#J56%
MC4BWR@!946HTTVM\N]++*F<SB+7!=VR#]U/\.Y#P@2@"AAHC\GE@RA_?V7-N
MJ#+)U??[6QC^U:E">"E-C<\Y;Q/J]'#(>@[P/E#CJ8^N*8J(<^.CR*#)%/PQ
M>%4O*>"0K8IW1-$@8_:[:U 8Y=RD#8/KHW! =FH!-1.6[<<9E2:?I1RO7Y;?
MGMP5R7)NG?;^'8?4[%A:!Y%:05[71I]>&[VM:Z/K(9<VY J2Z7:QD/F.%OP!
M%CM1[%"77]K4;ER SA0:*/:PL-(9><EXS4'N*=,[LZF=N7;CD"^/2HKSGWZ?
M%V9DC_SO[^0)$*7%Q9;9Z/"D"U;E7=726[@%6WCL@6G"*P2>R.@'_9796UD(
MS1&U7[&FM<%W591!LR/CA@UM\;+<_6W?XCW?W$GZ5/;L#[Y#8+71G]BU2]+K
M*0_;4.5R781P._:24R=M!QBILID#_4UTF>Z6X+9(D\E&&WQ+4^+56[JI+56T
MRY/CZ]6KF?J$SS*Z/\]!JFD_[24>"IKRT@8?U//5\WU!1NO&9ZKG^YP'5R1%
M]D=8Z"+#NLCP5N_;<>_?=_XBF_87[/0%]>R%U\]^LFZ,^1HG=L3N_6!\_-,)
M_[H]N>.>.6YS)$^GWX*G%MG\$-;RZ\'1D\68FI6FV:KK0U%;@05DC%[U@5%*
MO\^RT.&).KF->MNLUG2]XS5@ ?<3<B?$N2=VG!P/Z$[@^WTWL"/N!)1X4(P!
M3Z/4TG"D:M8:9;-B;8&\V#;LP!0"J_)AU0C\RNGF:8I!]QSWSN'UC5-,W:Q4
M:V:EK,MT/4<S?@5M'+0_41?:U85V]W+?YA%OF4W;7A/1,LLURZQ6=.&AK<""
M#9F([6;+K.N2O^O @1TU$"VS5JD!G]B"GBW;AAW:0%P'W>R<@6B9;:ME5NHK
MJZVRO]CQ*AH9Z$BA+ARK"\?N\K[-(\0RF[:]9F"K6C/+V@#8#AS8D!'8*K=
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MY*$RW_VSG+VQ[A<M>!X[EO7RR7FV822\8 !J85(B]K4.%N#%\UEGK+L3Z/.
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M/\4$^T=PT%RB8X7[QC1&##(CGZGC'&,RLL-N,$:11X7V*K6N&_52TV8/@?4
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MH#7MPV5-(%V]WL2UX-I="'5-<:=UT^[>TSKT.ZT3?[C\;M"ZPLBP %%<4DY
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MFW7:,#/YVD BJ&[C?[XUNXUZ3H;\),.*?O_7P!F]P)6Q/[$N_Q]02P,$%
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M[;O(0=T"(-$2B2.M3(1(NH05HYW7O;]#E=EK[^(T\:_E1)=_D4*7;<#'F[=
MO\V$B\DYWB^_R2;D!7'9H[-WMP#;ZUN@3._&1D/Q3(N_[(#5BWJ8?5^)M)!!
M@OK;XUWR.TV*:A[2X*7J&$TYPX%W<;> YZ,E:#SA?IE#F<!90<Z'NNKQ85]]
MPG@AIF_)4(3B;^Z/(V\&R"VEGSMK&MU;Z\1^'I%^XN-^C]&,!RQC5&<R-HF\
MXAOQOE9;TXZCK.E=45!WLT/M@P?RW5,ZP[3V7</@K<(+:;_=?GI_@QI7;SPE
M'_$K;Q*RLNN-R/">]INW\U,C7- >S54J+4E 5N4CGZLN&I%)RV>KOATLQY!3
M948NY?DT^HHN3]1FLNPS?3VH4N!P.D*S[D:^<2.\B+&9Y7Z\LU ?DE47P1'=
M\"V?^>9.9:YAO&.U,UPS1615K6^Y"7I KC:^JF*8WY\\FLZ_^E/B#]G4M4U%
M&=U9P,*6#+E6K1?%2H=S5/=]WR5<22_0).I,=]=FCP1>*U*S84PP.Y_C@!S)
ML';0T KMTT9Q<A+;Q0J=(?^^LJ'?9*'?]OA6@]M5$!]T*])OG;4I=M$?NI^,
M]-)&KXYO&9@1CGR8?L']5HYH[S"R\%=[ *0U@G6.6N,-2DE+L[JNJ=R=KXQI
M1)'9H^?K=_HU^G6'^?HMT6@[B^$JG?>V)3/73Z\'7M>ZD'K6%NP865AM7EB=
MY&5PI,W*-"AW]+__T2MP(%"C2)_W.8U+UH<*>UTZ]ZQ*X?##Y(UGO?C<^9\K
M574!1,3'X$ 66$1LD03^+:!<:FO^E#G,F4DA,7=F]U/>9%R4N1=W[$1%=C-"
MG4Q__CO'L8PJ'<YU=^)?ZWGG%U(,]1QT\99.=;H!T.$Q\DUN>DYW6GL^:<QV
MRY712O A%.3'C1+;:E;O3+,&9Y1D)T"-NE[<O-76/7VB-[PN>9VD^CB9H'G9
M9A*^Z?>;EWSM&<'*2G5)MBK$]+0C)0C1O5=)-7LZ@^QDF!JNFH;TY(2;J#A9
MOQ#;$N"C7,K;+9814?CR[5&JZ'JDYD2ML,>G#]JVX<CF6%./+OA8#22PPN46
M()]VC^S8GK26%Q!2;O44.P8O&(R]^J*VSJ"JGRGD\;N5RMWS:(?!'?$6M9+9
M'[/M56:RROW\H"S*5AO&VK/\D;3&RNV09NO!DUY;#[,//7V3CA!K15B[R-%?
M_/&&C8O^&_&\=]M\^XU,TA>#L:+50O*,BSP?O;_X\=P"3#)0R3\>D (7/Z+2
M+P6Q_(N&%DHOI&IZ@#69<_J20AZ)\=7JY.(W<.RIF[0RB1^5.YNV!VMU8GQU
MJIDPC/L&?&W*\V'+5_1 \Z&4BD"Y//,,>^]#9KS6OE^C:<?<W/.L%W5%<?F&
M,#YRZM9]1.XW]QBBXAW^TJR0!3\9%@ZEW[7J\FDG#5S%FSHN?+ZA21OYQNA$
M]Z-VMP,;+>L)VD-5>PE*:)+P<*LOH?B2!&H]D__ =B+7#,XNP/Y(6^D--F/&
M45AI!^UY;,U]W;S4R^$H$]OLW@A:BVH2\U;\%O[.PK#N85]PK9S#3V39F5XZ
M7+(LX@IT:$!"[)WWX;-E2*J;9P%3R_CVXHN^DOLNPMRA%H/,H-\WXM!DF(5S
M;4V1) RBW.F?J* 12@P*^G-5H%6\Q*1;&B;Y9N2O(X]<PKI:)-P76J(V+G1_
MFW=:X)&_]3"[T($2K3?$I"[5&1@]W>$S\_A&6:5H)_B#TM-3KU1'5?G:>48G
M8SCC97E7B/3*+#,T=-/OM:N#BH* :>D7ST\%/$JYQJR/+=^#N ,P4JH>81TE
M;)H5!X*(/?6&0&BEY!Z"]9N$L;#-Q/O\$#VZNE-^[;&<W"F>AUVN]S>?THTQ
MIR9KRYGK0=M[>Z"Y'R;3O94/N'.@4[IE*=ZBHWBG>OGJZ(*3BV$%?BTE GVN
MKMDE;W!.ADUGS4?A5;K!C"=YXVO@B!]7-O,VX6>V61E0F*V">>=I'4_\S^ZG
M>VN8JZ+:HLZQM8P4.<']E=!F-;/N#F-)B_HA72UNU1;=$/^/7T& 5* Z&[9N
M_&#MDZUBH@.*IT>\#U%*A^R(/$[C?J?[6+][1?F+W<;404\5F,I]4L>P&<8>
M""(04?Z"RYDMH'7C:#-IRV=:41DZ03!#RD5!^!6/1I2Z4,>I8IIE-"^K3"O@
M[-."5[->SUC56=2H7*B$J4E3;WJ@S(NU6,_E/[^HSFI5*HV>3M ;F=(]3QA/
M3?+TX<'F%T5[*2*4EY6C5_HR8J"76IU^1WL"-WBWP'%^:7OD8(:K0/SIW[]=
M)8045Q"FA_B)M0@Q#[C[8_%%J+@"(U$1]2M\$KA=2H)1L3(_^ZM89E!%C/^-
M"S>K0@ %C;;S74$"R4B *SL2X$FI_:YJV"FY:?)&G:^)JC-N)B*55KH]&)D4
MHP0-L\MKB%RQ=?YLWZ2X2!PU*79$$AZ'L1>*JC@G^N@P68!V2'O_,CO01\Z6
M_^?BIF,-MJ3_>_I3=@0DYB7NG%-L4OP@8;/1$UKLG=Q"K!)D(X\ORHU%NMLR
M>GJ.2$Y-89O_CN>?+<-R.*T@7X(\.:+F93\1J3N'<H*/$JF'S "\-HTO-(NO
M,^55*EDG[OS+<N"K:0=3,*6:(F27AT[R?5W% 8-A2?J);JV89L\[Q%8_1WPB
M650&BM0IT F=JW4IVE4;#(GHSG([F3G?1BRN]7.$6P(!F82DBGB_2IQK&@@R
MJA?GZ?FM&EYC62!'E37=W7J90G'<5B.\R^65E>;VCX87W166XLR8RV0N[O+3
M"MV+QG6/AZQDKL,/L9!#0Y^L'@^:9%GVC#FZ92M\?U5%>P>0@>U JM-)47_:
M)RRV,Y&"W1]84%G^B"/!_@>TVN!D1=QJ.$*>64X7,/A0"?_@&+= _>OK@1@A
M7D=13 ,E^K&>$A%6.7/6(28]38\$5"P9??UY'%*MST=M8M!&<=2T6J,4N,L2
MNQ0P0*([40X'AU7Q;,U!7M;":&7V/@[V"AJA/=C8)# W.I[@>_!X60\JN5&^
M=0U'R[CZI !_)>FU6><?:&67EC!;:BT8[ZG;QU[ZB.R&C%PC5'[;C56:&XG(
MHW:T1LWX]G+MZ"Y?%@?B -5"&:$'[Z!(/+*;Z4'CCXFEI$#WB]\V>$7X#ME.
M"E=FG/^*:7;"UA8[OR]^1,XX]R>R4(<M;25#VX?<!"VJJTZ\X1C!YO#1-E.>
MJ^9HYJ<>7Z-CJ;M4_1_,!JR]4Q".*%DRO Q:\_AD;\_<N1<]D[N3;A: 5AX8
M64%JUPQO\]L_>IVG4I#'*E<FAI$+GI5 ]R<&3=U++4TS$B86?7%\_TCQ8SB;
M/;\<+0P_CLY9G'UI2^=71X/7E*PEY7-#*V%9=D>:A$?L"3IAT$Z?[_ WO-IC
M?%77DA.,DE(V!?UC.5TVC!UDR_QJKVN)  P]NKS?K+PN5J&Y*L-8M'9\1Y<K
MTQ[2G;M@V]@0CX"^7*IV%EBXU'\;P5[7##>-PS"VU=F+$M.)V_V($1I!"-S;
M&)KIO9N3:YG!;R[ (R(=KAW*?I2>O9K1WNV,.0%35 \4T'1TB;;S9<PZB?4X
MXH;/X=#U6J7?5R%=;/#L2WQ>DW9FI"HZEF5.64PN19>,EGLP=4CX\LC ^?-P
MN_M2=TH:#?K$);E.R3Q<O-XI#J?G7#$?[;DBS;% TGK_%]_-UPH2LLNYY8&M
MH,R@,:;59M,CQ5$7DGP[>]ZLNK3[SVU9=['<F_Y? 0#/G]!Z7G2,I9>@S.F!
MTD^]Q"$:'6UN?VI2@! 7$<F3/OO/1/CO<3O];U!+ P04    " #E@^Q6O!*-
MV",+   $#   &0   &<U,# X,S!G,#<P-S U,#4Q,# Y."YJ<&>=EF=0T^D6
MQO]I)/0:FJ%7D99 5NE-FH@(4@R( JY44:0(4DS "RI70&"!!5RDA!(" 26
M0!01)*#2(Q"JPM)"+Z(+2B[NW+T[<V<_[+W/F>?3.7-F?G/FG?=AC[(_  *G
MK&RM ! (!'@=%L >!RP ! <'G .&@,/AG)P(+AX17AYN;AX)(6%^$2E)&6DI
M211*5E%3159>70&%4CU^5%T;K:NK*Z.B9W0"8ZBIHXOYO@3$R<G)P\TCSLLK
MCI%#R6'^9[%? H((P B8AX#D ; @""((8G< ,@  @H%^%_!O@< 0*(P#CN#D
MXCX<J!< P" (! R%P&!0Z&$W[K /0 5A0G)H,PYA1V^X_ T13'QZ$4+!_$D;
MTFE@0U'')S2!DTM43%Q"4DE91?6HFB[VA^,G]/0M3EI:6=O8GCKG[.+J=A[G
M?OG'*[Y^_@&!8>$1-R.C;D7?^4=BTMU[]Y,S,G_*RL[Y.3>ON(186E9>0:I\
M6D>M;VA\UM3\JKWC=2>]J_O-X!#C_?#(*'/LX\SLKW/S"XM+K,VM[9U/NY^_
M_+;WG0L$0$!_Z"^Y! ^YP% H! K_S@4"1WX?$(3"Y- <0F:.<.\;PO*8>(2(
M>7K1DS9.!1VG#:1/Z "7J*+N1Z7-[VB_D_T]L(3_B^P_8']RC0$\$-#A\2""
M@ GP>4^UF,#UNRLTUX/#]WV?T9XE(]P2MK0="]H+=D!&R"2LAIOSB<&JQ.HG
M;""GQTS"5F;%HEW&X5%Y!=3U-ID8X"/'4:\TU1*A;>SRB()6-I+WK  .MOE.
M=!?R50E8F4%CG$;T/K !GIJ[ZI36"%Y:3F;NU-CHP3QJ \D!]^Y>"_.4 D0<
M+?^^_2#*E=,LT;'@QC%-XFA^0@60?=,(:3IW?P?Y>MG]]=P$&=K0*'0=K[6B
M;3YDS6?MD2END"^S]4Z ED(O 7@#OEX)"*MJ*P[ *(XT(MYE-F=R56Z<OYS3
MMO.JP.I#%'GZ\M!.!I;7:;NWJ5=T9HG^QF&C\[F8D7:)R@M[OP!WEYY$VG8Q
MO?RWIHSYW15BCA;=24RP$P#2:(4\P<AT<E2&E%H4_LG*T%D&Y9_6HD6D"]"T
M)B7\O4)6;#WGFBJ$=-R]H/*'T8Y=4?K!18KPY_)O76D.Y%GQ_3+*Z%)V,_[G
M?K+NX*.WN@_<;?E;I&_?*5R]\+XFE5JMU;X<,6,BL%@3(7',8&E00L%U!9"X
M.CO<M+OID&+H%U[>KA_<F5ZLD*2?^(YK: +$!@QG0RM%]C*_?!(!L729BC8E
M 8H1)TUQN:D A*1<=\0CB>X0\]Q3YDRR(41IJ//X8Z\'$P7MU:$?8RUG#?JP
MJ_BG.R=&Q856=139P"H5WX4&(M0F";KKL6>WS0=QW;Q9\0;"9YMAM-DEJ$4N
M?U'7+B_NX,A K.F!4K#O@ONP2=TII(>1669X!QL0RTXNEC7@LUU/7J)^ _>^
M\@Z=NO)^;;)L;:ZQ.\V,"=]7 W:)F\K4 IE^"I;# =T/2S99;T&I?NT!<(P(
M.R,U9/:65WPOP[2TP&K'14(]CE!5%S.C<9HT5!5,'0]C QJ?9 =/W7Y8A)*)
MA'_+N\2W6.=Q$BN%&US&/?+%;;Z"=)V$KU7L+D]C?7:WYO=LU75)8!MC'*5K
MHG8OGG4PV=(/X^</;.[86R.5!@8'A#=X<UUT/SEP5-UX]JAO.W]U^/MS]D/!
M5#*VOMZ^@F_>)[273D:O.51[37I$)6;'])SK>+@D>C;;*R^N&<TY2LL\EA"7
MD-9)T,\[1MAH>%[#2OC"C"MQHF(2J32&BYR+(R-34G.E@*#%2 YDN2=\*9,R
MG[U48(]ANDL4IP(/)WJC%1&@F_107 6D/XC_PJ9O5N%K]+.LLCR1J=W=V9B*
M3]?>&(W&GYVH_[9:E:-/7"4&/$GHX7'BU[=D \'T"?B 'AOP#Z^,-KZ+G+@?
M<\-;*CN7^U9V]A'P7.L"M1W5&L)_IKR <,18AK$>$7=4JR:\<X@VU*RJF!.;
M;R F#CK/!B)5I.O)CNV&;@)5M:<R.J<C!NY =N2)A6#RU"7F4O]O(XTA'M:/
MX'FFA,>G\^;P#66,-8I/:PMML##)U2P81B2K)Q,?4$O1]7<5WK:A8B<3R?86
M[=&QG1X>W'U4#&&(DA.F3C$9PZO7W58F8/D:GJ(]#+CWGR*Z;6+KV]8DS2O;
MOPT&N-L'>H>0D8EY!!YAPQ2]S]/B"/B'^3QLF]J=X#)6V,*3!FTVL#CY4QLI
M2(>TI<MQOR6N84T7OIGVSJ04\.HFLX[WH&ZZN;^?N)N4;S=4E#2Q?[>IR_M@
M&>L\N--ZWZ*C?^)BT.X=<QQFN$XQ] (F6M0FW<R8GA8]]OZ3QO4S0V-[:Y^M
M!F=.@ZMY&A-'=US:3]I)$P!;[.5785')\YTQ-0)$@6[=ENK"5*,4U/G9J(G1
MRR,2)WHQ_I#;R:J%8%)@<VE#2KEMS,V>N3+ 6<+/)Z2RI$DEWBVHCPU\1+5N
MICW0Q,H(MJE+*N?J6)0MK81H(CZ6/XP\-V#&,O#: AGG2Y?,Y!=5V-V3E?TM
MTK'6V%WF8Z-BI$ST-3;0UHE85*%1^XO2[&OKMU4$<X60)UPN;MDLK#U84/RU
M((2SY^KA9\4#ZN>BMVQTYN(K>FZ%9[Q=4./TQJ0+K^RW_!2W?OA>>X ;[F6E
M)%;CQOC8>(HYCFA\<@10*KX,#T>CO^U.\><Q(2::80TDVS+_,1[,EP0/',VM
M1NQ\;U%XA^F/-[F>T!]1,"%@CDZ$HEOIM'_TQ7)US*7S9B'])&<A35,X]$&X
M@BQ*^H-S<U+NE4K<$8/QB.R)+ .,%4(/*M@EFUI,T(/U[]CKKPVS@8YML[@J
MI$9PH/Q$[8ZBQSC%06:J[7KTM,YRWL/Q('! B.!!\R*GLHD-8_62S[NX8<K2
MF'$^48'R^/+UX'E4EX^I1!]9NBJNYV(AGY;]QF0VF9+B_FMW=/:UM]#/#O.Z
M3\/]I-+-4&K \S/'J,6UL=8S_E2=X  H[ZW*J8R&;']336M7GR@7J;XYTR-A
M=B("AG5=Z1W)N,DNKI(FQ5V*AR?C*G95*,8CQF[\K1OHQ7NPFJ6T'I^TE:47
M^A%)GCQ*:GZ&BP!CG_O^T)TL?'#?=XHPZZ_ 6,-?=?T:?3K'27V/1@IEC9?$
M@P0Z8V++UP59>$ 5DCN@]=6OVK0A+S57*N5G@S-%UT.0"PXN5M"RN-"XYT'U
M]?4);Y@:J\7GB\T(E>@#>WM+P.T%S8Y;3_/BT3EG"2;47J&QUK&;XAW.78/L
M0:[?+T8SK<97J81IU9V >_NK!WV3TI]&!DQ1(_>\AA>"/(_9U#9(QMYSG;FE
MO#6,7111^TK?H)=9>@X:&@249OW2.JAE?G5[TG2T=3+%&O&B?;/GJJ.I^.,K
MCUV&8Y>?,77WK;YU8%0[!O%]YD9BC:U&B<$""%F"&8M70P0$*\TJ>PQ/OQ+$
M2]73F&L7M^QFA1@P=AQ-82*'=F9@$>'+-Q1;<B<3+(5"!_46*XWPW\+SLDM$
M\Z]1/M">:J>*NZV?6BA.VUR$JR23B*.>8OJIY%J6$'\VUB"#Z; A][*O)=+X
MY5F8IXYE4U.K9Y"GM](&&TB+<0D>P$&8,3H%:U:W9+TB%OW_"#/_Y2X&#4T,
MW/OE14E,X(_-C1:2VED,$2,7@JSVKEYUM"KH83N2=HP'3;PA^ZI8%61="'YL
M*0(X_H5=#K-0PP"564.9ONJ8>F==SQ#F.)'Y4KJ,,GQE_NYU?!6.=1S3H\($
MH3V$>.3Z-K,Z[?CHAKX$M<6\.,:0E)^K>>.VIGRCC[B[%9X@^-4Z@5X0U0N[
M-O!GNL&SF?\"4$L#!!0    ( .6#[%;M_WVV=UP  /IL   9    9S4P,#@S
M,&<P-S W,#4P-3$P-#<S+FIP9^R[!51<7;,H>' (3H! T.#!W2T0/+C32()+
M&G=)$PB0X!(\. 0+$-S=(;@%&AJ'((V[/O+)_?]W;<V\^V;6FC?W]*K>W>?4
MKKUK2]FN<__S?@G 4Y15D 40$!" UP\?X!X*2 /HJ*AHJ"CH:&AH&!CHC[ (
ML;$P,;%("1[C$E(\I:*D>$I.3DW'SDA-PTI+3LXD\)R5DXN7EY>*44A,D%N4
MG8>7^S<1! P,#"Q,+!)L;!+N9^3/N/]O7_=M #XZ@BJB!!("#8"(CX"$CW#?
M!5 !  (*PA\7\->%@(B$C(**AH[Q"/,!H1H/0$1 0D)$1D)!049^>.KW\!Q
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M\1TV[-Y%Y)1T3DFX^042X1U!B+!YQS>U<'++O:F2#O*C\9,5/&7YA1'&:99
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MZ^H=U)YUI&;D9J+](>%!'9/2?>&6LVU@G%4DGI.[.,M;+H6_5\WE20>T O<
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MZ6!(V5MXO*WQE/ TV]*\T.P(E)KB*,N99N=C*LT,Y3PG\(K,(QU!=K^\!](
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MGX$S9@/(5.&L9O:W-Y?IMQY6AYFXRI$O$_AB!71E274TH^7*\W6H@E1<^W]
M#K?M\Z[YA;U\ZGIK7$+G'Z8X[&&;GHR<YOQ9_ Z[M$+N@5?W@('$7^7O+*7_
MCR,5>4?FSKDJZM'%R;MW/S*OBO@ET>//V-H:J%+#H]*%M:R%59G>AK-18*"G
M"G%."2[(Y#Y&*74N]\G0N=-*, "OSD?(J7,IN,KMK9+. B>4=Z?%U_? E=75
M*'*5EDGK/? 54D+U9_$[PO;GL['_$$7]GUWFF:R=.X\SBFEXTAQ/^%7H\0#
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M>YQBSY5>_".H1IP+Y1-)@)5?:A#/K])@W0.$@1?QK1_<,S$U=AZD7^L@?>M
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MS)51W:_Z SA^<3#O/]OM KX8^R]02P,$%     @ Y8/L5COA=&[.4@  ,F0
M !D   !G-3 P.#,P9S W,#<P-3 U,3 W-S$N:G!G[+P%5!U-ES;:!SO! \&=
M ,$A$-P)P8.[)\$]N 4.@:#!"23!78(%/3A)< CN'CBXNW/X3_*^^73^-=^=
MF35S[UW3K%J+WK5[5^WJVD\_N[OJW$[>_@#N*LC(RP @$ AXAO@#;F< *> .
M&AH8#?4.& Q&1[^#@46 C86)B46*?P^7@)*,FHJ2C(*"AIZ#D>8^&QT%!1,_
M,]M#+AX>'FI&05$!;A&.1SS</XV T-'1L3"Q2+"Q2;AI*6BY_Q\?MU\ O#L@
M%21Q9-!]  D/A(P'NFT#J $ A KZ=0!_'B D9!14-/ == Q,A$+U70 )A(R,
MA(*,BHJ"@JCU1=0#*'BH^+1<DFCWU)Z#[SL1<+^.S;Q#][C\*Z'ZT#[]HQ?.
M >@81,0DI&0,#QB9F%EX>/GX!02%I)Y(R\C*R2MH:&IIZ^CJZ9N:F5M86EG;
MN+BZN7MX>GD'O@D*#@D-"X^+?Y>0^/[#QZ2L[)S<O/R"PD\5E575-=#:NOIO
MK6WM'9U=W3W#(Z-CXQ.34].+2[#EE=6U]8W-@\.CXY/3L_.+RY]^@0!DT._C
MW_0+#^$7$@H*,@KXIU\@)(^?"G@HJ+1<:/B2:N#G3O?N<[^^0_ X-K/\*SK=
M(_5]PA?.0QA$]#R+# <_7?OEV;_F6,!_R+._./97OZ8!+&00XN8AXP'BP-DE
M4Y8_QK];BNE@E)A7,K8$#7'6]OV,5NS+<0(J5\XL"2IMX<!<5E9-7?#AN'"R
M-9&<N6K7UM#K=6E%"50"M3^+)C^_^ZE5F1-+1^DB0?EFIS^X"5"25JL>VW9T
M(^_%](+.3B7<R^L@Y\>*DOMZS7("$*AIDNN/O#=0(IEC/ ULL]!]Z*SJ<9R!
M>:RFFCO7^%Y].N?32!LH%K0BN9$$)(6S"NM-N-X"N-,,X[F/6I&[RL&ZJ7 +
M =)I'+$\?QZKXKY';60.91X^MN;"C:?*^*Y61ACXW&+[I-<L.V/?W=TK#'OH
MN3H:DGLC4\NW/Z&+^V>@%Y3JJ)Q'+]HKVWJ6G* 3S-9%$:<-6ZG+4FH^RE#W
MK4S:I(]]$;;L\D::K9,2R "KZ<5Z!BJE2PK-/I)_D':W>Y4>IZ_*31B8N]2<
M5BXQ+[5^::/O.N^6LU4OR,>][$N"Q(2T0Z!AU.94&=/&U(V1D_X%1PD0"E^K
M6B!?)VN9&>_8U3,?N05@J[@5/16=MX!=3["X/V])O@W?94F$1V*S8SPCZ^JW
M ZY;P+\6C!@75TWNN9E6)^S&N$]]?*^J&!,[#7U9R74.$M]FVB1>.F2R#QL9
MIDB$F?,$2*WGJ@;XOE[RYU_/42>5POH1<<CUM[?JOZ;<-9%E&R?&^S+SP'-*
MK0F=0B?IFFO,[A7_8O"@V]1PKU[PJ@H?>C]]+?V:,W+OV@SO)H\J..Z\5[,)
M.E$*2]P]4JI48E/,Z<0J 1+7Q#TP(W=&E@4OM<%A)W/JV.K/?8OG]8PAWP08
M;3WWJ&A/4YP. P#'Y\9'TH GO=_]IJ1>8ZT#U.725\*$DZR>,W$_?)=JQ9E/
MD*F6JG@B+0UTFL2H1CEYN47$XI]6]A]=>.C"R,-:J7<CO)>:;(V&%B>.%4M8
MEJRS C:PG'D8I.Q%G6KQ+C7KE5/J9>)M\SM%1CKM22+IDQT.LU^G9N"DC8)@
M-61YA?P!)_9/MJQHX-\?:$5KIUDOU5&W*;)<R!9,XHBB/OHV?;.SLG(3<!ZU
MS%9/H!Z69EG+I9)"A$P?N(G&.FN5@4L&G[D"!_'*Y=:-T7_DR(3:)BMIRV>Y
M,Y+*&[ADP ]/*"-=;@'K^M$J4=1JQ:VI[.H#BAB1$B<FYKM7=?8SS6]2KB8&
MJU3!80M;23G\?AS083?A[OO!FY-XI^]C?_C_D--Q8O#MVM"K3VOPPBG$<I_>
MV1_L**)PAXH[QI_%OKOH.)QR ]<Q$NZ-JH+3KQ\=@&KW_3+="FV,[;0]*LO2
M1=I[VG![$QGI3>M*^=NG2_H2R[+.X43#?5E&)&]JSO+D+8)JIS6>4>!XFH:?
ML3 A]W*ZU5:G4[[UN;&Y;)5+ZQ>L*BS>U6?X>'3DW"BX4_WZ4D?4!:5FH@4O
M;1ZF&:T6P9:8)UR8<+I#S8>,^SWZN?$&XDX:Y;\EY<5V=RG:U)CF"$,)_SQ7
M+N8("B?JTMB4*)ZJ?OOQ%5V9_L+F(T4"H9+"&F*-JHA/+Y5)NU^(#Q >\Q*
M%I>FC8QO@8[W9'R%3I0G.0=&C]DYIKD>:I)J3WMI##<Q2B4*-/+R0;W/B+)V
M.<6>--1[Z,K,![K<;0FRW:Q7V"Q"JEY9@<;3Q-^0&:597K%_[4E7: XMS\J*
M8(D 25#1[9^UEGM"): ^J18//H]4DSI()S1*?9^K3>"XB@87@*0E<\_C5B%$
M"#0?A8V4VI5AYH[!4H3P"0*_91[? <.,=Q N$J8U>4%R-A[:U+=O;@Q;$Z.:
M$RN+7,6FL H(O@#OQP_DNC=CC,SHG[.:FMM[.3F^M ^-LK5.XI='<^J)\3XA
MW"!0!;]?ASB,O<)D.+X,SLY;D'(\I1:2SX_Q"I^T9*Z-DX=YJ KVV5V+->N4
MCR;J64(J>\,XR%5]&MR_+'?2Q7WQ#AR<<)0&O#BJ<R+503!QE+FO?-7/=BOI
M<4@=L@>X:H1AN8_:A?K+"0>"?WBA)B:X6?31QYG(6[Q]Z8V60! ;O7LLNC6!
MF+Q45Z*#YY&+I+R]=0P)56MHMEZKNLLQ_"17=5V;7 /J+'MMJ08J-0=G@?BV
MDW2V/E"O0#EP8NY+3&_D/>-"Q#B@Y2[Y)(OC;=K;+F%FW9_X$472=U3AQ7[V
M17V2]1)CZ]C@@I>3W&9PBZPFV_J3_KQ#>6748IQ@R>EU2\.*D4]\Q-5$@9H$
MU;T;:,F%D["-Q\(,)\./,?O(UB!HD.:V_<<V71@6P#@Z+AH=NCL_WD[=3O;Z
MJ(IY)255^FBMB#)EMP>J_(&QV79]DPFYK:Q1MGAVZORI4@&+-=3;FMNHMT#>
M*M)M9"V)EY'N*C]POLFR-=V1BJJ<+.5 Q?,^E5VYI6VZ6@SN.JMZ.,"4]:\7
M(:RDGI"V:8I3'?[RS7%[6QNXX9%7;P7?,6-&"7,"%3J1A (AK?^FM-=$R+54
MUGK-=)*2!VK'QV>J!O,/4;\*^P=% 6Q<G5*! X7 ;LYX56W)C@/]J+TZ>461
M(YU"ICG[(/. X&FA8S6F*/=8J6-I9LUK.33Y%)8 3XJDH^IXA<H*G2C/M?+Z
MBOK@J6SAF &VY.]JL5]%=DBVJBZU5S,+#/1K(D5OEI6(TCI8U[B1:#]\>[QW
M3)^"=0MX>@^"E1X4/L>>:RI^7[/AY(P>\" &[1U.@RSD6R*V0L?JX=(P9BU#
M';0S%5\.4S8M.<3F*!3?UO;!YUI<JFP?PK)3;_X%EM(VT$8E3;KR27[VO,&,
MR31;90[W1M9.]0/WZ?M8%^0#5[)8HA(#-L".>%4QI$HY_;16;/K>=S[XLP7H
MU8PW;#Y+R5$A;GQU@Y=<&UK]HK+G@7HYWBC7 ,E9*<M.FL],I-C849%8QH1U
MU74',A'RVE7MA<M6NY;\C_?;.HEK9.[IV#G>(6>F9J]BYC>ZQ3ZN^HNRS"^1
M-WCNLJ_(/X^5H@^=T@;7\C(\/]=]/\*8*L]W-*?(7K=MROZ5JFTYNL1!%20M
M7>-XL9E^AG@V&T=6W@(#FK= L_CE,8B=D&CJ%EC[!%F@OO'F&[@%1#7@Y[?
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M\!9H7/@^WO?"TVC42C7@"V7?Z%72U-&]JZV+0>2"O#\<_==.<[!*!@./>:I
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MQ4>D?[Z38*KATN=V_@,CUD5$?<R1A7P%":@'LGUH:]Z('K14(PO L+D_?H]
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M@+)O<\>\]=-1]$QZ"W:2+I(),SR,L.XV&+#?N(I.G3!\?*SK'[$IUI9L9<#
MY&)@JC\%H0\!!P!A#C,UPLSH0?$2#?65$;US^X=G^8HG$]C!C9\[8BKRG1V2
M8K.T)'\%*F5/JH<B2)/?/TW3=[6.%EJK\2+M?WXT-2!!IGOS\[$3-]_@^\JJ
MQ-6(1PZ%1?,.LP#62 HJ.-_:.Z>Y6!LX=KG"OSJTO([A2SK6H#NILC\7#\$G
M ]<\H[Z?YBL2J ^F,0O]@01F9:[YR(6H9P#BG-<C"2R%!#S(H_\/E61%OF,4
MI,^7%(]M9(B7379&AP1<J[& P2B.^>"T*)\'0=%FM/BCA?$J, WC>P&0V!+_
M^H3"(&BU<-45JTLI&21-+]C>[FWCLG7D![5=!-TVE'5* ^NK.I#\ A!6OB46
MX(_B R0"N S+.^X?8R/ TU3$'FQJ?TQJN%3YAM&?LP_]8U:J Q+4T 4_S'PY
MDHR1';CV2-E?Z1Q:A2BC]U$$1>;GZ;UU;<>_.[HRAO4?"IK_80$^#F(0R1\*
MIOX_C47XVU+VS8$_@=6K1:5_S;80+" Y?7ZA6N-S\"1 CN26\ACC^;#\"I"&
MYW9N!]<UQ/NQ4ZI D3[LV<A4">O]:4P20Q3\+1FTV:9QZELPXP*5K*@L3GP1
MH1?UH?M':<WC&[NID8.II\ZYTYNZID=M*RF<B3;E;-A.[VG':ZW!^@A>T/B?
M, 6*7R"+FVW135NG+^)UBBB,(,#.QG+5WX,]&[LYQWS4L6?<FY5?RS':-4RE
M_,"G;8A"\FB.)G/1(//3%OL1/N:&[6P:W(8CS8F "[\Y*78'KE_@#;\4L2IH
MYKV2/#]0CGG.S3UE>)6LEVTRE5E(#S^'\X+65*M"F&S3N[/ORZK!]?.#%ZR?
M(X$68?\\AL32",G<'RW$[RF](T)K4O&.1A\QR*GY=V!0L847[QX7PR8K[G29
M5&CMG:FDN=<6R^PD7JQB4+HIW^Q5,QC>.F3F^V1%REBAYUA5)1,6,"%!ST09
MQC.:OTF>V)M=6E'HSP)Y&/NAM4>#F#7ZE=QJ<L=P8"_LV1[IT&&-@BMO"U7M
MTPJV^Y%$W$$X+SQF0"MI-26CG*MW6CE2J@MC[NW0OHADDPWHW!S>"U7* [2,
M2+L>*<1RJ&T]2K-VZ>MP(WE5J?(#3AL)'\RW\*1-.E$)$<I;#!E=^WXLH,D0
M_UU0).!QDES'2W62IJ'&;(N;/:_;WWXPW,%P)W[U\_DLOYS0NJILBJ6PGEBK
M]<U6)Q:NP@^WIMJE(ANH$[Q#=8$X"+$\).OIX&/2(;J$B2\5-#R]V#6"ZQ45
M^9;5+OF'3XH43=%FIME5=60HX:9A<Q#!N1#,CGDE*([^M"&WOL+M(9-X.(2@
M/Y:!I33?S;I?O(S(14N%*W?(0(_O**6-*A*8Y&^WQS[Y;HLG[)2,YRL[3*%2
M;!9U3V@A_.L7]66I[*:.HKG0/*-<.(52Y/,BD\21;8;PC"^1VSO&?6(!Z+MY
MY !S%@HH3I1^N8;1-,HAKH/M^GZ2__.K++&KWN1R3+AG:S*/Y?"$2Y"P@55&
MWQSVYO#$))Z&W&Y?==BZ:7I6[5_1#KNC_1-VYA9+M0T>-]JPDE+ZP<Z[56M7
M&H,C[KK\:A",VJ*? IG'8EIZ9V68Y,T]*(Z3RW'100.O@"3GQ2NP66$[^HP2
M!W)=LH)AV9D>29S;L%^0VE"-@A$)H@&5_UK57WC9O?)WRE_YNB0/)^JN<LB]
ML&9V0R_]0Z_L(2MLMU"@%WC>A2.X']\PZ"4RP<I9TG8U= U:XG^:YIKW_<_6
M_0%X&^:@HSZ7&,/ZP8+223U!6D9X)[<^E\8B#2W=:8A+?_I;QWZ7"OGALCQ>
M'>VR@IC[K0WF&,N'IAUVHUX/<547$40JZ759VHJ928RS$7I.6(N3HT5S>P93
M8;,U>A+%';;1QZ/P.I,IN!\WFN"-%TMF0:,^%FY!G@\J:HDFZW(UC<Q$OKL&
M_<00CUW(4?QJ*; N-KT4';XA]*%I:9LKE./3PZV@?6U?N,2]E+$>M[OPHRE:
MI5?]E'NM\C?'BB/']X+.1VA.Y8[NTP[AIF>-ZBH')AF[BCR%3#WG^4$XE,=Y
MS'>@\ST#%0A<I3#&;2\\&@^4"JYQ&+<;BPPTNZ2KSHZYT,@L0?S4D6(^JTWT
MQK(6.R>:U04>+V*^5J^L*%,J;J*$O#,(6?M>I,^\YA0FWV\3-1HB8Q5*C5_I
M330QLT%G94=IX:E/M:7RR53DW4_:U>3\1ELN"6J/A8M/.=;/Y5;&; XK&5R6
M_*$E'^DDOC5%*;V2I[+L\"Z[LZH_P9AIEW=6?%;@]L/5BAP.L!P)4>44U\2-
M8CM%["W(R6I^]FK($[^#U_.XQ%RPV1C-B_[W&6'B'N1# 2^VG&)2@.,W>=MV
M4>G@\"3@H9*$/,*Q^YUXV6CFV-*H#?PP4;Q;.Y_V O<#*/I)E'H)S0*9YFJY
MQ^:0E; 8OE* EJ(JZ0UG%NQF?LJ'HR\ZEM<3LE:\>,TSGBX_<-9XJ"&/)0RS
M7.:%W+&,09 -\^EP<*1%$_02<W6J^]QZ*KX=A.(1!M(.6DETM7(<Y'VC+/16
MG!7Z;$4@8\!4BZ95?E'43HN/XY6I?Q-OYT+TPL7*ISYZ6HF:CX*KF32JS.BO
M Y=BVHEZB#:PS1$M:$\@V)%UV$7ZG,85-Q(0=QT4]FZV;:>2*]ZPL'!>N0H?
MCEA%(72-0Q?I%C/ZUY2J+[4J#/5?V;IN&"N$.%B:=AV(_J@I"8EW=UO)R0S<
M>:] /!K&<338QA!W2^1IIZU 4JOM<S 6L)F5>T6C["'3E:2NGL1"3A:EU$WU
M'$\L%&,O#PM@SCC[>'5TN79PYV+S[ =ZUO_"RV\EED[WD,!F@75JQ\FRRI45
M-X3,Q?/6A"-S8@W[BR)P6#+N!%LB$GA?309='%(8SA<C?5P&Y39'C(]E(@&5
M%.G;8N0+<&C8BI<P*UOBY((KX@H18XY_N2\3%GJQ$;JEL-ZPN-,Z9KUY;%N(
M!-A_8$C*H=//:0@=>?!/BCM>%1L7?3;;SRV:YZ#JLTFKJH'H;,<B@0>L2^1X
M 9 >-X\D62>)C@->D,ZE<<JMGW>'4)O]M#^_\65VPVZDHL"EF[EN0KV_7&TR
M]([>QZ7V&N/] 5G31N(=+G!]0R+@,M;F/DO9?ROIG,/OZ'--O)O>4WH&NR;!
M.0<#2$LOHSL,>_T$0:OPL4Q#7["&?HOV",L%8Z8F]-?-U*^@'E!AP)%X]G_5
MY5RM!A*XOPZ=,EK6+BM9B,"K8;E!6.;FP?;/6/J.7G*3/@)C.[Y@6!G#55J@
M1VFG8%4V%C9KU.=%]9^ZE'!D GF+MZ.NB95!?RD89'O\% JA6!]L@G_,/M+N
MK16WP-&H+LC@.5WXLCLZI[_N%I0GMG1 4;+2Y4@2+3]>>W,+:)/?8_A*?K/P
MLR'_9IF&@GPK>X>5K?;A79H6N4$.ZC.B[H5QC]S(XT_A(EW[!0P!RZ&6 #SK
MSQ3+G&S#_/CTZ5EAGKQ23A;IC:;'@C11#N)D>\%(X .?G17_IV,1!YLA3,5N
M.?F;$J1J:QW[>4B 0';5Q4'MT];*JD=NSA*Z+Z/Z9=7)NJ'%;GGSX&QKY'>K
MFY]A:V]PCLN+'R\M1YZ\H=@Q(Z..1\55;I-HZGZ"KP0%U_6#80&.[Q'3E4GN
M]QVA-%'D[13?!:</&M[-%W6D.QXJ8[ )!/ )%!5KY^>E5NMQ%D[SC[(:"YY%
M7GT-X>E@3(,I#F>^O2"?G.S*Z%K^6?JUO(LLU,IF9]9')' ]*QGOB8NPN0;'
MB^K0+9XTR4-!D:FO'%%; B:^L&88]<>L]3<GA*(\'2:1%+<ERQ=,A$2N[#I)
MMZQR4KR$7N^V]8XL<K0.X K+>X[N9HFTMO&')\4[].=;$N]F)+_2R:BIL)K4
M"!1AQ'+R"UJ"G-B .N8-/(A!B:D6^Q:C[)%RQ?H*=(H\M,TQOX,GYN1;9W9(
MP [*JL0*WN9<1K$#LF79J[;+K/U4Q )"_9P9E*2.6G/=H?_8G-/F2?M.=^0=
MPZ+3  <[^[+O&Q/13YW3AI,ZSIZ4 P7;<2L[S\KBG#;IPWUF$P$SZ6^;)(3W
M*W:W[5-/BOL^X-<++\"63E,\<](F"HI+"A%1/U*^/4@)8@T"1+!T@55H(9\.
M$EC<- I#O^0_7J<&DX/G<8;2D$!HS:?-!B/Q.23P3$M:&C">/-62+.^(2=>C
MA'H((($UG3SF7'@R:> $:4<*[5T^8J#_U[1EHVA.2/8S!R1P_M#*5>67RA[_
MO[>#5A$L(,>?$@!NSM#ZOU#!=_3H5O0$M_=1GJQY]Z_G/%-_"A#-0@*5#5'B
M@8#9KQ%2NT,O/IVIK27?^@\ZI-_V6GK@N\4R_ ]^_<NW\?=4]03?L5'&1!,:
M?IM""W_Z?'I2CQ)/*?F$#]S2OU6P]?UXH/2XI-@JM8*UFT&$A!VT2M6 Y=PJ
M_]I7JCR:(IY-N8*N)VY;;)[$"DW=&8*H,W=YVKH^81)=D*.0+1>1V$^+_KT3
MPQP]N:E_48+B\,\W]?8(H>CM%BF8>EE-0]#$9/]%_!/<NB^W-<';25:QNS</
MQY*8K>/ZJK+T/@F12S>4[!-25EMW4";8%$B.WJ^N'.!,+@Z3=6:HR7WHQA9U
M7VE5W\BWE KR=.]9A"7)G7[(,35.1;W-Z&NUX/IQ.O&90] :7_!"?+#,6,O)
M'0O+]OFG2RG^IL^">Y)WY<@$\^(RO^GT>F0J0B!O1XLKF[N_4= HNP4"BXY@
MH@W^.)E07O+/>!6$0B2&<FRBJ11TX*GI3J8BTOQ(O9HZG2UV]M=Z[I_*W_0H
MB[=IL-OBWTC"6-11G'MBS3\S=O'T19.IGC]7#N;[(+)ZM>8$;Q^ANU\=4F9F
M1?UVXJ;A*[BFW ]*9.+Y"\6KNC8E2 =.<Y2KO,N(34)FVAY</*, '7R)S7EQ
MC$Y&796'2Z=37SELG;0B;67PI'?I"0$Z?K2MT$X8IKA_NCA^F0ZMM@U#R(@J
M7Q(.VD/1DBAV-]\(AY"J5 1A56[<PD+[WH2ZO'C;'59XA9E(/-EFY.8/.PGB
M[5II=RM7L0/A1'&15+-C6U\GR57/[0;W(#<-Q[$CE_?W5*=DQMP"I=B)/G@1
M8%+<,#XM]^%**BL4Y:2,00+F2<LSMR!"<*=@_U<U"JL%SZ=Y>J5H? <X$HV4
MOVP3RY27?*;(&^7Y##@W;2:5@M*_&O:Z&]-6O1B:[-F5FWLAI'92-$D;./1-
MUS"AVC2L@H@W7R<M0I.46X0RPA(.\/2&HB*-@94.)"!&<I"^/X1:X"K+F:BU
MG'SCP!@))'WZ[\;_2QKQ,-KH^?\6U92_4P7&3 & OT IW5@9I%=/]**ZBUV"
M6LWQ/+ Y;Q83<(RXC7&B.+;!C%[U3U*SMDW+2LK=/_F$-_NR+]FRUE9'Q^/#
M5A2)SK *'LI.X_Z Y0'Z_W3/-_L-W3?BT"^\"L>.6C%TV_YK2J,?'3GX:< ]
M<0P7PCD*X2?H;YDV)4A$QY' :@KBK6L1$NB7OES#I  DLV^8V"G\HX:#'PD2
M,%0]@JEUH2@<1F,6P@*=*Z/G1.]YIF:O'ZSW6ML=*S!&DI"(:]MFTIF_.53K
M?U =U[I'[2=>9UX^L(%O1<;P6D.B:7A75@R_#N"V5MV?;;6^$7Q'.UAT"OAT
M<$]S%?9,DWGO7AZ.LA3O0%U[)J7JY*,@$*3N. H)6)G3^KC%S9)C&EA2#+@@
M ;.0L:T&4ZYLG/KTZA'!2RJBR2[*F"&YC:SHB+MDY>K6G1CY^ ZC7I1QR[T%
M 8Y"JY-B,S"Z9B.; 3;\:EMA,SIPL#)B=/3>U5MT-_^S97W#,[;6U]RK2^L)
MP0W/K9ZX>)IZ:8LUQ?7-,PKT=:,KT"WB</TX:A<DS<#' H>O)*H:?\-\DN.Q
MG#_O-WYK)G:R8RP.Z%8BWM!2YMNRIE1>WVL=4WF#T??:/L_WDA84OAFW#>K$
M&*UJF;LPY5_'[2G2^R83PP7@3TCR+T_] 6=M;S^#5L4%]V[%N-HYIUA.>&RL
M.WU5;,_$;&ZBX^RNK[J/>C9H>33^89\'.)GT1')<;!X&A?,M;L>I3R2+N)E1
MXC]3=^MO*1\],I#9L+8YGIG9UEZZX+UQHYO5Z[E;0A9?V3P47VE^;2<5IIJ$
M!.!W/FK*]^G(M.E[?@8U_+E?WH)\T"39'<VJX.XBOC6H0A^.4YP_%"&VI\_D
MQ5@!)<C_KJ@%YS"['[V]CTY4.1.KS!-R"Z#R$L^H*2"D5W4Q4Y=_G\%8^EDP
M8">\=!72D.ZZTV)T*AM206%A/WV5^[.O6.*DUSZ<M><;MQ*0@"8F8XX^8IY2
M5*LFGFX]?_'Q;>'?]JZVQW-AW+;F*,XY5X9_;UK/_/R-4P7$?K_1YB%DO@+/
MV$_N9CDE[G1H!O[='Y9C8\_?3HH);TDS;.O!]=!?WA4P0>\0Q6_W$C#/)P<3
M;P@\XD\)"=<;3S.R\*(5=^"Y^^9.)SH9Z=%**:_':\2B2IG[%PVXXQV!2 ()
M41C[G,/P$MIS]Q\8:M)V)X8/ZLMJDZ[2<#,[G-ZT%3Y.\.N[FG:H"7K;ID5^
M7$1041R]3+ZI(F?J\Y+(&[+"3_K''E*WAEZ94GS(]K. /4TO&E^L=@>]\Y9
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MS .N66CSD_*%EX+[GOTGHG6?AD2/^G6!V=\QR,8C"P#K$8 ^@5KH+)A8F/2
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M4(>5U69KV4@ A@()90T3?NRRJ#:+*\%45O8M38) BVU4[J2:UB%Z9^BISR
M^:RFY;4!FU8?S]Y#B'<P?<7S\@MZ._HS;0X'K. 2JWUDM2!P/CK'0"$>S7]
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M>G14T@]M0*J\#2]*6;+E]R'M1260UH!#==$PEZM'2>[5BU^30EM7-@\9@:Z
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M4$L! A0#%     @ Y8/L5J4_).[  @   0T  !4              ( !R0,
M &-P<G@M,C R,C$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( .6#[%;(MJF'X0(
M &@0   5              "  ;P&  !C<')X+3(P,C(Q,C,Q7VQA8BYX;6Q0
M2P$"% ,4    " #E@^Q6M1JBUVL"  #="0  %0              @ '0"0
M8W!R>"TR,#(R,3(S,5]P<F4N>&UL4$L! A0#%     @ Y8/L5HSIU$->_@
MPY\* !(              ( !;@P  &0U,# X,S!D9&5F,31A+FAT;5!+ 0(4
M Q0    ( .6#[%: A=4#6Q@  /88   9              "  ?P* 0!G-3 P
M.#,P9S W,#<P-3 U,#DY,#$N:G!G4$L! A0#%     @ Y8/L5KP2C=@C"P
M! P  !D              ( !CB,! &<U,# X,S!G,#<P-S U,#4Q,# Y."YJ
M<&=02P$"% ,4    " #E@^Q6[?]]MG=<  #Z;   &0              @ 'H
M+@$ 9S4P,#@S,&<P-S W,#4P-3$P-#<S+FIP9U!+ 0(4 Q0    ( .6#[%8[
MX71NSE(  #)D   9              "  9:+ 0!G-3 P.#,P9S W,#<P-3 U
M,3 W-S$N:G!G4$L! A0#%     @ Y8/L5G^M\[> 40  /F,  !D
M     ( !F]X! &<U,# X,S!G,#<P-S U,#4Q,3 Q-RYJ<&=02P4&      H
,"@"K @  4C "

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
